<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006737</article-id><article-id pub-id-type="pmc">PMC11860421</article-id><article-id pub-id-type="doi">10.3390/vaccines13020191</article-id><article-id pub-id-type="publisher-id">vaccines-13-00191</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Molecular Farming for Immunization: Current Advances and Future Prospects in Plant-Produced Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vo</surname><given-names>Dang-Khoa</given-names></name><xref rid="af1-vaccines-13-00191" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Trinh</surname><given-names>Kieu The Loan</given-names></name><xref rid="af2-vaccines-13-00191" ref-type="aff">2</xref><xref rid="c1-vaccines-13-00191" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Grill</surname><given-names>Laurence K.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Phiri</surname><given-names>Kelvin</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00191"><label>1</label>College of Pharmacy, Gachon University, 191 Hambakmoe-ro, Yeonsu-gu, Incheon 21936, Republic of Korea</aff><aff id="af2-vaccines-13-00191"><label>2</label>Bionano Applications Research Center, Gachon University, 1342 Seongnam-daero, Sujeong-gu, Seongnam-si 13120, Gyeonggi-do, Republic of Korea</aff><author-notes><corresp id="c1-vaccines-13-00191"><label>*</label>Correspondence: <email>tktloan@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>191</elocation-id><history><date date-type="received"><day>10</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>07</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Using plants as bioreactors, molecular farming has emerged as a versatile and sustainable platform for producing recombinant vaccines, therapeutic proteins, industrial enzymes, and nutraceuticals. This innovative approach leverages the unique advantages of plants, including scalability, cost-effectiveness, and reduced risk of contamination with human pathogens. Recent advancements in gene editing, transient expression systems, and nanoparticle-based delivery technologies have significantly enhanced the efficiency and versatility of plant-based systems. Particularly in vaccine development, molecular farming has demonstrated its potential with notable successes such as Medicago&#x02019;s Covifenz for COVID-19, illustrating the capacity of plant-based platforms to address global health emergencies rapidly. Furthermore, edible vaccines have opened new avenues in the delivery of vaccines, mainly in settings with low resources where the cold chain used for conventional logistics is a challenge. However, optimization of protein yield and stability, the complexity of purification processes, and regulatory hurdles are some of the challenges that still remain. This review discusses the current status of vaccine development using plant-based expression systems, operational mechanisms for plant expression platforms, major applications in the prevention of infectious diseases, and new developments, such as nanoparticle-mediated delivery and cancer vaccines. The discussion will also touch on ethical considerations, the regulatory framework, and future trends with respect to the transformative capacity of plant-derived vaccines in ensuring greater global accessibility and cost-effectiveness of the vaccination. This field holds great promise for the infectious disease area and, indeed, for applications in personalized medicine and biopharmaceuticals in the near future.</p></abstract><kwd-group><kwd>plant-based vaccines</kwd><kwd>immunization</kwd><kwd>molecular farming</kwd><kwd>personalized medicine</kwd><kwd>infectious diseases</kwd><kwd>cancer vaccines</kwd><kwd>recombinant proteins</kwd><kwd>biopharming</kwd><kwd>vaccine development</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00191"><title>1. Introduction</title><p>Over the past century, many changes have been observed on the international health scene. With these changes comes innovation in vaccine technologies to try and match increasing complexity [<xref rid="B1-vaccines-13-00191" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-13-00191" ref-type="bibr">2</xref>]. Some of the big challenges for infectious diseases like COVID-19, influenza, and malaria are the development of new pathogens and the resurgence of vaccine-preventable diseases [<xref rid="B3-vaccines-13-00191" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-13-00191" ref-type="bibr">4</xref>]. All inactivated vaccines and live-attenuated vaccines represent traditional approaches for vaccine manufacturing that have so far been remarkably effective [<xref rid="B5-vaccines-13-00191" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-13-00191" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-13-00191" ref-type="bibr">7</xref>]. Their limitations are becoming progressively more apparent, particularly with regard to preparation against pandemics [<xref rid="B8-vaccines-13-00191" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-13-00191" ref-type="bibr">9</xref>]. Factors such as high production costs, reliance on cold-chain transportation, and manufacturing constraints slow down the rapid and fair distribution of vaccines, especially in low- and middle-income countries (LMICs) [<xref rid="B10-vaccines-13-00191" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-13-00191" ref-type="bibr">11</xref>]. During the COVID-19 pandemic, the disparities in vaccine accessibility were felt more by the marginalized communities, hence exposing inherent vulnerabilities of the global health framework [<xref rid="B12-vaccines-13-00191" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-13-00191" ref-type="bibr">13</xref>]. These problems reveal a great need for developing new vaccine technologies that are affordable, highly scalable, and deployable in a very short time against new health threats [<xref rid="B14-vaccines-13-00191" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-13-00191" ref-type="bibr">15</xref>]. Plant-based vaccine technologies, through molecular farming advances, represent one of the innovative platforms well placed to fill these massive gaps [<xref rid="B16-vaccines-13-00191" ref-type="bibr">16</xref>].</p><p>Molecular farming is the process of using plants that are typically used in agriculture to produce proteins or other metabolites including plasma proteins, enzymes, growth factors, and recombinant antibodies, that have been heralded to revolutionize the approach of vaccine development [<xref rid="B17-vaccines-13-00191" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-13-00191" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-13-00191" ref-type="bibr">19</xref>]. In contradistinction to conventional production platforms, namely mammalian cell culture and microbial fermentation systems, molecular farming exploits the natural biosynthetic capabilities of plants in producing high-quality antigens for immunizations [<xref rid="B20-vaccines-13-00191" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-13-00191" ref-type="bibr">21</xref>]. This is achieved either through transient expression systems, through stable plant transformation, or by chloroplast engineering towards efficient production of target antigens [<xref rid="B22-vaccines-13-00191" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-13-00191" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-13-00191" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-13-00191" ref-type="bibr">25</xref>]. Transient expression systems, rely on the bacterial pathogen <italic toggle="yes">Agrobacterium tumefaciens</italic> as a powerful tool to introduce viral vectors or, in more advanced applications, to deliver components of a deconstructed viral vector into a host plant, allowing the shortest production cycles, and, therefore, uniquely suit responses to pandemics or outbreaks [<xref rid="B26-vaccines-13-00191" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-13-00191" ref-type="bibr">27</xref>]. Indeed, Medicago&#x02019;s plant-derived COVID-19 vaccine, Covifenz, has become the first such vaccine to be approved by regulatory authorities in Canada, a major milestone in the field [<xref rid="B28-vaccines-13-00191" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-13-00191" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-13-00191" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-13-00191" ref-type="bibr">31</xref>]. In addition to human health vaccine production, molecular farming has been widely conducted in the field of veterinary medicine to produce vaccines&#x02014;again proving to be more versatile and scalable [<xref rid="B32-vaccines-13-00191" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-13-00191" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-13-00191" ref-type="bibr">34</xref>]. The concept of edible vaccines, in which the antigenic proteins are produced in edible plants like lettuce or tomatoes, adds even another dimension in that there would theoretically not be any need for cold-chain distribution systems, thereby making vaccination more accessible under resource-constrained settings [<xref rid="B35-vaccines-13-00191" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-13-00191" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-13-00191" ref-type="bibr">37</xref>].</p><p>Molecular farming makes plant-based vaccine systems very attractive, as they can surmount the limitations of the traditional platforms of vaccine production [<xref rid="B38-vaccines-13-00191" ref-type="bibr">38</xref>]. First, plants could be grown in scale at a much lower cost, with no prerequisites for expensive bioreactors and stringent conditions for growth [<xref rid="B39-vaccines-13-00191" ref-type="bibr">39</xref>]. This is particularly the case for low- and middle-income countries where resources, both financial and technical, are in short supply [<xref rid="B40-vaccines-13-00191" ref-type="bibr">40</xref>]. Second, plant-based systems are free from the risk of contamination with human pathogens, which is an issue to some degree with mammalian cell-based production [<xref rid="B41-vaccines-13-00191" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-13-00191" ref-type="bibr">42</xref>]. Plants are inherently safe biofactories since they cannot harbor or propagate viruses or prions that can infect humans [<xref rid="B43-vaccines-13-00191" ref-type="bibr">43</xref>]. Plant cell cultures are a controlled and scalable method of recombinant protein production independent of soil cultivation, with year-round production possibilities [<xref rid="B44-vaccines-13-00191" ref-type="bibr">44</xref>]. The bioreactor-grown systems provide a sterile, defined environment for growth with full control over the conditions, maximizing protein yield. Perhaps most importantly, they can produce complicated proteins with precise post-translational modifications, crucial for therapeutic proteins and monoclonal antibodies. Advances in genetic tools such as CRISPR and metabolic engineering have increased productivity [<xref rid="B45-vaccines-13-00191" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-13-00191" ref-type="bibr">46</xref>]. Plant cell cultures are highly suited to vaccine antigens and biopharmaceuticals and offer consistency, flexibility, and scalability and are, thus, the prime focus of molecular farming strategies to produce biopharmaceuticals [<xref rid="B47-vaccines-13-00191" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-13-00191" ref-type="bibr">48</xref>]. Third, plants are scalable, allowing very rapid ramp-up to meet surges in demand&#x02014;such as those occurring due to pandemics [<xref rid="B49-vaccines-13-00191" ref-type="bibr">49</xref>]. Lastly, plant-based vaccines offer added advantages in that their production is more sustainable, producing a lower carbon footprint compared to traditional systems [<xref rid="B50-vaccines-13-00191" ref-type="bibr">50</xref>,<xref rid="B51-vaccines-13-00191" ref-type="bibr">51</xref>]. All of these characteristics make molecular farming a very powerful tool to achieve global health equity by making vaccines inexpensive and widely available [<xref rid="B52-vaccines-13-00191" ref-type="bibr">52</xref>].</p><p>This review will attempt to give an in-depth overview of the state-of-the-art of plant-based vaccine development, pointing out the important milestones, breakthroughs, challenges, and future directions of the field. First, it discusses the historical development and use of molecular farming in vaccine development. It then goes on to describe the mechanism of action of plant-based vaccine production in a detailed manner, covering major expression systems, host plants, and downstream processing techniques. Reviewing in more detail, the following describes various applications of plant-based vaccines in infectious disease prevention, cancer immunotherapy, veterinary medicine, advantages offered by the plant-based approach against the conventional vaccine platforms, and challenges that need to be overcome for the full exploitation of their potential. This work will hence outline the possible areas of research and innovation, discussing several needs for integrated approaches that bring together molecular farming with new delivery systems and improved biotechnologies. With such a dealing of topics, the present review tends to underline the turning point role that plant-made vaccines might play in changing the current situation in vaccine production and distribution worldwide.</p></sec><sec id="sec2-vaccines-13-00191"><title>2. Historical Perspective on Plant-Based Vaccines</title><p>The idea of a biofactory in plants for producing therapeutic proteins emerged at the beginning of the 1990s, encouraged by great achievements in molecular biology and genetic engineering [<xref rid="B53-vaccines-13-00191" ref-type="bibr">53</xref>,<xref rid="B54-vaccines-13-00191" ref-type="bibr">54</xref>]. In the early stages, research in molecular farming focused on the production of simple recombinant proteins, such as antibodies and enzymes, produced mainly in tobacco and potato [<xref rid="B55-vaccines-13-00191" ref-type="bibr">55</xref>,<xref rid="B56-vaccines-13-00191" ref-type="bibr">56</xref>]. In 1990, a breakthrough in human growth hormone production in transgenic tobacco plants showed that plants could serve as effective, scalable production platforms for proteins [<xref rid="B57-vaccines-13-00191" ref-type="bibr">57</xref>]. Not long thereafter, the first plant-derived vaccine antigen was expressed: a surface protein of the hepatitis B virus (HBV), both in transgenic tobacco and potato plants [<xref rid="B58-vaccines-13-00191" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-13-00191" ref-type="bibr">59</xref>,<xref rid="B60-vaccines-13-00191" ref-type="bibr">60</xref>,<xref rid="B61-vaccines-13-00191" ref-type="bibr">61</xref>]. This indeed opened up the avenue to start exploiting plants in vaccine development. Several earlier studies related to edible vaccines expressed vaccine antigens in consumable crops like tomatoes and bananas as one such methodology to be conducted with simplified vaccine administration in the most resource-poor setting [<xref rid="B62-vaccines-13-00191" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-13-00191" ref-type="bibr">63</xref>,<xref rid="B64-vaccines-13-00191" ref-type="bibr">64</xref>]. These experiments being critical for proving a number of plants as production platforms of immunologically active antigens marked the start of molecular farming as one of the revolutionary biotechnological approaches.</p><p>As the field evolved, researchers worked towards the optimization of yield, functionality, and immunogenicity of plant-derived vaccines, resulting in key milestones shaping the trajectory of molecular farming. Among the milestones marking this evolution has been the development of transient expression systems, capable of producing recombinant proteins in plants much faster without stable genetic modification [<xref rid="B65-vaccines-13-00191" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-13-00191" ref-type="bibr">66</xref>,<xref rid="B67-vaccines-13-00191" ref-type="bibr">67</xref>]. This technique is a potent way to introduce viral vectors into host plants, usually by employing vectors from plant viruses like tobacco mosaic virus (TMV) or by using the bacterial pathogen <italic toggle="yes">A. tumefaciens</italic> [<xref rid="B68-vaccines-13-00191" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-13-00191" ref-type="bibr">69</xref>]. While Agrobacterium-mediated plant transformation has been used since the 1980s, its use in recombinant protein production was initially limited by the low expression levels of foreign proteins [<xref rid="B70-vaccines-13-00191" ref-type="bibr">70</xref>]. The breakthrough with agroinfiltration truly changed the landscape of plant-based protein production [<xref rid="B71-vaccines-13-00191" ref-type="bibr">71</xref>]. This concept of rapid scalability of plant-based vaccines was first demonstrated through the transient expression of a candidate vaccine against the Norwalk virus in tobacco plants in 2005 [<xref rid="B64-vaccines-13-00191" ref-type="bibr">64</xref>,<xref rid="B72-vaccines-13-00191" ref-type="bibr">72</xref>]. The other major milestone was the expression of complex multimeric antigens in plants such as virus-like particles (VLPs) [<xref rid="B73-vaccines-13-00191" ref-type="bibr">73</xref>,<xref rid="B74-vaccines-13-00191" ref-type="bibr">74</xref>]. Due to a close mimicry of the native virus structure, VLPs are highly immunogenic and very effective in vaccine applications [<xref rid="B75-vaccines-13-00191" ref-type="bibr">75</xref>,<xref rid="B76-vaccines-13-00191" ref-type="bibr">76</xref>]. Successful plant-derived influenza and rotavirus VLP vaccines have reached clinical trials, further validating this technology for human immunization [<xref rid="B77-vaccines-13-00191" ref-type="bibr">77</xref>,<xref rid="B78-vaccines-13-00191" ref-type="bibr">78</xref>].</p><p>Medicago and GlaxoSmithKline (GSK) collaborated to create Covifenz, a plant-derived COVID-19 vaccine, which uses VLPs as its platform [<xref rid="B79-vaccines-13-00191" ref-type="bibr">79</xref>]. <italic toggle="yes">Nicotiana benthamiana</italic> expresses the SARS-CoV-2 spike protein, which allows for structural mimicry of the virus without its genetic material [<xref rid="B80-vaccines-13-00191" ref-type="bibr">80</xref>]. In this approach, plant cells were genetically engineered to produce proteins that self-assemble into VLPs. VLPs are mixed with GSK&#x02019;s exclusive adjuvant AS03 to increase immunogenicity, which stimulates T cell and antibody responses [<xref rid="B81-vaccines-13-00191" ref-type="bibr">81</xref>]. The two doses of the immunization are spaced three weeks apart [<xref rid="B82-vaccines-13-00191" ref-type="bibr">82</xref>]. Covifenz was made using molecular farming, a technique that allows for quick scalability, a crucial benefit in pandemic response [<xref rid="B30-vaccines-13-00191" ref-type="bibr">30</xref>]. Phase III trials confirmed its effectiveness, and preclinical and clinical trials showed a strong immune response and a good safety profile. In February 2022, Health Canada granted emergency use authorization for Covifenz [<xref rid="B31-vaccines-13-00191" ref-type="bibr">31</xref>]. However, broader international approval was hindered by regulatory delays, commercial challenges, and competition from mRNA and protein subunit vaccines. Despite its innovative plant-based approach, which offers scalable and flexible vaccine production, Medicago&#x02019;s closure in 2022 and limited market uptake raised concerns about the commercial viability of plant-based vaccines [<xref rid="B83-vaccines-13-00191" ref-type="bibr">83</xref>]. While Covifenz marked a significant milestone in vaccine technology, its market limitations underscore the need for further advancements to integrate plant-based platforms into global immunization strategies.</p><p>Beyond human health, veterinary medicine has also benefited, with the successful development of vaccines against animal diseases such as Newcastle disease and porcine epidemic diarrhea virus [<xref rid="B84-vaccines-13-00191" ref-type="bibr">84</xref>,<xref rid="B85-vaccines-13-00191" ref-type="bibr">85</xref>,<xref rid="B86-vaccines-13-00191" ref-type="bibr">86</xref>]. These show the wide applicability of plant-based platforms that keep being developed through new genetic engineering, synthetic biology, and improved technologies of downstream processing. Collectively, these signify the remarkable advancements in the evolution of plant-based vaccines, which hold the promise to transform healthcare on a global level.</p></sec><sec id="sec3-vaccines-13-00191"><title>3. Mechanisms of Molecular Farming</title><sec id="sec3dot1-vaccines-13-00191"><title>3.1. Plant Expression Systems</title><p>Plant expression systems have been developed as the major tools in molecular farming for only a few approaches regarding the production of recombinant proteins, including vaccines [<xref rid="B87-vaccines-13-00191" ref-type="bibr">87</xref>]. The two prevailing methodologies hitherto being explored in this domain include transient expression and stable transformation [<xref rid="B21-vaccines-13-00191" ref-type="bibr">21</xref>,<xref rid="B88-vaccines-13-00191" ref-type="bibr">88</xref>,<xref rid="B89-vaccines-13-00191" ref-type="bibr">89</xref>]. Both possess certain peculiar advantages and applications in molecular farming.</p><p>During plant-based production of vaccines, viral vectors generally introduce target proteins into the plant cells. Agroinfiltration is one of the most applied techniques wherein the bacterium <italic toggle="yes">A. tumefaciens</italic> is utilized as a vehicle to deliver viral vector constructs encoding the desired protein due to its natural capacity to transfer DNA into plant cells [<xref rid="B90-vaccines-13-00191" ref-type="bibr">90</xref>,<xref rid="B91-vaccines-13-00191" ref-type="bibr">91</xref>,<xref rid="B92-vaccines-13-00191" ref-type="bibr">92</xref>]. Because it will express the protein of interest in days, this methodology offers the advantages of transient expression, and can, therefore, represent an efficient methodology towards fast vaccine production. Among the well-known transient expression systems, one is based on the vectors from the Potato Virus X [<xref rid="B93-vaccines-13-00191" ref-type="bibr">93</xref>]. PVX is a plant virus that replicates in a wide range of plant species, thus, being an ideal vector for the production of proteins [<xref rid="B94-vaccines-13-00191" ref-type="bibr">94</xref>]. The systemic expression of the target protein induced by this virus in infected plant tissues allows recombinant proteins to be easily harvested. These vectors are very helpful in large-scale production due to the less time-consuming process and low cost compared with traditional expression systems in mammalian or bacterial cells. Agroinfiltration and PVX-based vectors have contributed much to plant molecular farming, enabling scalable production of recombinant proteins, including vaccine candidates. In addition, both systems are currently under investigation for flexibility and efficiency, which will extend their wider applicability in biotechnological and pharmaceutical areas.</p><p>In the case of stable transformation, however, the gene of interest has to be integrated into the plant genome to produce transgenic plants that can express the required protein in subsequent generations [<xref rid="B95-vaccines-13-00191" ref-type="bibr">95</xref>]. This is achieved by nuclear or chloroplast transformation. Nuclear transformation inserts genes into the plant&#x02019;s nuclear genome; this can take place with Agrobacterium-mediated transformation and biolistic (gene gun) methods [<xref rid="B96-vaccines-13-00191" ref-type="bibr">96</xref>,<xref rid="B97-vaccines-13-00191" ref-type="bibr">97</xref>]. Transgenic plants provide long-term production of proteins without repeated introduction of the gene. However, high-level expression and uniform yields are not always easy to achieve because of position effects and gene silencing [<xref rid="B98-vaccines-13-00191" ref-type="bibr">98</xref>,<xref rid="B99-vaccines-13-00191" ref-type="bibr">99</xref>]. Chloroplast transformation overcomes many of the limitations associated with nuclear transformation because integration of the gene into the chloroplast genome allows for higher levels of protein expression [<xref rid="B100-vaccines-13-00191" ref-type="bibr">100</xref>,<xref rid="B101-vaccines-13-00191" ref-type="bibr">101</xref>]. Chloroplasts can carry multiple copies of the gene of interest, and the lack of gene silencing enhances stability. Furthermore, the risk of transgene escape through pollen is minimized in chloroplast transformation because chloroplasts are maternally inherited in most plants [<xref rid="B102-vaccines-13-00191" ref-type="bibr">102</xref>]. By such means, antigens against a range of diseases such as cholera, tuberculosis, and anthrax have been fashioned into vaccine candidates [<xref rid="B103-vaccines-13-00191" ref-type="bibr">103</xref>]. Compared to transient systems, stable transformation is slower, but it comes into its own in long-term production and applications that require large-scale cultivation of plants. These plant expression systems now come together to give a strong molecular farming toolkit for the development of plant-based vaccines for diverse needs.</p></sec><sec id="sec3dot2-vaccines-13-00191"><title>3.2. Plant Hosts in Molecular Farming</title><p>The choice of the plant host is one of the critical parameters affecting the efficiency, scalability, and economic viability of the process in recombinant protein production with molecular farming [<xref rid="B104-vaccines-13-00191" ref-type="bibr">104</xref>]. Examples of host plants include tobacco, lettuce, tomatoes, and maize, each having distinct advantages and certain limitations [<xref rid="B105-vaccines-13-00191" ref-type="bibr">105</xref>]. They are mainly chosen with considerations in their growth rate, yield of the target protein, capabilities in relation to post-translational protein modification, and appropriate application accordingly.</p><sec id="sec3dot2dot1-vaccines-13-00191"><title>3.2.1. Commonly Used Plants</title><p>Tobacco (<italic toggle="yes">Nicotiana</italic> species) is the most exploited plant for molecular farming, mainly because of its well-developed genetic transformation protocols and high biomass yield [<xref rid="B106-vaccines-13-00191" ref-type="bibr">106</xref>,<xref rid="B107-vaccines-13-00191" ref-type="bibr">107</xref>]. <italic toggle="yes">N. benthamiana</italic> has been the choice for transient expression systems since it supports high levels of recombinant protein production and is amenable to viral vector-based approaches [<xref rid="B108-vaccines-13-00191" ref-type="bibr">108</xref>]. In addition, tobacco plants are fast-growing and not part of the food chain for human consumption, thus, lessening the possibility of contamination of edible crops with recombinant proteins. On the other side, the use of tobacco in vaccine production calls for thorough purification since it contains alkaloids and other contaminants that may interfere with the final product [<xref rid="B109-vaccines-13-00191" ref-type="bibr">109</xref>].</p><p>Lettuce (<italic toggle="yes">Lactuca sativa</italic>) has been the focus of research as a host for edible vaccines [<xref rid="B110-vaccines-13-00191" ref-type="bibr">110</xref>]. Its leaves are edible in the raw state, thus, serving as a good candidate for the oral delivery of antigens with minimum processing [<xref rid="B111-vaccines-13-00191" ref-type="bibr">111</xref>]. Antigens against diseases such as hepatitis B and norovirus have been expressed in lettuce [<xref rid="B112-vaccines-13-00191" ref-type="bibr">112</xref>]. However, there is always a problem in obtaining consistent levels of protein expression in lettuce, and there is always a possibility of degradation of the antigens in the gut [<xref rid="B113-vaccines-13-00191" ref-type="bibr">113</xref>].</p><p>Tomatoes (<italic toggle="yes">Solanum lycopersicum</italic>) have also been explored for edible vaccine production [<xref rid="B114-vaccines-13-00191" ref-type="bibr">114</xref>]. Widespread cultivation, ease of transformation, and ability to accumulate high levels of recombinant proteins in the fruit make tomatoes convenient as hosts [<xref rid="B115-vaccines-13-00191" ref-type="bibr">115</xref>]. The antigens expressed in tomatoes are able to be stored in either a desiccated or powdered form for longer periods of time because of improved stability and utility [<xref rid="B116-vaccines-13-00191" ref-type="bibr">116</xref>]. The productivity of tomatoes is relatively low compared to tobacco, and fluctuating expression levels of transgene between batches of fruit limit large-scale industrial application [<xref rid="B117-vaccines-13-00191" ref-type="bibr">117</xref>,<xref rid="B118-vaccines-13-00191" ref-type="bibr">118</xref>].</p><p>Maize (<italic toggle="yes">Zea mays</italic>) is one of the most widely used cereal crops and has great potential for molecular farming, especially for stable transformation and large-scale production of therapeutic proteins and vaccines [<xref rid="B119-vaccines-13-00191" ref-type="bibr">119</xref>]. Maize seeds provide natural encapsulation, which protects the recombinant proteins from environmental degradation and gastrointestinal enzymes, thus, being suitable for oral delivery [<xref rid="B120-vaccines-13-00191" ref-type="bibr">120</xref>]. The scalability of maize cultivation and its compatibility with the existing agricultural infrastructure make it attractive for cost-effective production. However, the other major drawbacks include gene flow to wild relatives and food crops, besides the relatively slower transformation process [<xref rid="B121-vaccines-13-00191" ref-type="bibr">121</xref>].</p></sec><sec id="sec3dot2dot2-vaccines-13-00191"><title>3.2.2. Comparative Analysis of Plant-Based Systems with Other Expression Platforms</title><p>Plant expression systems benefit and are limited compared to animal, fungal, and bacterial systems.</p><p>Compared to bacteria (e.g., <italic toggle="yes">E. coli</italic>), which are good at producing simple proteins, plants are better at producing complex proteins with proper folding and post-translational modifications, e.g., glycosylation [<xref rid="B122-vaccines-13-00191" ref-type="bibr">122</xref>]. Plants provide glycosylation patterns closer to human systems than yeast or fungi and are, therefore, better suited for biopharmaceuticals like antibodies. Plants generally take longer production times compared to microbial systems, which can be rapidly scaled up for the production of less complex proteins.</p><p>Fungal systems, for example, Pichia pastoris, combine high rates of growth with eukaryotic-like protein processing but yield hypermannosylated glycoproteins preferentially, which can cause immunogenicity in human beings [<xref rid="B123-vaccines-13-00191" ref-type="bibr">123</xref>]. Plants occupy this niche by providing a compromise between cost, scalability, and human-compatible glycosylation. Despite these benefits, plant systems are also characterized by low protein titers and longer expression times compared to microbial and fungal systems.</p><p>Animal systems, including mammalian cell cultures, are the preferred choice for high-value biopharmaceuticals due to the potential to offer human-like post-translational modifications [<xref rid="B124-vaccines-13-00191" ref-type="bibr">124</xref>]. These systems are expensive, require sophisticated bioreactor facilities, and are also prone to contamination with human pathogens. Plants offer the safer, less expensive option with reduced risk of contamination and the potential for open field or closed system scale-up.</p></sec></sec></sec><sec id="sec4-vaccines-13-00191"><title>4. Applications of Plant-Based Vaccines</title><sec id="sec4dot1-vaccines-13-00191"><title>4.1. Infectious Diseases</title><p>Plant-based vaccines have had quite a few successes in fighting infectious diseases, including COVID-19, influenza, hepatitis B, and malaria. During the COVID-19 pandemic, Covifenz used plants of <italic toggle="yes">N. benthamiana</italic> to produce VLPs with a striking similarity to the SARS-CoV-2 spike protein [<xref rid="B125-vaccines-13-00191" ref-type="bibr">125</xref>]. Similarly, plant-produced influenza vaccines have shown good immunogenicity [<xref rid="B126-vaccines-13-00191" ref-type="bibr">126</xref>]; hemagglutinin antigens and VLPs expressed in tobacco plants are now in advanced clinical trials [<xref rid="B127-vaccines-13-00191" ref-type="bibr">127</xref>].</p><p>Early hepatitis B research focused on the expression of the surface antigen (HBsAg) in transgenic plants such as tobacco and potatoes, showing great promise as an alternative to traditional vaccines [<xref rid="B128-vaccines-13-00191" ref-type="bibr">128</xref>,<xref rid="B129-vaccines-13-00191" ref-type="bibr">129</xref>]. In present-day research, plant-based research into hepatitis B vaccines has moved beyond the initial focus on HBsAg. In fact, several efforts are going in the direction of a greater emphasis on recombinant VLPs and other immunogenic proteins for higher vaccine efficacy [<xref rid="B129-vaccines-13-00191" ref-type="bibr">129</xref>,<xref rid="B130-vaccines-13-00191" ref-type="bibr">130</xref>].</p><p>A promising malaria transmission-blocking vaccine (TBV) was developed using VLPs produced in N. benthamiana via a TMV-based &#x02018;launch&#x02019; vector. The vaccine targets Plasmodium falciparum Pfs25, a key protein on gametes, zygotes, and ookinetes. Jones, R.M. et al. engineered hybrid VLPs (Pfs25-CP VLPs) by fusing Pfs25 to the Alfalfa mosaic virus coat protein (CP), achieving 20&#x02013;30% Pfs25 incorporation on VLP surfaces. Mice immunized with Pfs25-CP VLPs plus Alhydrogel<sup>&#x000ae;</sup> developed strong, sustained antibodies with complete transmission-blocking activity for six months. This study demonstrates the potential of plant-based VLP vaccines for malaria control [<xref rid="B28-vaccines-13-00191" ref-type="bibr">28</xref>] (<xref rid="vaccines-13-00191-f001" ref-type="fig">Figure 1</xref>).</p><p>Vaccination against infectious diseases continues to be the central point of vaccine manufacturing, including vaccines produced in plants that are cost-effective, scalable, and safe alternatives to conventional vaccine systems [<xref rid="B131-vaccines-13-00191" ref-type="bibr">131</xref>]. Plants are biofactories where recombinant antigens are expressed in the form of VLPs, subunit vaccines, and monoclonal antibodies that confer protective immunity [<xref rid="B42-vaccines-13-00191" ref-type="bibr">42</xref>]. Some vaccines based on plants have shown encouraging preclinical and clinical outcomes, mainly for viral and bacterial pathogens. The advantages of plant-based vaccines include rapid production, potential for oral administration, and reduced chances of contamination with human or animal pathogens. The subsequent table gives an overview of significant examples of plant-based vaccine candidates (<xref rid="vaccines-13-00191-t001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec4dot2-vaccines-13-00191"><title>4.2. Edible Vaccines</title><p>Edible vaccines, produced using plant-based systems, represent a promising innovation for low-resource settings where the traditional infrastructure for vaccine production and distribution has been insufficient [<xref rid="B139-vaccines-13-00191" ref-type="bibr">139</xref>]. Plants like bananas, tomatoes, potatoes, and lettuce have been engineered to produce antigens from pathogens [<xref rid="B35-vaccines-13-00191" ref-type="bibr">35</xref>] (<xref rid="vaccines-13-00191-f002" ref-type="fig">Figure 2</xref>).</p><p>Edible vaccines, however, have a number of disadvantages. One of the big challenges in using plants to produce vaccines is the inconsistent level of antigen expression, as variable growing conditions can affect protein yield [<xref rid="B140-vaccines-13-00191" ref-type="bibr">140</xref>]. Furthermore, it is difficult to deliver a precise dose of antigen because of variability in the size and composition of the edible plant material [<xref rid="B141-vaccines-13-00191" ref-type="bibr">141</xref>]. The stability of antigens during storage and transit, and their degradation in the human digestive system, are other important issues that need to be overcome. Other strategies being considered to improve efficacy and stability involve freeze-drying plant material or encapsulating antigens to protect them from being destroyed by the stomach&#x02019;s digestive enzymes [<xref rid="B142-vaccines-13-00191" ref-type="bibr">142</xref>,<xref rid="B143-vaccines-13-00191" ref-type="bibr">143</xref>].</p><p>The success of edible vaccines depends on the delivery mechanism. Direct consumption of raw edible plants contributes to improved stability of the antigens, and the mechanism provides a controlled dosage in processed forms such as powders and capsules. Such mechanisms are very challenging for edible vaccines, but this is one clear area where efforts should focus on plant-based vaccine research related to diseases most affecting underserved populations.</p></sec><sec id="sec4dot3-vaccines-13-00191"><title>4.3. Therapeutic Vaccines</title><p>Therapeutic plant vaccines utilize the immune system to cure disease either by stimulating immune responses against chronic infections like cancer and viral infections or by inducing immune tolerance against autoimmune diseases. In contrast to prophylactic vaccines, which immunize the immune system against infection, therapeutic vaccines introduce disease-specific antigens to the immune system to modulate immune function [<xref rid="B144-vaccines-13-00191" ref-type="bibr">144</xref>].</p><p>For cancer and chronic infections, plant-based vaccines that express tumor-associated antigens (TAAs) or pathogen proteins stimulate cytotoxic T lymphocytes (CTLs) to recognize and kill cancer cells [<xref rid="B98-vaccines-13-00191" ref-type="bibr">98</xref>,<xref rid="B145-vaccines-13-00191" ref-type="bibr">145</xref>,<xref rid="B146-vaccines-13-00191" ref-type="bibr">146</xref>]. Plant-derived vaccines, for instance, have been engineered to express antigens such as HER2, a protein overexpressed in breast cancer, or mucin-1, a glycoprotein frequently expressed in ovarian and breast cancer; such vaccines have shown potential in preclinical studies as immunotherapeutic agents for cancer treatment [<xref rid="B147-vaccines-13-00191" ref-type="bibr">147</xref>,<xref rid="B148-vaccines-13-00191" ref-type="bibr">148</xref>]. The work by McCormick et al. in their 2008 PNAS-published Phase I clinical trial of plant-produced therapeutic vaccines for non-Hodgkins lymphoma is another relevant instance [<xref rid="B149-vaccines-13-00191" ref-type="bibr">149</xref>]. This phase I clinical trial showed that plant-derived idiotype vaccines are feasible, safe, and immunogenic in patients with follicular B-cell non-Hodgkin&#x02019;s lymphoma. Using a viral expression system of plants, tumor-derived personalized single-chain antibodies were prepared from each individual patient in a relatively short time, thus, making individualized immunotherapy possible. Vaccines administered either without or with the GM-CSF adjuvant were well tolerated with no serious adverse events. Resultant immune responses for over 70% of patients included antigen-specific responses induced in 47%. Of great importance, different glycosylation of plant-produced antigens neither impeded the immunogenicity nor impinged on safety. These plant-based idiotype vaccines are placed among the hopeful and feasible options for lymphoma immune therapy.</p><p>For autoimmune diseases such as type 1 diabetes and multiple sclerosis, therapeutic plant-based vaccines induce tolerance by expressing self-antigens in a regulated manner [<xref rid="B150-vaccines-13-00191" ref-type="bibr">150</xref>,<xref rid="B151-vaccines-13-00191" ref-type="bibr">151</xref>]. By this mechanism, the immune system is reeducated and autoimmune responses leading to destruction are abrogated. Oral administration is especially advantageous in these situations since plant vaccines can be targeted against the gut-associated lymphoid tissue (GALT) to activate regulatory T cells (Tregs), the cells responsible for immune tolerance [<xref rid="B152-vaccines-13-00191" ref-type="bibr">152</xref>,<xref rid="B153-vaccines-13-00191" ref-type="bibr">153</xref>]. This strategy has been explored in allergy and inflammatory bowel disease, in which plant vaccines can modulate mucosal immunity and abolish inflammation and hypersensitivity reactions. Outside of infectious and immune diseases, plant vaccines are being developed for neurodegenerative and chronic disease states such as Alzheimer&#x02019;s and cardiovascular disease. Anti-amyloid-beta plaque vaccines have been developed in plants to elicit an immune response that would help eliminate plaques in Alzheimer&#x02019;s patients [<xref rid="B154-vaccines-13-00191" ref-type="bibr">154</xref>]. Therapeutic vaccines against cholesterol metabolism are also being researched to avert atherosclerosis and cardiovascular disease risk [<xref rid="B155-vaccines-13-00191" ref-type="bibr">155</xref>].</p><p>The use of plant-based vaccine development is expanding into chronic infectious diseases such as HIV and tuberculosis [<xref rid="B111-vaccines-13-00191" ref-type="bibr">111</xref>,<xref rid="B156-vaccines-13-00191" ref-type="bibr">156</xref>]. Plant-derived HIV vaccines frequently contain envelope glycoproteins or conserved viral epitopes that generate neutralizing antibodies and CTL responses, with the goal of reducing viral load and preventing disease progression [<xref rid="B157-vaccines-13-00191" ref-type="bibr">157</xref>]. Similarly, plant-based tuberculosis vaccines produce important Mycobacterium tuberculosis antigens, such as Ag85B or ESAT-6, to boost Th1 immune responses [<xref rid="B158-vaccines-13-00191" ref-type="bibr">158</xref>].</p><p>Immunotherapies using plants for chronic diseases are still in their infancy; however, the versatility of plant systems in producing diverse therapeutic proteins does hold much hope for future advances. These developments have emphasized the great potential of plant-based vaccinations for therapeutic purposes and marked a new generation of immunotherapy that is inexpensive and scalable for wide application in the treatment of cancer and chronic diseases (<xref rid="vaccines-13-00191-f003" ref-type="fig">Figure 3</xref>). This will open ways to produce, in plants, disease-specific antigens or modulatory proteins, for the generation of vaccines that will prevent infection, induce immune tolerance, or restore immune function in the case of chronic diseases.</p></sec><sec id="sec4dot4-vaccines-13-00191"><title>4.4. Veterinary Applications</title><p>Plant-based vaccines have tremendous potential in veterinary medicine and for the prevention of zoonotic diseases in humans [<xref rid="B159-vaccines-13-00191" ref-type="bibr">159</xref>,<xref rid="B160-vaccines-13-00191" ref-type="bibr">160</xref>]. Such vaccines could be engineered against specific animal pathogens like viruses, bacteria, and parasites [<xref rid="B161-vaccines-13-00191" ref-type="bibr">161</xref>,<xref rid="B162-vaccines-13-00191" ref-type="bibr">162</xref>,<xref rid="B163-vaccines-13-00191" ref-type="bibr">163</xref>,<xref rid="B164-vaccines-13-00191" ref-type="bibr">164</xref>]. Vaccines could also be more effectively delivered using plants. Indeed, there are great successes reported for protection against avian influenza in poultry, swine fever in pigs, and rabies in cattle with the administration of plant-derived vaccines. Scientists using these plant expression systems, particularly the <italic toggle="yes">N. benthamiana</italic> or <italic toggle="yes">N. tabacum</italic>, have produced immunogenic proteins such as VLPs or recombinant antigens that elicit strong immune responses in animals [<xref rid="B162-vaccines-13-00191" ref-type="bibr">162</xref>] (<xref rid="vaccines-13-00191-f004" ref-type="fig">Figure 4</xref>). Vaccines are scalable and inexpensive and can meet the increased demand for animal vaccines in developed and developing regions.</p><p>The &#x0201c;Global One Health&#x0201d; paradigm is a model of the interconnectedness of human, animal, and environmental health [<xref rid="B165-vaccines-13-00191" ref-type="bibr">165</xref>]. It puts the promotion of collaboration and interdisciplinarity into action to meet global health challenges such as animal-borne diseases, antimicrobial resistance, and emerging pandemics. This paradigm will be relevant to plant-based vaccines since it would be able to prevent diseases of humans and animals with sustainability and lower environmental impact. <xref rid="vaccines-13-00191-t002" ref-type="table">Table 2</xref> provides a summary of notable examples of plant-based vaccines that have been developed and applied in veterinary medicine, highlighting their potential in preventing various animal diseases.</p><p>When such infection in an animal is controlled through a plant-derived vaccine, that would mean a reduction in zoonotic outbreaks, which may have devastating effects on human health. Examples of such plant-based vaccines target diseases like <italic toggle="yes">E. coli</italic> and Foot-and-Mouth Disease, FMD, show promise for stopping the livestock-to-human transmission of these pathogens, where this is often the case between free-roaming livestock and people living in very close proximity to the livestock herds [<xref rid="B170-vaccines-13-00191" ref-type="bibr">170</xref>,<xref rid="B171-vaccines-13-00191" ref-type="bibr">171</xref>]. Additional benefits of the new vaccines involve delivery as part of edible plants, such as fruits or feed; this mode of administration eases delivery by obviating injections, often a barrier when veterinary infrastructure is rudimentary or missing [<xref rid="B172-vaccines-13-00191" ref-type="bibr">172</xref>].</p><p>The continued development of plant-based vaccine technology has great potential to improve global livestock health and prevent zoonotic disease transmission; hence, an innovative solution to modern agricultural challenges.</p></sec></sec><sec id="sec5-vaccines-13-00191"><title>5. Benefits of Plant-Based Vaccines</title><sec id="sec5dot1-vaccines-13-00191"><title>5.1. Cost-Effectiveness and Scalability</title><p>Economic feasibility and probable large-scale production, some of the most important advantages, make the plant-based vaccine very attractive in generating mass vaccines [<xref rid="B173-vaccines-13-00191" ref-type="bibr">173</xref>]. This will be considered with the traditional approach to vaccine production, which usually involves expensive bioreactors among other infrastructures. Plant expression systems take advantage of the plants to produce proteins relatively at a much lower cost [<xref rid="B174-vaccines-13-00191" ref-type="bibr">174</xref>]. Plant expression systems, represented by <italic toggle="yes">N. benthamiana</italic> and <italic toggle="yes">N. tabacum</italic>, on the other hand, require very minimal infrastructure and can be cultivated in the field or in greenhouses, hence lowering the cost of operations [<xref rid="B175-vaccines-13-00191" ref-type="bibr">175</xref>]. Besides the economic reasons above, plant-derived vaccines are highly scalable [<xref rid="B176-vaccines-13-00191" ref-type="bibr">176</xref>]. Plants being host species for vaccine candidates are grown at scale and in minimal consumption of resources; therefore, enabling an upscale rise in vaccine candidate production. Another very essential scalability factor would extend to the vaccine distribution part, in which cultivation can be performed locally to reduce transport costs and reduce dependency on cold-chain logistics, which happens to be one of the huge challenges in the traditional method of vaccine distribution [<xref rid="B177-vaccines-13-00191" ref-type="bibr">177</xref>]. Further, this also adds potential in edible vaccines as a factor of cost-effectiveness, in that vaccines are deliverable through food crops themselves, without needing complex delivery systems like injections.</p><p>Taken together, these advantages make plant-based vaccines an extremely cost-efficient and scalable alternative to supplement production for vaccines targeting both humans and animals.</p></sec><sec id="sec5dot2-vaccines-13-00191"><title>5.2. Rapid Response to Pandemics and Emerging Diseases</title><p>One of the most attractive benefits of plant-based vaccines is their potential to act with great speed in the face of pandemics and newly emerging diseases. Compared to traditional vaccine production, which can take a very long time, sometimes months or even years, to increase production due to reliance on mammalian cell cultures or avian eggs, plant-based systems offer a much faster turnaround [<xref rid="B178-vaccines-13-00191" ref-type="bibr">178</xref>].</p><p>Indoor production of plant-based vaccines offers the possibility of producing vaccines in a reproducible, easily scalable manner. Plants for the production of such vaccines can be grown under strictly controlled conditions of light, temperature, and humidity in greenhouses or so-called plant factories, ensuring reproducibility of yields besides minimizing risks with regard to contaminants by pests and pathogens. This setup has the added advantage of being able to produce year-round, independent of seasonal or geographical constraints, and meets biosafety needs through containment of genetically modified plants. Indoor systems enhance quality control and give homogeneous vaccine output, hence making regulation easier to comply with, especially in rapid responses to global health challenges.</p><p>Such rapid manufacturing capacity is of particular importance when outbreaks occur because of new or re-emerging infectious diseases and require timely intervention in order to halt further spread. Plant systems allow for fast reprogramming in the event of new pathogens, since they can be genetically engineered to develop antigens to recently isolated viruses or bacteria [<xref rid="B179-vaccines-13-00191" ref-type="bibr">179</xref>].</p></sec><sec id="sec5dot3-vaccines-13-00191"><title>5.3. Reduced Risk of Contamination with Human Pathogens</title><p>Perhaps most fundamentally, the development of vaccines within plants eliminates, almost by default, much risk of contamination from human pathogens [<xref rid="B180-vaccines-13-00191" ref-type="bibr">180</xref>]. Vaccine systems based on plant-based technologies offer a safer choice, since plants are naturally non-susceptible to the same human pathogens, therefore, significantly reducing the potential for contamination [<xref rid="B181-vaccines-13-00191" ref-type="bibr">181</xref>].</p><p>The use of plants to synthesize vaccines negates the need for materials like fetal bovine serum, derived from animals and typically used in more traditional cell culture systems. Such a system reduces the risks of zoonotic diseases (those which are transmitted between animals and humans) and satisfies other ethical concerns as it avoids using animals in the production process for biotechnology [<xref rid="B105-vaccines-13-00191" ref-type="bibr">105</xref>,<xref rid="B182-vaccines-13-00191" ref-type="bibr">182</xref>].</p><p>Also, plant-based systems are highly adaptable, enabling a rapid scale-up of production under controlled conditions. This ability to produce vaccines on a large scale while reducing the risk of contamination with human pathogens increases their suitability for global health programs [<xref rid="B183-vaccines-13-00191" ref-type="bibr">183</xref>].</p></sec><sec id="sec5dot4-vaccines-13-00191"><title>5.4. Environmental Sustainability and Low Carbon Footprint</title><p>Plant-based vaccines offer major environmental sustainability and a low carbon footprint [<xref rid="B184-vaccines-13-00191" ref-type="bibr">184</xref>]. The manufacturing process of vaccines traditionally would involve highly energy-, water-, and raw material-intensive methods, such as mammalian cell cultures or chicken eggs, hence very resource-intensive and contributory to greenhouse gas emissions. Plant systems are environmentally sustainable as they require fewer resources, such as water and energy, and generate minimal waste compared to traditional biomanufacturing systems.</p><p>Plants used for vaccine production, like <italic toggle="yes">N. benthamiana</italic> and <italic toggle="yes">N. tabacum</italic>, can be grown in different environments, either in the field or in greenhouses, with very minimal chemical inputs. Unlike the conventional animal-based systems, plants do not require large-scale infrastructure; hence, they minimize the need for energy-intensive facilities. Moreover, plant-based vaccine production can be localized, reducing transportation and associated carbon emissions, especially in remote or underserved regions [<xref rid="B185-vaccines-13-00191" ref-type="bibr">185</xref>].</p><p>Moreover, plant-based vaccines contribute to sustainability by dispensing with animal-derived materials like fetal bovine serum, normally used in vaccine production. For example, making this change lowers the environmental footprint associated with cattle rearing or animal husbandry, thus, again providing more justification for adopting the plant-based technologies of vaccine manufacture as the way forward for ecological reasons [<xref rid="B186-vaccines-13-00191" ref-type="bibr">186</xref>].</p><p>In short, the ecological sustainability and lower carbon emissions related to plant-derived vaccines represent a significant advantage in concordance with international initiatives focused on reducing the environmental impacts of biotechnological production and increasing the number of more sustainable options in healthcare.</p></sec></sec><sec id="sec6-vaccines-13-00191"><title>6. Challenges in Plant-Based Vaccine Development</title><sec id="sec6dot1-vaccines-13-00191"><title>6.1. Production Challenges</title><p>In addition to the issue of protein expression consistency, which is subject to variation depending on the plant host and/or growth conditions, low protein yields are one of the primary obstacles to the development of plant-based vaccines [<xref rid="B187-vaccines-13-00191" ref-type="bibr">187</xref>]. The specific challenges for transient expression plants are scalability and uniformity. Vaccine antigen production in plants would generally depend on factors such as plant species, growth environment, and specific methodologies of transformation utilized [<xref rid="B188-vaccines-13-00191" ref-type="bibr">188</xref>]. Such variability could, in turn, provide inconsistent yields of the target protein, hence not easy to standardize for the production and ensure the potency that vaccines normally would need. Unlike mammalian cell culture systems, where conditions can be tightly controlled, plant systems can be influenced by environmental factors such as temperature, light, and soil quality, all of which can affect protein expression levels [<xref rid="B189-vaccines-13-00191" ref-type="bibr">189</xref>,<xref rid="B190-vaccines-13-00191" ref-type="bibr">190</xref>].</p><p>In addition, it is a big challenge to produce high yields of the antigen of interest without metabolic imbalance specific to stably transformed plants [<xref rid="B191-vaccines-13-00191" ref-type="bibr">191</xref>]. Plants are complex organisms that have evolved for growth and reproduction, not for protein production; hence, directing a significant portion of their metabolic resources to produce foreign proteins can limit overall plant health and yield. Yield improvement methodologies, for example, the optimization of expression vectors or plant promoters that improve antigen expressions, have been developed though this is thought to yield in a high continuous matter [<xref rid="B192-vaccines-13-00191" ref-type="bibr">192</xref>].</p><p>The challenges regard the better methodology for the plant transformation, superior conditions of growing plants, more complete knowledge on primary metabolism of the plants for production assurances on higher and low-cost qualities.</p></sec><sec id="sec6dot2-vaccines-13-00191"><title>6.2. Downstream Processing</title><p>Downstream processing remains one of the major challenges in plant-based vaccine development, mainly because of the complexity and cost of protein purification and standardization [<xref rid="B193-vaccines-13-00191" ref-type="bibr">193</xref>]. Following the production of recombinant proteins in plants, the extraction and purification process is considered critical to ensure the quality, safety, and efficacy of the final vaccine product [<xref rid="B194-vaccines-13-00191" ref-type="bibr">194</xref>]. Most plant-derived proteins are part of complex plant matrices, and the target antigen has to be purified from other plant proteins, carbohydrates, and lipids, which can be very labor-intensive and expensive [<xref rid="B195-vaccines-13-00191" ref-type="bibr">195</xref>].</p><p>One of the major problems is heterogeneity in plant-produced proteins. Unlike mammalian systems, plant expression systems can produce a variety of glycoforms that may affect the antigen&#x02019;s function and immune response [<xref rid="B196-vaccines-13-00191" ref-type="bibr">196</xref>]. Achieving consistent glycosylation and folding of proteins in plant-based vaccines is challenging due to variability in plant growing circumstances and genetic backgrounds, which can result in batch-to-batch inconsistencies [<xref rid="B197-vaccines-13-00191" ref-type="bibr">197</xref>,<xref rid="B198-vaccines-13-00191" ref-type="bibr">198</xref>]. The standardization of plant-derived vaccines is challenging, necessitating comprehensive optimization of the purifying process and meticulous oversight of protein quality [<xref rid="B199-vaccines-13-00191" ref-type="bibr">199</xref>].</p></sec><sec id="sec6dot3-vaccines-13-00191"><title>6.3. Regulatory Hurdles</title><p>Perhaps the most significant challenge in the development of plant-based vaccines is regulatory hurdles brought about by the present frameworks and their limitations to approve plant-derived biopharmaceuticals [<xref rid="B200-vaccines-13-00191" ref-type="bibr">200</xref>,<xref rid="B201-vaccines-13-00191" ref-type="bibr">201</xref>]. Since regulatory agencies, such as FDA and EMA, are set up based on conventional vaccines from animal or microbial systems, it becomes difficult for plant-based vaccines to meet some of the set standards in terms of safety and efficiency [<xref rid="B202-vaccines-13-00191" ref-type="bibr">202</xref>]. This novelty in the vaccine production sector using genetically engineered plants challenges the regulatory process because there are no standardized protocols that assess the safety of transgenic plants for environmental impact, allergenicity, and other unforeseen effects [<xref rid="B203-vaccines-13-00191" ref-type="bibr">203</xref>,<xref rid="B204-vaccines-13-00191" ref-type="bibr">204</xref>].</p><p>One of the key concerns is the approval of genetically modified organisms (GMOs), as many plant-based vaccines are produced using transgenic plants [<xref rid="B205-vaccines-13-00191" ref-type="bibr">205</xref>]. The regulatory authorities have strict policies for the release and consumption of GMOs, and every new product is put to rigorous testing to be declared safe for use. Most of the vaccines produced using plants take a long time before hitting the market due to a time-consuming and costly process of going through regulatory approval [<xref rid="B206-vaccines-13-00191" ref-type="bibr">206</xref>].</p></sec><sec id="sec6dot4-vaccines-13-00191"><title>6.4. Public Acceptance</title><p>Public acceptance still is one of the most important challenges for the development and wide diffusion of plant-based vaccines, mainly because of ethical concerns and societal misconceptions about genetically modified plants [<xref rid="B207-vaccines-13-00191" ref-type="bibr">207</xref>]. Misconceptions at the social level about GMOs also play a role in skepticism towards vaccines made from plants. The public&#x02019;s general view on GMOs is normally misguided by misinformation, fear of unnatural food sources, and an inability to draw a line between genetically modified food and biopharmaceutical products [<xref rid="B208-vaccines-13-00191" ref-type="bibr">208</xref>]. Public awareness of the safety, benefits, and ethical issues of plant-based vaccines is a prerequisite for these challenges to be met [<xref rid="B209-vaccines-13-00191" ref-type="bibr">209</xref>]. The transparent communication, education, and scientific outreach engaged in will dispel myths and foster a better-informed public discourse on the potential of plant-based vaccines to contribute to global health improvement.</p></sec></sec><sec id="sec7-vaccines-13-00191"><title>7. Recent Innovations in Molecular Farming</title><p>Recent innovations in molecular farming are revolutionizing the plant-based vaccine development landscape and offering new avenues for the improvement of production systems [<xref rid="B210-vaccines-13-00191" ref-type="bibr">210</xref>]. Gene editing, nanoparticle-based delivery systems, and artificial intelligence represent some of the more significant recent advances that accelerate progress in the optimal development of plant expression systems and improvement of vaccine efficacy.</p><sec id="sec7dot1-vaccines-13-00191"><title>7.1. Advances in Gene Editing (e.g., CRISPR) for Optimizing Plant Systems</title><p>The development of gene editing tools, especially CRISPR-Cas9, has greatly improved this method by allowing for the precise introduction of changes into plant genomes [<xref rid="B211-vaccines-13-00191" ref-type="bibr">211</xref>]. This has led to advances in the reliability of plant recombinant protein production [<xref rid="B212-vaccines-13-00191" ref-type="bibr">212</xref>,<xref rid="B213-vaccines-13-00191" ref-type="bibr">213</xref>]. CRISPR technology allows the editing of plant DNA at very specific points, hence allowing optimization of particular traits relevant to protein production, such as yield, stability, and glycosylation profiles [<xref rid="B214-vaccines-13-00191" ref-type="bibr">214</xref>]. The application of CRISPR to plant genomes can achieve high and more consistent yields of vaccine antigens from plants&#x02014;a problem that has long been haunting plant-based production platforms [<xref rid="B215-vaccines-13-00191" ref-type="bibr">215</xref>]. Additionally, this powerful gene editor is capable of ridding transgenic plants of unwanted characteristics, including allergenicity and immunogenicity, increasing safety and efficacy in plant-derived vaccines [<xref rid="B216-vaccines-13-00191" ref-type="bibr">216</xref>].</p><p>These exact modifications not only enhance the yield and quality but also the time period taken in order to genetically modify plants. This will include CRISPR application to optimize plant promoters that drive antigen expression and, thus, enable the production of proteins efficiently in plant tissues such as leaves, stems, and roots [<xref rid="B217-vaccines-13-00191" ref-type="bibr">217</xref>].</p></sec><sec id="sec7dot2-vaccines-13-00191"><title>7.2. Development of Nanoparticle-Based Delivery Systems</title><p>Nanoparticle-based delivery systems have emerged as a promising strategy for enhancing the efficacy of vaccines, including plant-based vaccines, by improving antigen stability, bioavailability, and targeted delivery. These nanoparticles, such as lipid, polymeric, and inorganic nanoparticles, protect vaccine antigens from degradation and enable controlled release for a sustained immune response [<xref rid="B218-vaccines-13-00191" ref-type="bibr">218</xref>] (<xref rid="vaccines-13-00191-f005" ref-type="fig">Figure 5</xref>). In plant-based vaccines, nanoparticle carriers can facilitate oral or mucosal administration, making vaccination more efficient, non-invasive, and cost-effective.</p><p>Probably the most promising strategy is the utilization of non-infectious-derived VLPs from plant systems with a structure like a virus [<xref rid="B219-vaccines-13-00191" ref-type="bibr">219</xref>,<xref rid="B220-vaccines-13-00191" ref-type="bibr">220</xref>,<xref rid="B221-vaccines-13-00191" ref-type="bibr">221</xref>,<xref rid="B222-vaccines-13-00191" ref-type="bibr">222</xref>]. These can be engineered to display specific antigens and often serve as potent vaccines in vivo. This delivery method has been shown to improve the immune response by providing a more stable, targeted release of the vaccine into the body [<xref rid="B29-vaccines-13-00191" ref-type="bibr">29</xref>,<xref rid="B223-vaccines-13-00191" ref-type="bibr">223</xref>,<xref rid="B224-vaccines-13-00191" ref-type="bibr">224</xref>].</p><p>Other key approaches under consideration in the development of plant-based vaccines are nanoparticle-based delivery systems [<xref rid="B225-vaccines-13-00191" ref-type="bibr">225</xref>,<xref rid="B226-vaccines-13-00191" ref-type="bibr">226</xref>]. Most of the approaches use nanoparticles that encapsulate vaccine antigens, hence delivering them more efficiently and in a controlled manner inside the host cells [<xref rid="B46-vaccines-13-00191" ref-type="bibr">46</xref>,<xref rid="B227-vaccines-13-00191" ref-type="bibr">227</xref>,<xref rid="B228-vaccines-13-00191" ref-type="bibr">228</xref>]. Nanoparticles, such as lipid nanoparticles, gold nanoparticles, and chitosan nanoparticles, are combined with plant-derived proteins for enhanced bioavailability and stability of vaccines [<xref rid="B229-vaccines-13-00191" ref-type="bibr">229</xref>]. These nanoparticles can also protect the vaccine antigens from degradation to reach the target site in the body without deterioration [<xref rid="B230-vaccines-13-00191" ref-type="bibr">230</xref>]. Such systems may also enable edible vaccines whereby the antigen is encapsulated within a nanoparticle carrier in the plant tissue. This can allow for oral vaccine administration, thereby making vaccine administration non-invasive and less costly than conventional methods.</p></sec><sec id="sec7dot3-vaccines-13-00191"><title>7.3. Integration of Artificial Intelligence in Plant Biotechnology</title><p>Artificial intelligence (AI) is a very recent and important tool for plant biotechnology, especially in optimizing plant-based vaccine production systems [<xref rid="B231-vaccines-13-00191" ref-type="bibr">231</xref>,<xref rid="B232-vaccines-13-00191" ref-type="bibr">232</xref>]. AI-powered algorithms, on the other hand, examine genomic data, protein structure, and conditions for growth to select an optimum combination that maximizes antigen expression by way of genetic modifications along with changes in environmental conditions [<xref rid="B233-vaccines-13-00191" ref-type="bibr">233</xref>]. Furthermore, using machine learning and deep learning methods, AI hastens the development process from design and testing to improvement in plant transformation systems [<xref rid="B234-vaccines-13-00191" ref-type="bibr">234</xref>]. The experimental data would also automatically analyze using such emerging technologies and consequently accelerate new vaccine development quite fast [<xref rid="B235-vaccines-13-00191" ref-type="bibr">235</xref>].</p><p>AI finds its way into high-throughput screening systems, where it predicts how different plant types will react to genetic modifications [<xref rid="B236-vaccines-13-00191" ref-type="bibr">236</xref>]. In this way, the best-performing plant lines can be selected quickly, reducing trial-and-error work. AI can also optimize growth conditions such as light intensity, temperature, and nutrient availability to make sure that the plants are at peak productivity during the production of vaccine antigens [<xref rid="B237-vaccines-13-00191" ref-type="bibr">237</xref>]. Besides accelerating research and development, AI can also point out the probable safety risks through the analysis of large datasets about biological interactions for the intended and unintended consequences of genetic modification [<xref rid="B238-vaccines-13-00191" ref-type="bibr">238</xref>]. This would help a great deal in ensuring better safety standards and hastening the regulatory process for approval in respect of plant-based vaccines.</p><p>Recent gene-editing innovations, nanoparticle-based delivery, and artificial intelligence have made immense improvements to the possibility of molecular farming in the manufacture of plant-based vaccines [<xref rid="B239-vaccines-13-00191" ref-type="bibr">239</xref>]. This would improve yield and consistency, with even safer production and more effective delivery.</p></sec></sec><sec id="sec8-vaccines-13-00191"><title>8. Future Directions</title><sec id="sec8dot1-vaccines-13-00191"><title>8.1. Exploration of Personalized Vaccines Through Molecular Farming</title><p>Personalized medicine has been the catch-all phrase among all vaccine stakeholders, and plant-based vaccine technologies are unique in place to contribute to this emerging discipline [<xref rid="B240-vaccines-13-00191" ref-type="bibr">240</xref>]. Personalized vaccines take into consideration the genetic constitution, susceptibility to disease, and immune response profile at an individual level for vaccination strategies [<xref rid="B241-vaccines-13-00191" ref-type="bibr">241</xref>]. To sum up, molecular farming is the most viable platform to produce such products with a production capacity in the manufacture of recombinant protein and antigen production in plants. Using such a technique, the antigens can be genetically engineered to produce specific needs a patient may present. For instance, plants can produce anti-cancer vaccines that can attack tumor-specific antigens peculiar to a person&#x02019;s cancerous cells [<xref rid="B242-vaccines-13-00191" ref-type="bibr">242</xref>]. Being an approach that would give an opportunity to rapidly produce customized vaccine candidates, it caters to the precision required in treatments such as cancer vaccines. Indeed, a recent study also investigated plant-based vaccines for oral delivery of type 1 diabetes-related autoantigens by evaluating oral tolerance mechanisms and disease prevention in a non-obese diabetic (NOD) mouse model [<xref rid="B243-vaccines-13-00191" ref-type="bibr">243</xref>]. Furthermore, plant-based platforms offer a cost-effective and scalable manufacturing method for these tailored vaccines in combination with more recent advanced technologies involving CRISPR gene editing and accompanying bioinformatic tools to analyze genetic data. This could significantly lower the cost of production and make personalized immunotherapy a globally applicable approach.</p></sec><sec id="sec8dot2-vaccines-13-00191"><title>8.2. Synergistic Approaches: Combining Plant-Based Vaccines with Nanotechnology and Other Platforms</title><p>With the help of nanoparticles, plant-based vaccines can also serve as carriers to enhance the immunogenicity of antigens derived from plants [<xref rid="B216-vaccines-13-00191" ref-type="bibr">216</xref>]. For example, nanoparticle formulation can envelope plant-produced VLPs for better mimicry of the pathogen structure, thus, inducing an improved immune response [<xref rid="B244-vaccines-13-00191" ref-type="bibr">244</xref>,<xref rid="B245-vaccines-13-00191" ref-type="bibr">245</xref>]. Nanoparticles in vaccine formulation enhance vaccine stability, protect antigens from environmental degradation, and increase shelf-life without refrigeration.</p><p>Further synergy may be obtained by combining plant-based vaccines with other platforms, such as mRNA vaccines. For example, plant systems could serve in the biomanufacturing of mRNA vaccines by synthesizing viral proteins in plants, which afterward can be utilized for the production of mRNA, already embedded in the vaccine formulations [<xref rid="B246-vaccines-13-00191" ref-type="bibr">246</xref>].</p></sec><sec id="sec8dot3-vaccines-13-00191"><title>8.3. Expanding Applications Beyond Human Vaccines</title><p>Most plant vaccines are under development therapeutics and diagnostic tools are on the rise. Plant platforms are also tested for their possible use in therapeutic vaccines, especially against cancer and other chronic diseases. These vaccines trigger the immune response to attack cancer cells or the agent causing a disease. Chronic diseases such as HIV/AIDS and autoimmune diseases could also benefit from plant-based immunotherapies, where the plant platform can be used to deliver specific immune-modulating agents [<xref rid="B156-vaccines-13-00191" ref-type="bibr">156</xref>,<xref rid="B247-vaccines-13-00191" ref-type="bibr">247</xref>]. Furthermore, plant-based systems are being studied as platforms for diagnostics, e.g., plants can be designed to produce antibody-like proteins for diagnosis of infectious diseases, serving as a diagnostic tool far simpler and cheaper than the diagnostics themselves [<xref rid="B248-vaccines-13-00191" ref-type="bibr">248</xref>,<xref rid="B249-vaccines-13-00191" ref-type="bibr">249</xref>].</p></sec><sec id="sec8dot4-vaccines-13-00191"><title>8.4. Addressing Global Health Inequities and Pandemic Preparedness</title><p>Plant vaccines hold great promise, especially in attempting to bridge gaps in health inequities on a global scale and preparing better against pandemic outbreaks [<xref rid="B250-vaccines-13-00191" ref-type="bibr">250</xref>,<xref rid="B251-vaccines-13-00191" ref-type="bibr">251</xref>]. Scalability in the production of plant-based vaccine systems also ensures rapid deployment even in the low-resource environment where it would be far more challenging for the scaling-up process using the conventional vaccine production platforms [<xref rid="B252-vaccines-13-00191" ref-type="bibr">252</xref>]. Royal et al. investigated a SARS-CoV-2 vaccine candidate using plant-based manufacturing and tobacco mosaic virus-like nanoparticles [<xref rid="B253-vaccines-13-00191" ref-type="bibr">253</xref>]. This study illustrates that by combining the SARS-CoV-2 receptor-binding domain with a tobacco mosaic virus nanoparticle, the CoV-RBD121-NP vaccine has high ACE2 binding, neutralizing antibody recognition, and 12-month stability. This finding suggest a stable and scalable COVID-19 vaccination.</p></sec></sec><sec sec-type="conclusions" id="sec9-vaccines-13-00191"><title>9. Conclusions</title><p>Plant-based vaccines have the potential to revolutionize the face of immunization by offering an affordable, scalable, and ecologically friendly alternative to traditional methods of vaccine production. The vaccines can be produced in a very short time, hence reducing the time taken to respond to emerging infectious diseases and pandemics, as was realized during the rapid development of Medicago&#x02019;s Covifenz for COVID-19. The capacity for vaccine production in plants has great potential to level the playing field with regard to global health disparities by providing affordable immunization options, especially in resource-poor settings where traditional vaccine production infrastructure may not exist. Since then, plant-based systems have expanded well beyond human vaccines to include applications in veterinary medicine, cancer immunotherapy, and diagnostic methods. Molecular farming for personalized vaccines, added to other developments such as nanotechnology and artificial intelligence, will further expand the boundaries of what has been believed possible in immunization strategies to make vaccines even more personalized, efficient, and accessible. The complete exploitation of plant-based vaccines does, however, require the overcoming of some restrictions present nowadays. Those inhibit its application, including low yields of protein, challenges in downstream processing, and regulatory problems related to the use of genetically modified organisms. Some of those hurdles have been conquered with continued innovation in plant biotechnology hand in hand with research institutions, regulatory organizations, and the pharmaceutical industry. With these obstacles finally overcome, plant-based vaccines have provided groundbreaking responses for global health in a sustainable and scalable platform that could meet the world&#x02019;s needs in the battle against infectious diseases.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, D.-K.V. and K.T.L.T.; methodology, D.-K.V.; formal analysis, D.-K.V. and K.T.L.T.; data curation, D.-K.V.; writing&#x02014;original draft preparation, D.-K.V.; writing&#x02014;review and editing, K.T.L.T.; visualization, D.-K.V. and K.T.L.T.; supervision, K.T.L.T. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00191"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Forni</surname><given-names>G.</given-names></name>
<name><surname>Mantovani</surname><given-names>A.</given-names></name>
<name><surname>Forni</surname><given-names>G.</given-names></name>
<name><surname>Mantovani</surname><given-names>A.</given-names></name>
<name><surname>Moretta</surname><given-names>L.</given-names></name>
<name><surname>Rappuoli</surname><given-names>R.</given-names></name>
<name><surname>Rezza</surname><given-names>G.</given-names></name>
<name><surname>Bagnasco</surname><given-names>A.</given-names></name>
<name><surname>Barsacchi</surname><given-names>G.</given-names></name>
<name><surname>Bussolati</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 vaccines: Where we stand and challenges ahead</article-title><source>Cell Death Differ.</source><year>2021</year><volume>28</volume><fpage>626</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1038/s41418-020-00720-9</pub-id><pub-id pub-id-type="pmid">33479399</pub-id>
</element-citation></ref><ref id="B2-vaccines-13-00191"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Excler</surname><given-names>J.-L.</given-names></name>
<name><surname>Saville</surname><given-names>M.</given-names></name>
<name><surname>Berkley</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Vaccine development for emerging infectious diseases</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>591</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01301-0</pub-id><pub-id pub-id-type="pmid">33846611</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00191"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feldman</surname><given-names>A.G.</given-names></name>
<name><surname>O&#x02019;Leary</surname><given-names>S.T.</given-names></name>
<name><surname>Danziger-Isakov</surname><given-names>L.</given-names></name>
</person-group><article-title>The Risk of Resurgence in Vaccine-Preventable Infections Due to Coronavirus Disease 2019&#x02014;Related Gaps in Immunization</article-title><source>Clin. Infect. Dis.</source><year>2021</year><volume>73</volume><fpage>1920</fpage><lpage>1923</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab127</pub-id><pub-id pub-id-type="pmid">33580243</pub-id>
</element-citation></ref><ref id="B4-vaccines-13-00191"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Monrad</surname><given-names>J.T.</given-names></name>
<name><surname>Sandbrink</surname><given-names>J.B.</given-names></name>
<name><surname>Cherian</surname><given-names>N.G.</given-names></name>
</person-group><article-title>Promoting versatile vaccine development for emerging pandemics</article-title><source>npj Vaccines</source><year>2021</year><volume>6</volume><fpage>26</fpage><pub-id pub-id-type="doi">10.1038/s41541-021-00290-y</pub-id><pub-id pub-id-type="pmid">33574335</pub-id>
</element-citation></ref><ref id="B5-vaccines-13-00191"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pulendran</surname><given-names>B.</given-names></name>
<name><surname>Arunachalam</surname><given-names>P.S.</given-names></name>
<name><surname>O&#x02019;Hagan</surname><given-names>D.T.</given-names></name>
</person-group><article-title>Emerging concepts in the science of vaccine adjuvants</article-title><source>Nat. Rev. Drug Discov.</source><year>2021</year><volume>20</volume><fpage>454</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00163-y</pub-id><pub-id pub-id-type="pmid">33824489</pub-id>
</element-citation></ref><ref id="B6-vaccines-13-00191"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Xia</surname><given-names>H.</given-names></name>
<name><surname>Zou</surname><given-names>J.</given-names></name>
<name><surname>Muruato</surname><given-names>A.E.</given-names></name>
<name><surname>Periasamy</surname><given-names>S.</given-names></name>
<name><surname>Kurhade</surname><given-names>C.</given-names></name>
<name><surname>Plante</surname><given-names>J.A.</given-names></name>
<name><surname>Bopp</surname><given-names>N.E.</given-names></name>
<etal/>
</person-group><article-title>A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>4337</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-31930-z</pub-id><pub-id pub-id-type="pmid">35896528</pub-id>
</element-citation></ref><ref id="B7-vaccines-13-00191"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arunachalam</surname><given-names>P.S.</given-names></name>
<name><surname>Walls</surname><given-names>A.C.</given-names></name>
<name><surname>Golden</surname><given-names>N.</given-names></name>
<name><surname>Atyeo</surname><given-names>C.</given-names></name>
<name><surname>Fischinger</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Aye</surname><given-names>P.</given-names></name>
<name><surname>Navarro</surname><given-names>M.J.</given-names></name>
<name><surname>Lai</surname><given-names>L.</given-names></name>
<name><surname>Edara</surname><given-names>V.V.</given-names></name>
<etal/>
</person-group><article-title>Adjuvanting a subunit COVID-19 vaccine to induce protective immunity</article-title><source>Nature</source><year>2021</year><volume>594</volume><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03530-2</pub-id><pub-id pub-id-type="pmid">33873199</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00191"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Isaguliants</surname><given-names>M.</given-names></name>
<name><surname>Burt</surname><given-names>F.J.</given-names></name>
</person-group><article-title>Perspective Technologies of Vaccination: Do We Still Need Old Vaccines?</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>891</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10060891</pub-id><pub-id pub-id-type="pmid">35746498</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00191"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Okamura</surname><given-names>S.</given-names></name>
<name><surname>Ebina</surname><given-names>H.</given-names></name>
</person-group><article-title>Could live attenuated vaccines better control COVID-19?</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>5719</fpage><lpage>5726</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.08.018</pub-id><pub-id pub-id-type="pmid">34426024</pub-id>
</element-citation></ref><ref id="B10-vaccines-13-00191"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ulmer</surname><given-names>J.B.</given-names></name>
<name><surname>Valley</surname><given-names>U.</given-names></name>
<name><surname>Rappuoli</surname><given-names>R.</given-names></name>
</person-group><article-title>Vaccine manufacturing: Challenges and solutions</article-title><source>Nat. Biotechnol.</source><year>2006</year><volume>24</volume><fpage>1377</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1038/nbt1261</pub-id><pub-id pub-id-type="pmid">17093488</pub-id>
</element-citation></ref><ref id="B11-vaccines-13-00191"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fox</surname><given-names>A.</given-names></name>
</person-group><article-title>Market Failure, State Failure: The Political Economy of Supply Chain Strengthening to Ensure Equitable Access to Vaccines and Medicines in Low- and Middle-Income Countries</article-title><source>J. Health Polit. Policy Law</source><year>2024</year><volume>49</volume><fpage>43</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1215/03616878-10910242</pub-id><pub-id pub-id-type="pmid">37522368</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00191"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Glover</surname><given-names>R.E.</given-names></name>
<name><surname>van Schalkwyk</surname><given-names>M.C.I.</given-names></name>
<name><surname>Akl</surname><given-names>E.A.</given-names></name>
<name><surname>Kristjannson</surname><given-names>E.</given-names></name>
<name><surname>Lotfi</surname><given-names>T.</given-names></name>
<name><surname>Petkovic</surname><given-names>J.</given-names></name>
<name><surname>Petticrew</surname><given-names>M.P.</given-names></name>
<name><surname>Pottie</surname><given-names>K.</given-names></name>
<name><surname>Tugwell</surname><given-names>P.</given-names></name>
<name><surname>Welch</surname><given-names>V.</given-names></name>
</person-group><article-title>A framework for identifying and mitigating the equity harms of COVID-19 policy interventions</article-title><source>J. Clin. Epidemiol.</source><year>2020</year><volume>128</volume><fpage>35</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2020.06.004</pub-id><pub-id pub-id-type="pmid">32526461</pub-id>
</element-citation></ref><ref id="B13-vaccines-13-00191"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van De Pas</surname><given-names>R.</given-names></name>
<name><surname>Widdowson</surname><given-names>M.-A.</given-names></name>
<name><surname>Ravinetto</surname><given-names>R.</given-names></name>
<name><surname>N Srinivas</surname><given-names>P.</given-names></name>
<name><surname>Ochoa</surname><given-names>T.J.</given-names></name>
<name><surname>Fofana</surname><given-names>T.O.</given-names></name>
<name><surname>Van Damme</surname><given-names>W.</given-names></name>
</person-group><article-title>COVID-19 vaccine equity: A health systems and policy perspective</article-title><source>Expert Rev. Vaccines</source><year>2022</year><volume>21</volume><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1080/14760584.2022.2004125</pub-id><pub-id pub-id-type="pmid">34758678</pub-id>
</element-citation></ref><ref id="B14-vaccines-13-00191"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghattas</surname><given-names>M.</given-names></name>
<name><surname>Dwivedi</surname><given-names>G.</given-names></name>
<name><surname>Lavertu</surname><given-names>M.</given-names></name>
<name><surname>Alameh</surname><given-names>M.-G.</given-names></name>
</person-group><article-title>Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1490</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9121490</pub-id><pub-id pub-id-type="pmid">34960236</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00191"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wouters</surname><given-names>O.J.</given-names></name>
<name><surname>Shadlen</surname><given-names>K.C.</given-names></name>
<name><surname>Salcher-Konrad</surname><given-names>M.</given-names></name>
<name><surname>Pollard</surname><given-names>A.J.</given-names></name>
<name><surname>Larson</surname><given-names>H.J.</given-names></name>
<name><surname>Teerawattananon</surname><given-names>Y.</given-names></name>
<name><surname>Jit</surname><given-names>M.</given-names></name>
</person-group><article-title>Challenges in ensuring global access to COVID-19 vaccines: Production, affordability, allocation, and deployment</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>1023</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00306-8</pub-id><pub-id pub-id-type="pmid">33587887</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00191"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chung</surname><given-names>Y.H.</given-names></name>
<name><surname>Church</surname><given-names>D.</given-names></name>
<name><surname>Koellhoffer</surname><given-names>E.C.</given-names></name>
<name><surname>Osota</surname><given-names>E.</given-names></name>
<name><surname>Shukla</surname><given-names>S.</given-names></name>
<name><surname>Rybicki</surname><given-names>E.P.</given-names></name>
<name><surname>Pokorski</surname><given-names>J.K.</given-names></name>
<name><surname>Steinmetz</surname><given-names>N.F.</given-names></name>
</person-group><article-title>Integrating plant molecular farming and materials research for next-generation vaccines</article-title><source>Nat. Rev. Mater.</source><year>2022</year><volume>7</volume><fpage>372</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1038/s41578-021-00399-5</pub-id><pub-id pub-id-type="pmid">34900343</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00191"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shanmugaraj</surname><given-names>B.</given-names></name>
<name><surname>Bulaon</surname><given-names>C.J.I.</given-names></name>
<name><surname>Phoolcharoen</surname><given-names>W.</given-names></name>
</person-group><article-title>Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production</article-title><source>Plants</source><year>2020</year><volume>9</volume><elocation-id>842</elocation-id><pub-id pub-id-type="doi">10.3390/plants9070842</pub-id><pub-id pub-id-type="pmid">32635427</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00191"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bharathi</surname><given-names>J.K.</given-names></name>
<name><surname>Suresh</surname><given-names>P.</given-names></name>
<name><surname>Prakash</surname><given-names>M.A.S.</given-names></name>
<name><surname>Muneer</surname><given-names>S.</given-names></name>
</person-group><article-title>Exploring recent progress of molecular farming for therapeutic and recombinant molecules in plant systems</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e37634</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e37634</pub-id><pub-id pub-id-type="pmid">39309966</pub-id>
</element-citation></ref><ref id="B19-vaccines-13-00191"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>A.</given-names></name>
<name><surname>Rajput</surname><given-names>V.</given-names></name>
<name><surname>Singh</surname><given-names>A.K.</given-names></name>
<name><surname>Sengar</surname><given-names>R.S.</given-names></name>
<name><surname>Singh</surname><given-names>R.K.</given-names></name>
<name><surname>Minkina</surname><given-names>T.</given-names></name>
</person-group><article-title>Chapter 23&#x02014;Transformation Techniques and Their Role in Crop Improvements: A Global Scenario of GM Crops</article-title><source>Policy Issues in Genetically Modified Crops</source><person-group person-group-type="editor">
<name><surname>Singh</surname><given-names>P.</given-names></name>
<name><surname>Borthakur</surname><given-names>A.</given-names></name>
<name><surname>Singh</surname><given-names>A.A.</given-names></name>
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Singh</surname><given-names>K.K.</given-names></name>
</person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2021</year><fpage>515</fpage><lpage>542</lpage></element-citation></ref><ref id="B20-vaccines-13-00191"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schillberg</surname><given-names>S.</given-names></name>
<name><surname>Finnern</surname><given-names>R.</given-names></name>
</person-group><article-title>Plant molecular farming for the production of valuable proteins&#x02014;Critical evaluation of achievements and future challenges</article-title><source>J. Plant Physiol.</source><year>2021</year><volume>258&#x02013;259</volume><fpage>153359</fpage><pub-id pub-id-type="doi">10.1016/j.jplph.2020.153359</pub-id><pub-id pub-id-type="pmid">33460995</pub-id>
</element-citation></ref><ref id="B21-vaccines-13-00191"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eidenberger</surname><given-names>L.</given-names></name>
<name><surname>Kogelmann</surname><given-names>B.</given-names></name>
<name><surname>Steinkellner</surname><given-names>H.</given-names></name>
</person-group><article-title>Plant-based biopharmaceutical engineering</article-title><source>Nat. Rev. Bioeng.</source><year>2023</year><volume>1</volume><fpage>426</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1038/s44222-023-00044-6</pub-id><pub-id pub-id-type="pmid">37317690</pub-id>
</element-citation></ref><ref id="B22-vaccines-13-00191"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cardi</surname><given-names>T.</given-names></name>
<name><surname>Lenzi</surname><given-names>P.</given-names></name>
<name><surname>Maliga</surname><given-names>P.</given-names></name>
</person-group><article-title>Chloroplasts as expression platforms for plant-produced vaccines</article-title><source>Expert Rev. Vaccines</source><year>2010</year><volume>9</volume><fpage>893</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1586/erv.10.78</pub-id><pub-id pub-id-type="pmid">20673012</pub-id>
</element-citation></ref><ref id="B23-vaccines-13-00191"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Komarova</surname><given-names>T.V.</given-names></name>
<name><surname>Baschieri</surname><given-names>S.</given-names></name>
<name><surname>Donini</surname><given-names>M.</given-names></name>
<name><surname>Marusic</surname><given-names>C.</given-names></name>
<name><surname>Benvenuto</surname><given-names>E.</given-names></name>
<name><surname>Dorokhov</surname><given-names>Y.L.</given-names></name>
</person-group><article-title>Transient expression systems for plant-derived biopharmaceuticals</article-title><source>Expert Rev. Vaccines</source><year>2010</year><volume>9</volume><fpage>859</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1586/erv.10.85</pub-id><pub-id pub-id-type="pmid">20673010</pub-id>
</element-citation></ref><ref id="B24-vaccines-13-00191"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Langridge</surname><given-names>W.H.R.</given-names></name>
</person-group><article-title>A plant-based multicomponent vaccine protects mice from enteric diseases</article-title><source>Nat. Biotechnol.</source><year>2001</year><volume>19</volume><fpage>548</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1038/89297</pub-id><pub-id pub-id-type="pmid">11385459</pub-id>
</element-citation></ref><ref id="B25-vaccines-13-00191"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sala</surname><given-names>F.</given-names></name>
<name><surname>Manuela Rigano</surname><given-names>M.</given-names></name>
<name><surname>Barbante</surname><given-names>A.</given-names></name>
<name><surname>Basso</surname><given-names>B.</given-names></name>
<name><surname>Walmsley</surname><given-names>A.M.</given-names></name>
<name><surname>Castiglione</surname><given-names>S.</given-names></name>
</person-group><article-title>Vaccine antigen production in transgenic plants: Strategies, gene constructs and perspectives</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>803</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00603-5</pub-id><pub-id pub-id-type="pmid">12531364</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00191"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krenek</surname><given-names>P.</given-names></name>
<name><surname>Samajova</surname><given-names>O.</given-names></name>
<name><surname>Luptovciak</surname><given-names>I.</given-names></name>
<name><surname>Doskocilova</surname><given-names>A.</given-names></name>
<name><surname>Komis</surname><given-names>G.</given-names></name>
<name><surname>Samaj</surname><given-names>J.</given-names></name>
</person-group><article-title>Transient plant transformation mediated by Agrobacterium tumefaciens: Principles, methods and applications</article-title><source>Biotechnol. Adv.</source><year>2015</year><volume>33</volume><fpage>1024</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2015.03.012</pub-id><pub-id pub-id-type="pmid">25819757</pub-id>
</element-citation></ref><ref id="B27-vaccines-13-00191"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>C Thuenemann</surname><given-names>E.</given-names></name>
<name><surname>Lenzi</surname><given-names>P.</given-names></name>
<name><surname>J Love</surname><given-names>A.</given-names></name>
<name><surname>Taliansky</surname><given-names>M.</given-names></name>
<name><surname>B&#x000e9;cares</surname><given-names>M.</given-names></name>
<name><surname>Zu&#x000f1;iga</surname><given-names>S.</given-names></name>
<name><surname>Enjuanes</surname><given-names>L.</given-names></name>
<name><surname>G Zahmanova</surname><given-names>G.</given-names></name>
<name><surname>N Minkov</surname><given-names>I.</given-names></name>
<name><surname>Matic</surname><given-names>S.</given-names></name>
</person-group><article-title>The use of transient expression systems for the rapid production of virus-like particles in plants</article-title><source>Curr. Pharm. Des.</source><year>2013</year><volume>19</volume><fpage>5564</fpage><lpage>5573</lpage><pub-id pub-id-type="doi">10.2174/1381612811319310011</pub-id><pub-id pub-id-type="pmid">23394559</pub-id>
</element-citation></ref><ref id="B28-vaccines-13-00191"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Su</surname><given-names>H.</given-names></name>
<name><surname>Van Eerde</surname><given-names>A.</given-names></name>
<name><surname>Rimstad</surname><given-names>E.</given-names></name>
<name><surname>Bock</surname><given-names>R.</given-names></name>
<name><surname>Branza-Nichita</surname><given-names>N.</given-names></name>
<name><surname>Yakovlev</surname><given-names>I.A.</given-names></name>
<name><surname>Clarke</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Plant-made vaccines against viral diseases in humans and farm animals</article-title><source>Front. Plant Sci.</source><year>2023</year><volume>14</volume><elocation-id>1170815</elocation-id><pub-id pub-id-type="doi">10.3389/fpls.2023.1170815</pub-id><pub-id pub-id-type="pmid">37056490</pub-id>
</element-citation></ref><ref id="B29-vaccines-13-00191"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stander</surname><given-names>J.</given-names></name>
<name><surname>Mbewana</surname><given-names>S.</given-names></name>
<name><surname>Meyers</surname><given-names>A.E.</given-names></name>
</person-group><article-title>Plant-Derived Human Vaccines: Recent Developments</article-title><source>BioDrugs</source><year>2022</year><volume>36</volume><fpage>573</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1007/s40259-022-00544-8</pub-id><pub-id pub-id-type="pmid">35821564</pub-id>
</element-citation></ref><ref id="B30-vaccines-13-00191"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benvenuto</surname><given-names>E.</given-names></name>
<name><surname>Broer</surname><given-names>I.</given-names></name>
<name><surname>D&#x02019;Aoust</surname><given-names>M.-A.</given-names></name>
<name><surname>Hitzeroth</surname><given-names>I.</given-names></name>
<name><surname>Hundleby</surname><given-names>P.</given-names></name>
<name><surname>Menassa</surname><given-names>R.</given-names></name>
<name><surname>Oksman-Caldentey</surname><given-names>K.-M.</given-names></name>
<name><surname>Peyret</surname><given-names>H.</given-names></name>
<name><surname>Salgueiro</surname><given-names>S.</given-names></name>
<name><surname>Saxena</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Plant molecular farming in the wake of the closure of Medicago Inc</article-title><source>Nat. Biotechnol.</source><year>2023</year><volume>41</volume><fpage>893</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1038/s41587-023-01812-w</pub-id><pub-id pub-id-type="pmid">37217754</pub-id>
</element-citation></ref><ref id="B31-vaccines-13-00191"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hager</surname><given-names>K.J.</given-names></name>
<name><surname>P&#x000e9;rez Marc</surname><given-names>G.</given-names></name>
<name><surname>Gobeil</surname><given-names>P.</given-names></name>
<name><surname>Diaz</surname><given-names>R.S.</given-names></name>
<name><surname>Heizer</surname><given-names>G.</given-names></name>
<name><surname>Llapur</surname><given-names>C.</given-names></name>
<name><surname>Makarkov</surname><given-names>A.I.</given-names></name>
<name><surname>Vasconcellos</surname><given-names>E.</given-names></name>
<name><surname>Pillet</surname><given-names>S.</given-names></name>
<name><surname>Riera</surname><given-names>F.</given-names></name>
</person-group><article-title>Efficacy and safety of a recombinant plant-based adjuvanted COVID-19 vaccine</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>2084</fpage><lpage>2096</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2201300</pub-id><pub-id pub-id-type="pmid">35507508</pub-id>
</element-citation></ref><ref id="B32-vaccines-13-00191"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zahmanova</surname><given-names>G.</given-names></name>
<name><surname>Aljabali</surname><given-names>A.A.</given-names></name>
<name><surname>Takova</surname><given-names>K.</given-names></name>
<name><surname>Toneva</surname><given-names>V.</given-names></name>
<name><surname>Tambuwala</surname><given-names>M.M.</given-names></name>
<name><surname>Andonov</surname><given-names>A.P.</given-names></name>
<name><surname>Lukov</surname><given-names>G.L.</given-names></name>
<name><surname>Minkov</surname><given-names>I.</given-names></name>
</person-group><article-title>The Plant Viruses and Molecular Farming: How Beneficial They Might Be for Human and Animal Health?</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>1533</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24021533</pub-id><pub-id pub-id-type="pmid">36675043</pub-id>
</element-citation></ref><ref id="B33-vaccines-13-00191"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Basaran</surname><given-names>P.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Cerezo</surname><given-names>E.</given-names></name>
</person-group><article-title>Plant Molecular Farming: Opportunities and Challenges</article-title><source>Crit. Rev. Biotechnol.</source><year>2008</year><volume>28</volume><fpage>153</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1080/07388550802046624</pub-id><pub-id pub-id-type="pmid">18937106</pub-id>
</element-citation></ref><ref id="B34-vaccines-13-00191"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liew</surname><given-names>P.S.</given-names></name>
<name><surname>Hair-Bejo</surname><given-names>M.</given-names></name>
</person-group><article-title>Farming of Plant-Based Veterinary Vaccines and Their Applications for Disease Prevention in Animals</article-title><source>Adv. Virol.</source><year>2015</year><volume>2015</volume><fpage>936940</fpage><pub-id pub-id-type="doi">10.1155/2015/936940</pub-id><pub-id pub-id-type="pmid">26351454</pub-id>
</element-citation></ref><ref id="B35-vaccines-13-00191"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sahoo</surname><given-names>A.</given-names></name>
<name><surname>Mandal</surname><given-names>A.K.</given-names></name>
<name><surname>Dwivedi</surname><given-names>K.</given-names></name>
<name><surname>Kumar</surname><given-names>V.</given-names></name>
</person-group><article-title>A cross talk between the immunization and edible vaccine: Current challenges and future prospects</article-title><source>Life Sci.</source><year>2020</year><volume>261</volume><fpage>118343</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.118343</pub-id><pub-id pub-id-type="pmid">32858038</pub-id>
</element-citation></ref><ref id="B36-vaccines-13-00191"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kurup</surname><given-names>V.M.</given-names></name>
<name><surname>Thomas</surname><given-names>J.</given-names></name>
</person-group><article-title>Edible Vaccines: Promises and Challenges</article-title><source>Mol. Biotechnol.</source><year>2020</year><volume>62</volume><fpage>79</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1007/s12033-019-00222-1</pub-id><pub-id pub-id-type="pmid">31758488</pub-id>
</element-citation></ref><ref id="B37-vaccines-13-00191"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Daniell</surname><given-names>H.</given-names></name>
<name><surname>Streatfield</surname><given-names>S.J.</given-names></name>
<name><surname>Wycoff</surname><given-names>K.</given-names></name>
</person-group><article-title>Medical molecular farming: Production of antibodies, biopharmaceuticals and edible vaccines in plants</article-title><source>Trends Plant Sci.</source><year>2001</year><volume>6</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/S1360-1385(01)01922-7</pub-id><pub-id pub-id-type="pmid">11335175</pub-id>
</element-citation></ref><ref id="B38-vaccines-13-00191"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rybicki</surname><given-names>E.P.</given-names></name>
</person-group><article-title>Plant molecular farming of virus-like nanoparticles as vaccines and reagents</article-title><source>WIREs Nanomed. Nanobiotechnol.</source><year>2020</year><volume>12</volume><elocation-id>e1587</elocation-id><pub-id pub-id-type="doi">10.1002/wnan.1587</pub-id><pub-id pub-id-type="pmid">31486296</pub-id>
</element-citation></ref><ref id="B39-vaccines-13-00191"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waheed</surname><given-names>M.T.</given-names></name>
<name><surname>Sameeullah</surname><given-names>M.</given-names></name>
<name><surname>Khan</surname><given-names>F.A.</given-names></name>
<name><surname>Syed</surname><given-names>T.</given-names></name>
<name><surname>Ilahi</surname><given-names>M.</given-names></name>
<name><surname>Gottschamel</surname><given-names>J.</given-names></name>
<name><surname>L&#x000f6;ssl</surname><given-names>A.G.</given-names></name>
</person-group><article-title>Need of cost-effective vaccines in developing countries: What plant biotechnology can offer?</article-title><source>SpringerPlus</source><year>2016</year><volume>5</volume><fpage>65</fpage><pub-id pub-id-type="doi">10.1186/s40064-016-1713-8</pub-id><pub-id pub-id-type="pmid">26839758</pub-id>
</element-citation></ref><ref id="B40-vaccines-13-00191"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murad</surname><given-names>S.</given-names></name>
<name><surname>Fuller</surname><given-names>S.</given-names></name>
<name><surname>Menary</surname><given-names>J.</given-names></name>
<name><surname>Moore</surname><given-names>C.</given-names></name>
<name><surname>Pinneh</surname><given-names>E.</given-names></name>
<name><surname>Szeto</surname><given-names>T.</given-names></name>
<name><surname>Hitzeroth</surname><given-names>I.</given-names></name>
<name><surname>Freire</surname><given-names>M.</given-names></name>
<name><surname>Taychakhoonavudh</surname><given-names>S.</given-names></name>
<name><surname>Phoolcharoen</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Molecular Pharming for low and middle income countries</article-title><source>Curr. Opin. Biotechnol.</source><year>2020</year><volume>61</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2019.10.005</pub-id><pub-id pub-id-type="pmid">31751895</pub-id>
</element-citation></ref><ref id="B41-vaccines-13-00191"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kyrylenko</surname><given-names>A.</given-names></name>
<name><surname>Eijlander</surname><given-names>R.T.</given-names></name>
<name><surname>Alliney</surname><given-names>G.</given-names></name>
<name><surname>de Bos</surname><given-names>E.L.-v.</given-names></name>
<name><surname>Wells-Bennik</surname><given-names>M.H.J.</given-names></name>
</person-group><article-title>Levels and types of microbial contaminants in different plant-based ingredients used in dairy alternatives</article-title><source>Int. J. Food Microbiol.</source><year>2023</year><volume>407</volume><elocation-id>110392</elocation-id><pub-id pub-id-type="doi">10.1016/j.ijfoodmicro.2023.110392</pub-id><pub-id pub-id-type="pmid">37729802</pub-id>
</element-citation></ref><ref id="B42-vaccines-13-00191"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Monreal-Escalante</surname><given-names>E.</given-names></name>
<name><surname>Ramos-Vega</surname><given-names>A.</given-names></name>
<name><surname>Angulo</surname><given-names>C.</given-names></name>
<name><surname>Ba&#x000f1;uelos-Hern&#x000e1;ndez</surname><given-names>B.</given-names></name>
</person-group><article-title>Plant-Based Vaccines: Antigen Design, Diversity, and Strategies for High Level Production</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>100</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10010100</pub-id><pub-id pub-id-type="pmid">35062761</pub-id>
</element-citation></ref><ref id="B43-vaccines-13-00191"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tekoah</surname><given-names>Y.</given-names></name>
<name><surname>Shulman</surname><given-names>A.</given-names></name>
<name><surname>Kizhner</surname><given-names>T.</given-names></name>
<name><surname>Ruderfer</surname><given-names>I.</given-names></name>
<name><surname>Fux</surname><given-names>L.</given-names></name>
<name><surname>Nataf</surname><given-names>Y.</given-names></name>
<name><surname>Bartfeld</surname><given-names>D.</given-names></name>
<name><surname>Ariel</surname><given-names>T.</given-names></name>
<name><surname>Gingis&#x02013;Velitski</surname><given-names>S.</given-names></name>
<name><surname>Hanania</surname><given-names>U.</given-names></name>
<etal/>
</person-group><article-title>Large-scale production of pharmaceutical proteins in plant cell culture&#x02014;The protalix experience</article-title><source>Plant Biotechnol. J.</source><year>2015</year><volume>13</volume><fpage>1199</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1111/pbi.12428</pub-id><pub-id pub-id-type="pmid">26102075</pub-id>
</element-citation></ref><ref id="B44-vaccines-13-00191"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karki</surname><given-names>U.</given-names></name>
<name><surname>Fang</surname><given-names>H.</given-names></name>
<name><surname>Guo</surname><given-names>W.</given-names></name>
<name><surname>Unnold-Cofre</surname><given-names>C.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
</person-group><article-title>Cellular engineering of plant cells for improved therapeutic protein production</article-title><source>Plant Cell Rep.</source><year>2021</year><volume>40</volume><fpage>1087</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1007/s00299-021-02693-6</pub-id><pub-id pub-id-type="pmid">33837823</pub-id>
</element-citation></ref><ref id="B45-vaccines-13-00191"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jako&#x0010d;i&#x0016b;nas</surname><given-names>T.</given-names></name>
<name><surname>Jensen</surname><given-names>M.K.</given-names></name>
<name><surname>Keasling</surname><given-names>J.D.</given-names></name>
</person-group><article-title>CRISPR/Cas9 advances engineering of microbial cell factories</article-title><source>Metab. Eng.</source><year>2016</year><volume>34</volume><fpage>44</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.ymben.2015.12.003</pub-id><pub-id pub-id-type="pmid">26707540</pub-id>
</element-citation></ref><ref id="B46-vaccines-13-00191"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shkryl</surname><given-names>Y.</given-names></name>
<name><surname>Tsydeneshieva</surname><given-names>Z.</given-names></name>
<name><surname>Degtyarenko</surname><given-names>A.</given-names></name>
<name><surname>Yugay</surname><given-names>Y.</given-names></name>
<name><surname>Balabanova</surname><given-names>L.</given-names></name>
<name><surname>Rusapetova</surname><given-names>T.</given-names></name>
<name><surname>Bulgakov</surname><given-names>V.</given-names></name>
</person-group><article-title>Plant Exosomal Vesicles: Perspective Information Nanocarriers in Biomedicine</article-title><source>Appl. Sci.</source><year>2022</year><volume>12</volume><elocation-id>8262</elocation-id><pub-id pub-id-type="doi">10.3390/app12168262</pub-id></element-citation></ref><ref id="B47-vaccines-13-00191"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Daniell</surname><given-names>H.</given-names></name>
<name><surname>Singh</surname><given-names>N.D.</given-names></name>
<name><surname>Mason</surname><given-names>H.</given-names></name>
<name><surname>Streatfield</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Plant-made vaccine antigens and biopharmaceuticals</article-title><source>Trends Plant Sci.</source><year>2009</year><volume>14</volume><fpage>669</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1016/j.tplants.2009.09.009</pub-id><pub-id pub-id-type="pmid">19836291</pub-id>
</element-citation></ref><ref id="B48-vaccines-13-00191"><label>48.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Elisabeth</surname><given-names>Z.M.</given-names></name>
<name><surname>Toghueo</surname><given-names>R.M.K.</given-names></name>
</person-group><article-title>Plant Cell Culture for Biopharmaceuticals</article-title><source>Plants as Bioreactors for Industrial Molecules</source><publisher-name>Wiley</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2023</year><fpage>89</fpage><lpage>125</lpage></element-citation></ref><ref id="B49-vaccines-13-00191"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>S.</given-names></name>
<name><surname>Khan</surname><given-names>S.</given-names></name>
<name><surname>Imran</surname><given-names>I.</given-names></name>
<name><surname>Al Mughairbi</surname><given-names>F.</given-names></name>
<name><surname>Sheikh</surname><given-names>F.S.</given-names></name>
<name><surname>Hussain</surname><given-names>J.</given-names></name>
<name><surname>Khan</surname><given-names>A.</given-names></name>
<name><surname>Al-Harrasi</surname><given-names>A.</given-names></name>
</person-group><article-title>Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>836</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9080836</pub-id><pub-id pub-id-type="pmid">34451961</pub-id>
</element-citation></ref><ref id="B50-vaccines-13-00191"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tus&#x000e9;</surname><given-names>D.</given-names></name>
<name><surname>Nandi</surname><given-names>S.</given-names></name>
<name><surname>McDonald</surname><given-names>K.A.</given-names></name>
<name><surname>Buyel</surname><given-names>J.F.</given-names></name>
</person-group><article-title>The emergency response capacity of plant-based biopharmaceutical manufacturing-what it is and what it could be</article-title><source>Front. Plant Sci.</source><year>2020</year><volume>11</volume><elocation-id>594019</elocation-id><pub-id pub-id-type="doi">10.3389/fpls.2020.594019</pub-id><pub-id pub-id-type="pmid">33193552</pub-id>
</element-citation></ref><ref id="B51-vaccines-13-00191"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zahmanova</surname><given-names>G.</given-names></name>
<name><surname>Aljabali</surname><given-names>A.A.A.</given-names></name>
<name><surname>Takova</surname><given-names>K.</given-names></name>
<name><surname>Minkov</surname><given-names>G.</given-names></name>
<name><surname>Tambuwala</surname><given-names>M.M.</given-names></name>
<name><surname>Minkov</surname><given-names>I.</given-names></name>
<name><surname>Lomonossoff</surname><given-names>G.P.</given-names></name>
</person-group><article-title>Green Biologics: Harnessing the Power of Plants to Produce Pharmaceuticals</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>17575</elocation-id><pub-id pub-id-type="doi">10.3390/ijms242417575</pub-id><pub-id pub-id-type="pmid">38139405</pub-id>
</element-citation></ref><ref id="B52-vaccines-13-00191"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shin</surname><given-names>M.D.</given-names></name>
<name><surname>Shukla</surname><given-names>S.</given-names></name>
<name><surname>Chung</surname><given-names>Y.H.</given-names></name>
<name><surname>Beiss</surname><given-names>V.</given-names></name>
<name><surname>Chan</surname><given-names>S.K.</given-names></name>
<name><surname>Ortega-Rivera</surname><given-names>O.A.</given-names></name>
<name><surname>Wirth</surname><given-names>D.M.</given-names></name>
<name><surname>Chen</surname><given-names>A.</given-names></name>
<name><surname>Sack</surname><given-names>M.</given-names></name>
<name><surname>Pokorski</surname><given-names>J.K.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 vaccine development and a potential nanomaterial path forward</article-title><source>Nat. Nanotechnol.</source><year>2020</year><volume>15</volume><fpage>646</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1038/s41565-020-0737-y</pub-id><pub-id pub-id-type="pmid">32669664</pub-id>
</element-citation></ref><ref id="B53-vaccines-13-00191"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Dolan</surname><given-names>M.C.</given-names></name>
<name><surname>Medrano</surname><given-names>G.</given-names></name>
<name><surname>Cramer</surname><given-names>C.L.</given-names></name>
<name><surname>Weathers</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Green factory: Plants as bioproduction platforms for recombinant proteins</article-title><source>Biotechnol. Adv.</source><year>2012</year><volume>30</volume><fpage>1171</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2011.08.020</pub-id><pub-id pub-id-type="pmid">21924345</pub-id>
</element-citation></ref><ref id="B54-vaccines-13-00191"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tschofen</surname><given-names>M.</given-names></name>
<name><surname>Knopp</surname><given-names>D.</given-names></name>
<name><surname>Hood</surname><given-names>E.</given-names></name>
<name><surname>St&#x000f6;ger</surname><given-names>E.</given-names></name>
</person-group><article-title>Plant Molecular Farming: Much More than Medicines</article-title><source>Annu. Rev. Anal. Chem.</source><year>2016</year><volume>9</volume><fpage>271</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1146/annurev-anchem-071015-041706</pub-id><pub-id pub-id-type="pmid">27049632</pub-id>
</element-citation></ref><ref id="B55-vaccines-13-00191"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fischer</surname><given-names>R.</given-names></name>
<name><surname>Liao</surname><given-names>Y.C.</given-names></name>
<name><surname>Hoffmann</surname><given-names>K.</given-names></name>
<name><surname>Schillberg</surname><given-names>S.</given-names></name>
<name><surname>Emans</surname><given-names>N.</given-names></name>
</person-group><article-title>Molecular Farming of Recombinant Antibodies in Plants</article-title><source>Biol. Chem.</source><year>1999</year><volume>380</volume><fpage>825</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1515/BC.1999.102</pub-id><pub-id pub-id-type="pmid">10494831</pub-id>
</element-citation></ref><ref id="B56-vaccines-13-00191"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Twyman</surname><given-names>R.M.</given-names></name>
<name><surname>Stoger</surname><given-names>E.</given-names></name>
<name><surname>Schillberg</surname><given-names>S.</given-names></name>
<name><surname>Christou</surname><given-names>P.</given-names></name>
<name><surname>Fischer</surname><given-names>R.</given-names></name>
</person-group><article-title>Molecular farming in plants: Host systems and expression technology</article-title><source>Trends Biotechnol.</source><year>2003</year><volume>21</volume><fpage>570</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2003.10.002</pub-id><pub-id pub-id-type="pmid">14624867</pub-id>
</element-citation></ref><ref id="B57-vaccines-13-00191"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barta</surname><given-names>A.</given-names></name>
<name><surname>Sommergruber</surname><given-names>K.</given-names></name>
<name><surname>Thompson</surname><given-names>D.</given-names></name>
<name><surname>Hartmuth</surname><given-names>K.</given-names></name>
<name><surname>Matzke</surname><given-names>M.A.</given-names></name>
<name><surname>Matzke</surname><given-names>A.J.M.</given-names></name>
</person-group><article-title>The expression of a nopaline synthase&#x02014;Human growth hormone chimaeric gene in transformed tobacco and sunflower callus tissue</article-title><source>Plant Mol. Biol.</source><year>1986</year><volume>6</volume><fpage>347</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1007/BF00034942</pub-id><pub-id pub-id-type="pmid">24307385</pub-id>
</element-citation></ref><ref id="B58-vaccines-13-00191"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kapusta</surname><given-names>J.</given-names></name>
<name><surname>Modelska</surname><given-names>A.</given-names></name>
<name><surname>Figlerowicz</surname><given-names>M.</given-names></name>
<name><surname>Pniewski</surname><given-names>T.</given-names></name>
<name><surname>Letellier</surname><given-names>M.</given-names></name>
<name><surname>Lisowa</surname><given-names>O.</given-names></name>
<name><surname>Yusibov</surname><given-names>V.</given-names></name>
<name><surname>Koprowski</surname><given-names>H.</given-names></name>
<name><surname>Plucienniczak</surname><given-names>A.</given-names></name>
<name><surname>Legocki</surname><given-names>A.B.</given-names></name>
</person-group><article-title>A plant-derived edible vaccine against hepatitis B virus</article-title><source>FASEB J.</source><year>1999</year><volume>13</volume><fpage>1796</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1096/fasebj.13.13.1796</pub-id><pub-id pub-id-type="pmid">10506582</pub-id>
</element-citation></ref><ref id="B59-vaccines-13-00191"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Richter</surname><given-names>L.J.</given-names></name>
<name><surname>Thanavala</surname><given-names>Y.</given-names></name>
<name><surname>Arntzen</surname><given-names>C.J.</given-names></name>
<name><surname>Mason</surname><given-names>H.S.</given-names></name>
</person-group><article-title>Production of hepatitis B surface antigen in transgenic plants for oral immunization</article-title><source>Nat. Biotechnol.</source><year>2000</year><volume>18</volume><fpage>1167</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1038/81153</pub-id><pub-id pub-id-type="pmid">11062435</pub-id>
</element-citation></ref><ref id="B60-vaccines-13-00191"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>G.B.S.</given-names></name>
<name><surname>Ganapathi</surname><given-names>T.R.</given-names></name>
<name><surname>Bapat</surname><given-names>V.A.</given-names></name>
</person-group><article-title>Production of Hepatitis B Surface Antigen in Recombinant Plant Systems: An Update</article-title><source>Biotechnol. Prog.</source><year>2007</year><volume>23</volume><fpage>532</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1021/bp0602754</pub-id><pub-id pub-id-type="pmid">17348684</pub-id>
</element-citation></ref><ref id="B61-vaccines-13-00191"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thanavala</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>Y.F.</given-names></name>
<name><surname>Lyons</surname><given-names>P.</given-names></name>
<name><surname>Mason</surname><given-names>H.S.</given-names></name>
<name><surname>Arntzen</surname><given-names>C.</given-names></name>
</person-group><article-title>Immunogenicity of transgenic plant-derived hepatitis B surface antigen</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1995</year><volume>92</volume><fpage>3358</fpage><lpage>3361</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.8.3358</pub-id><pub-id pub-id-type="pmid">7724566</pub-id>
</element-citation></ref><ref id="B62-vaccines-13-00191"><label>62.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Saxena</surname><given-names>J.</given-names></name>
<name><surname>Rawat</surname><given-names>S.</given-names></name>
</person-group><article-title>Edible Vaccines</article-title><source>Advances in Biotechnology</source><person-group person-group-type="editor">
<name><surname>Ravi</surname><given-names>I.</given-names></name>
<name><surname>Baunthiyal</surname><given-names>M.</given-names></name>
<name><surname>Saxena</surname><given-names>J.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>New Delhi, India</publisher-loc><year>2014</year><fpage>207</fpage><lpage>226</lpage></element-citation></ref><ref id="B63-vaccines-13-00191"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>H.-T.</given-names></name>
<name><surname>Chia</surname><given-names>M.-Y.</given-names></name>
<name><surname>Pang</surname><given-names>V.F.</given-names></name>
<name><surname>Jeng</surname><given-names>C.-R.</given-names></name>
<name><surname>Do</surname><given-names>Y.-Y.</given-names></name>
<name><surname>Huang</surname><given-names>P.-L.</given-names></name>
</person-group><article-title>Oral immunogenicity of porcine reproductive and respiratory syndrome virus antigen expressed in transgenic banana</article-title><source>Plant Biotechnol. J.</source><year>2013</year><volume>11</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1111/pbi.12015</pub-id><pub-id pub-id-type="pmid">23116484</pub-id>
</element-citation></ref><ref id="B64-vaccines-13-00191"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Buehner</surname><given-names>N.A.</given-names></name>
<name><surname>Hutson</surname><given-names>A.M.</given-names></name>
<name><surname>Estes</surname><given-names>M.K.</given-names></name>
<name><surname>Mason</surname><given-names>H.S.</given-names></name>
</person-group><article-title>Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein</article-title><source>Plant Biotechnol. J.</source><year>2006</year><volume>4</volume><fpage>419</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1111/j.1467-7652.2006.00191.x</pub-id><pub-id pub-id-type="pmid">17177807</pub-id>
</element-citation></ref><ref id="B65-vaccines-13-00191"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gleba</surname><given-names>Y.</given-names></name>
<name><surname>Klimyuk</surname><given-names>V.</given-names></name>
<name><surname>Marillonnet</surname><given-names>S.</given-names></name>
</person-group><article-title>Magnifection&#x02014;A new platform for expressing recombinant vaccines in plants</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>2042</fpage><lpage>2048</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.01.006</pub-id><pub-id pub-id-type="pmid">15755568</pub-id>
</element-citation></ref><ref id="B66-vaccines-13-00191"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pogue</surname><given-names>G.P.</given-names></name>
<name><surname>Vojdani</surname><given-names>F.</given-names></name>
<name><surname>Palmer</surname><given-names>K.E.</given-names></name>
<name><surname>Hiatt</surname><given-names>E.</given-names></name>
<name><surname>Hume</surname><given-names>S.</given-names></name>
<name><surname>Phelps</surname><given-names>J.</given-names></name>
<name><surname>Long</surname><given-names>L.</given-names></name>
<name><surname>Bohorova</surname><given-names>N.</given-names></name>
<name><surname>Kim</surname><given-names>D.</given-names></name>
<name><surname>Pauly</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems</article-title><source>Plant Biotechnol. J.</source><year>2010</year><volume>8</volume><fpage>638</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1111/j.1467-7652.2009.00495.x</pub-id><pub-id pub-id-type="pmid">20514694</pub-id>
</element-citation></ref><ref id="B67-vaccines-13-00191"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sparkes</surname><given-names>I.A.</given-names></name>
<name><surname>Runions</surname><given-names>J.</given-names></name>
<name><surname>Kearns</surname><given-names>A.</given-names></name>
<name><surname>Hawes</surname><given-names>C.</given-names></name>
</person-group><article-title>Rapid, transient expression of fluorescent fusion proteins in tobacco plants and generation of stably transformed plants</article-title><source>Nat. Protoc.</source><year>2006</year><volume>1</volume><fpage>2019</fpage><lpage>2025</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.286</pub-id><pub-id pub-id-type="pmid">17487191</pub-id>
</element-citation></ref><ref id="B68-vaccines-13-00191"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gleba</surname><given-names>Y.</given-names></name>
<name><surname>Klimyuk</surname><given-names>V.</given-names></name>
<name><surname>Marillonnet</surname><given-names>S.</given-names></name>
</person-group><article-title>Viral vectors for the expression of proteins in plants</article-title><source>Curr. Opin. Biotechnol.</source><year>2007</year><volume>18</volume><fpage>134</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2007.03.002</pub-id><pub-id pub-id-type="pmid">17368018</pub-id>
</element-citation></ref><ref id="B69-vaccines-13-00191"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lico</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Santi</surname><given-names>L.</given-names></name>
</person-group><article-title>Viral vectors for production of recombinant proteins in plants</article-title><source>J. Cell. Physiol.</source><year>2008</year><volume>216</volume><fpage>366</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1002/jcp.21423</pub-id><pub-id pub-id-type="pmid">18330886</pub-id>
</element-citation></ref><ref id="B70-vaccines-13-00191"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gelvin</surname><given-names>S.B.</given-names></name>
</person-group><article-title>Agrobacterium-mediated plant transformation: The biology behind the &#x0201c;gene-jockeying&#x0201d; tool</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2003</year><volume>67</volume><fpage>16</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1128/MMBR.67.1.16-37.2003</pub-id><pub-id pub-id-type="pmid">12626681</pub-id>
</element-citation></ref><ref id="B71-vaccines-13-00191"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leuzinger</surname><given-names>K.</given-names></name>
<name><surname>Dent</surname><given-names>M.</given-names></name>
<name><surname>Hurtado</surname><given-names>J.</given-names></name>
<name><surname>Stahnke</surname><given-names>J.</given-names></name>
<name><surname>Lai</surname><given-names>H.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
</person-group><article-title>Efficient agroinfiltration of plants for high-level transient expression of recombinant proteins</article-title><source>J. Vis. Exp.</source><year>2013</year><fpage>50521</fpage><pub-id pub-id-type="doi">10.3791/50521-v</pub-id><pub-id pub-id-type="pmid">23913006</pub-id>
</element-citation></ref><ref id="B72-vaccines-13-00191"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rybicki</surname><given-names>E.P.</given-names></name>
</person-group><article-title>Plant-made vaccines for humans and animals</article-title><source>Plant Biotechnol. J.</source><year>2010</year><volume>8</volume><fpage>620</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1111/j.1467-7652.2010.00507.x</pub-id><pub-id pub-id-type="pmid">20233333</pub-id>
</element-citation></ref><ref id="B73-vaccines-13-00191"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Balke</surname><given-names>I.</given-names></name>
<name><surname>Zeltins</surname><given-names>A.</given-names></name>
</person-group><article-title>Use of plant viruses and virus-like particles for the creation of novel vaccines</article-title><source>Adv. Drug Deliv. Rev.</source><year>2019</year><volume>145</volume><fpage>119</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2018.08.007</pub-id><pub-id pub-id-type="pmid">30172923</pub-id>
</element-citation></ref><ref id="B74-vaccines-13-00191"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rold&#x000e3;o</surname><given-names>A.</given-names></name>
<name><surname>Mellado</surname><given-names>M.C.M.</given-names></name>
<name><surname>Castilho</surname><given-names>L.R.</given-names></name>
<name><surname>Carrondo</surname><given-names>M.J.T.</given-names></name>
<name><surname>Alves</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Virus-like particles in vaccine development</article-title><source>Expert Rev. Vaccines</source><year>2010</year><volume>9</volume><fpage>1149</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1586/erv.10.115</pub-id><pub-id pub-id-type="pmid">20923267</pub-id>
</element-citation></ref><ref id="B75-vaccines-13-00191"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohsen</surname><given-names>M.O.</given-names></name>
<name><surname>Zha</surname><given-names>L.</given-names></name>
<name><surname>Cabral-Miranda</surname><given-names>G.</given-names></name>
<name><surname>Bachmann</surname><given-names>M.F.</given-names></name>
</person-group><article-title>Major findings and recent advances in virus&#x02013;like particle (VLP)-based vaccines</article-title><source>Semin. Immunol.</source><year>2017</year><volume>34</volume><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2017.08.014</pub-id><pub-id pub-id-type="pmid">28887001</pub-id>
</element-citation></ref><ref id="B76-vaccines-13-00191"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Balke</surname><given-names>I.</given-names></name>
<name><surname>Zeltins</surname><given-names>A.</given-names></name>
</person-group><article-title>Recent Advances in the Use of Plant Virus-Like Particles as Vaccines</article-title><source>Viruses</source><year>2020</year><volume>12</volume><elocation-id>270</elocation-id><pub-id pub-id-type="doi">10.3390/v12030270</pub-id><pub-id pub-id-type="pmid">32121192</pub-id>
</element-citation></ref><ref id="B77-vaccines-13-00191"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nooraei</surname><given-names>S.</given-names></name>
<name><surname>Bahrulolum</surname><given-names>H.</given-names></name>
<name><surname>Hoseini</surname><given-names>Z.S.</given-names></name>
<name><surname>Katalani</surname><given-names>C.</given-names></name>
<name><surname>Hajizade</surname><given-names>A.</given-names></name>
<name><surname>Easton</surname><given-names>A.J.</given-names></name>
<name><surname>Ahmadian</surname><given-names>G.</given-names></name>
</person-group><article-title>Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers</article-title><source>J. Nanobiotechnology</source><year>2021</year><volume>19</volume><elocation-id>59</elocation-id><pub-id pub-id-type="doi">10.1186/s12951-021-00806-7</pub-id><pub-id pub-id-type="pmid">33632278</pub-id>
</element-citation></ref><ref id="B78-vaccines-13-00191"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Kennedy</surname><given-names>M.M.</given-names></name>
<name><surname>Abolnik</surname><given-names>C.</given-names></name>
<name><surname>Smith</surname><given-names>T.</given-names></name>
<name><surname>Motlou</surname><given-names>T.</given-names></name>
<name><surname>Goosen</surname><given-names>K.</given-names></name>
<name><surname>Sepotokele</surname><given-names>K.M.</given-names></name>
<name><surname>Roth</surname><given-names>R.</given-names></name>
<name><surname>du Preez</surname><given-names>I.</given-names></name>
<name><surname>Truyts</surname><given-names>A.</given-names></name>
<name><surname>Stark</surname><given-names>H.C.</given-names></name>
<etal/>
</person-group><article-title>Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><fpage>2261</fpage><lpage>2269</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.02.050</pub-id><pub-id pub-id-type="pmid">36868876</pub-id>
</element-citation></ref><ref id="B79-vaccines-13-00191"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dhawan</surname><given-names>M.</given-names></name>
<name><surname>Saied</surname><given-names>A.A.</given-names></name>
<name><surname>Sharma</surname><given-names>M.</given-names></name>
</person-group><article-title>Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2?</article-title><source>Health Sci. Rev.</source><year>2023</year><volume>9</volume><fpage>100127</fpage><pub-id pub-id-type="doi">10.1016/j.hsr.2023.100127</pub-id></element-citation></ref><ref id="B80-vaccines-13-00191"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruocco</surname><given-names>V.</given-names></name>
<name><surname>Strasser</surname><given-names>R.</given-names></name>
</person-group><article-title>Transient Expression of Glycosylated SARS-CoV-2 Antigens in <italic toggle="yes">Nicotiana benthamiana</italic></article-title><source>Plants</source><year>2022</year><volume>11</volume><elocation-id>1093</elocation-id><pub-id pub-id-type="doi">10.3390/plants11081093</pub-id><pub-id pub-id-type="pmid">35448821</pub-id>
</element-citation></ref><ref id="B81-vaccines-13-00191"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hao</surname><given-names>X.</given-names></name>
<name><surname>Yuan</surname><given-names>F.</given-names></name>
<name><surname>Yao</surname><given-names>X.</given-names></name>
</person-group><article-title>Advances in virus-like particle-based SARS-CoV-2 vaccines</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2024</year><volume>14</volume><elocation-id>1406091</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2024.1406091</pub-id><pub-id pub-id-type="pmid">38988812</pub-id>
</element-citation></ref><ref id="B82-vaccines-13-00191"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>England</surname><given-names>C.</given-names></name>
<name><surname>TrejoMartinez</surname><given-names>J.</given-names></name>
<name><surname>PerezSanchez</surname><given-names>P.</given-names></name>
<name><surname>Karki</surname><given-names>U.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
</person-group><article-title>Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19</article-title><source>Life</source><year>2023</year><volume>13</volume><elocation-id>617</elocation-id><pub-id pub-id-type="doi">10.3390/life13030617</pub-id><pub-id pub-id-type="pmid">36983772</pub-id>
</element-citation></ref><ref id="B83-vaccines-13-00191"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ponz</surname><given-names>F.</given-names></name>
<name><surname>Avesani</surname><given-names>L.</given-names></name>
</person-group><article-title>Editorial: Plant science&#x02019;s contribution to fighting viral pandemics: COVID-19 as a case study, volume II</article-title><source>Front. Plant Sci.</source><year>2023</year><volume>14</volume><elocation-id>1167529</elocation-id><pub-id pub-id-type="doi">10.3389/fpls.2023.1167529</pub-id><pub-id pub-id-type="pmid">37123854</pub-id>
</element-citation></ref><ref id="B84-vaccines-13-00191"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jacob</surname><given-names>S.S.</given-names></name>
<name><surname>Cherian</surname><given-names>S.</given-names></name>
<name><surname>Sumithra</surname><given-names>T.G.</given-names></name>
<name><surname>Raina</surname><given-names>O.K.</given-names></name>
<name><surname>Sankar</surname><given-names>M.</given-names></name>
</person-group><article-title>Edible vaccines against veterinary parasitic diseases&#x02014;Current status and future prospects</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>1879</fpage><lpage>1885</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.02.022</pub-id><pub-id pub-id-type="pmid">23485715</pub-id>
</element-citation></ref><ref id="B85-vaccines-13-00191"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Floss</surname><given-names>D.M.</given-names></name>
<name><surname>Falkenburg</surname><given-names>D.</given-names></name>
<name><surname>Conrad</surname><given-names>U.</given-names></name>
</person-group><article-title>Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants: An overview</article-title><source>Transgenic Res.</source><year>2007</year><volume>16</volume><fpage>315</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1007/s11248-007-9095-x</pub-id><pub-id pub-id-type="pmid">17436059</pub-id>
</element-citation></ref><ref id="B86-vaccines-13-00191"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gerdts</surname><given-names>V.</given-names></name>
<name><surname>Zakhartchouk</surname><given-names>A.</given-names></name>
</person-group><article-title>Vaccines for porcine epidemic diarrhea virus and other swine coronaviruses</article-title><source>Vet. Microbiol.</source><year>2017</year><volume>206</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2016.11.029</pub-id><pub-id pub-id-type="pmid">27964998</pub-id>
</element-citation></ref><ref id="B87-vaccines-13-00191"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schillberg</surname><given-names>S.</given-names></name>
<name><surname>Fischer</surname><given-names>R.</given-names></name>
<name><surname>Emans</surname><given-names>N.</given-names></name>
</person-group><article-title>Molecular farming of recombinant antibodies in plants</article-title><source>Cell. Mol. Life Sci. CMLS</source><year>2003</year><volume>60</volume><fpage>433</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1007/s000180300037</pub-id><pub-id pub-id-type="pmid">12737305</pub-id>
</element-citation></ref><ref id="B88-vaccines-13-00191"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>J.K.C.</given-names></name>
<name><surname>Drake</surname><given-names>P.M.W.</given-names></name>
<name><surname>Christou</surname><given-names>P.</given-names></name>
</person-group><article-title>The production of recombinant pharmaceutical proteins in plants</article-title><source>Nat. Rev. Genet.</source><year>2003</year><volume>4</volume><fpage>794</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1038/nrg1177</pub-id><pub-id pub-id-type="pmid">14526375</pub-id>
</element-citation></ref><ref id="B89-vaccines-13-00191"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fischer</surname><given-names>R.</given-names></name>
<name><surname>Vaquero-Martin</surname><given-names>C.</given-names></name>
<name><surname>Sack</surname><given-names>M.</given-names></name>
<name><surname>Drossard</surname><given-names>J.</given-names></name>
<name><surname>Emans</surname><given-names>N.</given-names></name>
<name><surname>Commandeur</surname><given-names>U.</given-names></name>
</person-group><article-title>Towards molecular farming in the future: Transient protein expression in plants</article-title><source>Biotechnol. Appl. Biochem.</source><year>1999</year><volume>30</volume><fpage>113</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1111/j.1470-8744.1999.tb00900.x</pub-id><pub-id pub-id-type="pmid">10512789</pub-id>
</element-citation></ref><ref id="B90-vaccines-13-00191"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Lai</surname><given-names>H.</given-names></name>
</person-group><article-title>Gene Delivery into Plant Cells for Recombinant Protein Production</article-title><source>BioMed Res. Int.</source><year>2015</year><volume>2015</volume><elocation-id>932161</elocation-id><pub-id pub-id-type="doi">10.1155/2015/932161</pub-id><pub-id pub-id-type="pmid">26075275</pub-id>
</element-citation></ref><ref id="B91-vaccines-13-00191"><label>91.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Gleba</surname><given-names>Y.Y.</given-names></name>
<name><surname>Tus&#x000e9;</surname><given-names>D.</given-names></name>
<name><surname>Giritch</surname><given-names>A.</given-names></name>
</person-group><article-title>Plant Viral Vectors for Delivery by Agrobacterium</article-title><source>Plant Viral Vectors</source><person-group person-group-type="editor">
<name><surname>Palmer</surname><given-names>K.</given-names></name>
<name><surname>Gleba</surname><given-names>Y.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2014</year><fpage>155</fpage><lpage>192</lpage></element-citation></ref><ref id="B92-vaccines-13-00191"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Siemiatkowska</surname><given-names>B.</given-names></name>
<name><surname>Toleco</surname><given-names>M.R.</given-names></name>
<name><surname>Jing</surname><given-names>Y.</given-names></name>
<name><surname>Strotmann</surname><given-names>V.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Stahl</surname><given-names>Y.</given-names></name>
<name><surname>Fernie</surname><given-names>A.R.</given-names></name>
</person-group><article-title>A Highly Efficient <italic toggle="yes">Agrobacterium</italic>-Mediated Method for Transient Gene Expression and Functional Studies in Multiple Plant Species</article-title><source>Plant Commun.</source><year>2020</year><volume>1</volume><fpage>100028</fpage><pub-id pub-id-type="doi">10.1016/j.xplc.2020.100028</pub-id><pub-id pub-id-type="pmid">33367253</pub-id>
</element-citation></ref><ref id="B93-vaccines-13-00191"><label>93.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Mardanova</surname><given-names>E.S.</given-names></name>
<name><surname>Ravin</surname><given-names>N.V.</given-names></name>
</person-group><article-title>Chapter Ten&#x02014;Transient expression of recombinant proteins in plants using potato virus X based vectors</article-title><source>Methods in Enzymology</source><person-group person-group-type="editor">
<name><surname>O&#x02019;Dell</surname><given-names>W.B.</given-names></name>
<name><surname>Kelman</surname><given-names>Z.</given-names></name>
</person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2021</year><volume>Volume 660</volume><fpage>205</fpage><lpage>222</lpage></element-citation></ref><ref id="B94-vaccines-13-00191"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mardanova</surname><given-names>E.S.</given-names></name>
<name><surname>Kotlyarov</surname><given-names>R.Y.</given-names></name>
<name><surname>Stuchinskaya</surname><given-names>M.D.</given-names></name>
<name><surname>Nikolaeva</surname><given-names>L.I.</given-names></name>
<name><surname>Zahmanova</surname><given-names>G.</given-names></name>
<name><surname>Ravin</surname><given-names>N.V.</given-names></name>
</person-group><article-title>High-Yield Production of Chimeric Hepatitis E Virus-Like Particles Bearing the M2e Influenza Epitope and Receptor Binding Domain of SARS-CoV-2 in Plants Using Viral Vectors</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>15684</elocation-id><pub-id pub-id-type="doi">10.3390/ijms232415684</pub-id><pub-id pub-id-type="pmid">36555326</pub-id>
</element-citation></ref><ref id="B95-vaccines-13-00191"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mason</surname><given-names>H.S.</given-names></name>
<name><surname>Arntzen</surname><given-names>C.J.</given-names></name>
</person-group><article-title>Transgenic plants as vaccine production systems</article-title><source>Trends Biotechnol.</source><year>1995</year><volume>13</volume><fpage>388</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/S0167-7799(00)88986-6</pub-id><pub-id pub-id-type="pmid">7546570</pub-id>
</element-citation></ref><ref id="B96-vaccines-13-00191"><label>96.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Daniell</surname><given-names>H.</given-names></name>
</person-group><article-title>Transformation and Foreign Gene Expression in Plants Mediated by Microprojectile Bombardment</article-title><source>Recombinant Gene Expression Protocols</source><person-group person-group-type="editor">
<name><surname>Tuan</surname><given-names>R.S.</given-names></name>
</person-group><publisher-name>Humana Press</publisher-name><publisher-loc>Totowa, NJ, USA</publisher-loc><year>1997</year><fpage>463</fpage><lpage>489</lpage></element-citation></ref><ref id="B97-vaccines-13-00191"><label>97.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Barampuram</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.J.</given-names></name>
</person-group><article-title>Recent Advances in Plant Transformation</article-title><source>Plant Chromosome Engineering: Methods and Protocols</source><person-group person-group-type="editor">
<name><surname>Birchler</surname><given-names>J.A.</given-names></name>
</person-group><publisher-name>Humana Press</publisher-name><publisher-loc>Totowa, NJ, USA</publisher-loc><year>2011</year><fpage>1</fpage><lpage>35</lpage></element-citation></ref><ref id="B98-vaccines-13-00191"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rahimian</surname><given-names>N.</given-names></name>
<name><surname>Miraei</surname><given-names>H.R.</given-names></name>
<name><surname>Amiri</surname><given-names>A.</given-names></name>
<name><surname>Ebrahimi</surname><given-names>M.S.</given-names></name>
<name><surname>Nahand</surname><given-names>J.S.</given-names></name>
<name><surname>Tarrahimofrad</surname><given-names>H.</given-names></name>
<name><surname>Hamblin</surname><given-names>M.R.</given-names></name>
<name><surname>Khan</surname><given-names>H.</given-names></name>
<name><surname>Mirzaei</surname><given-names>H.</given-names></name>
</person-group><article-title>Plant-based vaccines and cancer therapy: Where are we now and where are we going?</article-title><source>Pharmacol. Res.</source><year>2021</year><volume>169</volume><fpage>105655</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2021.105655</pub-id><pub-id pub-id-type="pmid">34004270</pub-id>
</element-citation></ref><ref id="B99-vaccines-13-00191"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takeyama</surname><given-names>N.</given-names></name>
<name><surname>Kiyono</surname><given-names>H.</given-names></name>
<name><surname>Yuki</surname><given-names>Y.</given-names></name>
</person-group><article-title>Plant-based vaccines for animals and humans: Recent advances in technology and clinical trials</article-title><source>Ther. Adv. Vaccines</source><year>2015</year><volume>3</volume><fpage>139</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1177/2051013615613272</pub-id><pub-id pub-id-type="pmid">26668752</pub-id>
</element-citation></ref><ref id="B100-vaccines-13-00191"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adem</surname><given-names>M.</given-names></name>
<name><surname>Beyene</surname><given-names>D.</given-names></name>
<name><surname>Feyissa</surname><given-names>T.</given-names></name>
</person-group><article-title>Recent achievements obtained by chloroplast transformation</article-title><source>Plant Methods</source><year>2017</year><volume>13</volume><fpage>30</fpage><pub-id pub-id-type="doi">10.1186/s13007-017-0179-1</pub-id><pub-id pub-id-type="pmid">28428810</pub-id>
</element-citation></ref><ref id="B101-vaccines-13-00191"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>A.U.</given-names></name>
<name><surname>Ling</surname><given-names>A.P.K.</given-names></name>
</person-group><article-title>Gene introduction approaches in chloroplast transformation and its applications</article-title><source>J. Genet. Eng. Biotechnol.</source><year>2021</year><volume>19</volume><elocation-id>148</elocation-id><pub-id pub-id-type="doi">10.1186/s43141-021-00255-7</pub-id><pub-id pub-id-type="pmid">34613540</pub-id>
</element-citation></ref><ref id="B102-vaccines-13-00191"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Dhingra</surname><given-names>A.</given-names></name>
<name><surname>Daniell</surname><given-names>H.</given-names></name>
</person-group><article-title>Stable transformation of the cotton plastid genome and maternal inheritance of transgenes</article-title><source>Plant Mol. Biol.</source><year>2004</year><volume>56</volume><fpage>203</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1007/s11103-004-2907-y</pub-id><pub-id pub-id-type="pmid">15604738</pub-id>
</element-citation></ref><ref id="B103-vaccines-13-00191"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tiwari</surname><given-names>S.</given-names></name>
<name><surname>Verma</surname><given-names>P.C.</given-names></name>
<name><surname>Singh</surname><given-names>P.K.</given-names></name>
<name><surname>Tuli</surname><given-names>R.</given-names></name>
</person-group><article-title>Plants as bioreactors for the production of vaccine antigens</article-title><source>Biotechnol. Adv.</source><year>2009</year><volume>27</volume><fpage>449</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2009.03.006</pub-id><pub-id pub-id-type="pmid">19356740</pub-id>
</element-citation></ref><ref id="B104-vaccines-13-00191"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Obembe</surname><given-names>O.O.</given-names></name>
<name><surname>Popoola</surname><given-names>J.O.</given-names></name>
<name><surname>Leelavathi</surname><given-names>S.</given-names></name>
<name><surname>Reddy</surname><given-names>S.V.</given-names></name>
</person-group><article-title>Advances in plant molecular farming</article-title><source>Biotechnol. Adv.</source><year>2011</year><volume>29</volume><fpage>210</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2010.11.004</pub-id><pub-id pub-id-type="pmid">21115109</pub-id>
</element-citation></ref><ref id="B105-vaccines-13-00191"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shahid</surname><given-names>N.</given-names></name>
<name><surname>Daniell</surname><given-names>H.</given-names></name>
</person-group><article-title>Plant-based oral vaccines against zoonotic and non-zoonotic diseases</article-title><source>Plant Biotechnol. J.</source><year>2016</year><volume>14</volume><fpage>2079</fpage><lpage>2099</lpage><pub-id pub-id-type="doi">10.1111/pbi.12604</pub-id><pub-id pub-id-type="pmid">27442628</pub-id>
</element-citation></ref><ref id="B106-vaccines-13-00191"><label>106.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Twyman</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Host plants, systems and expression strategies for molecular farming</article-title><source>Molecular Farming: Plant-Made Pharmaceuticals and Technical Proteins</source><publisher-name>Wiley</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2004</year><fpage>191</fpage><lpage>216</lpage></element-citation></ref><ref id="B107-vaccines-13-00191"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mirzaee</surname><given-names>M.</given-names></name>
<name><surname>Osmani</surname><given-names>Z.</given-names></name>
<name><surname>Fr&#x000e9;bortov&#x000e1;</surname><given-names>J.</given-names></name>
<name><surname>Fr&#x000e9;bort</surname><given-names>I.</given-names></name>
</person-group><article-title>Recent advances in molecular farming using monocot plants</article-title><source>Biotechnol. Adv.</source><year>2022</year><volume>58</volume><elocation-id>107913</elocation-id><pub-id pub-id-type="doi">10.1016/j.biotechadv.2022.107913</pub-id><pub-id pub-id-type="pmid">35081454</pub-id>
</element-citation></ref><ref id="B108-vaccines-13-00191"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Norkunas</surname><given-names>K.</given-names></name>
<name><surname>Harding</surname><given-names>R.</given-names></name>
<name><surname>Dale</surname><given-names>J.</given-names></name>
<name><surname>Dugdale</surname><given-names>B.</given-names></name>
</person-group><article-title>Improving agroinfiltration-based transient gene expression in <italic toggle="yes">Nicotiana benthamiana</italic></article-title><source>Plant Methods</source><year>2018</year><volume>14</volume><fpage>71</fpage><pub-id pub-id-type="doi">10.1186/s13007-018-0343-2</pub-id><pub-id pub-id-type="pmid">30159002</pub-id>
</element-citation></ref><ref id="B109-vaccines-13-00191"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vald&#x000e9;s</surname><given-names>R.</given-names></name>
<name><surname>G&#x000f3;mez</surname><given-names>L.</given-names></name>
<name><surname>Padilla</surname><given-names>S.</given-names></name>
<name><surname>Brito</surname><given-names>J.</given-names></name>
<name><surname>Reyes</surname><given-names>B.</given-names></name>
<name><surname>&#x000c1;lvarez</surname><given-names>T.</given-names></name>
<name><surname>Mendoza</surname><given-names>O.</given-names></name>
<name><surname>Herrera</surname><given-names>O.</given-names></name>
<name><surname>Ferro</surname><given-names>W.</given-names></name>
<name><surname>Pujol</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Large-scale purification of an antibody directed against hepatitis B surface antigen from transgenic tobacco plants</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2003</year><volume>308</volume><fpage>94</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(03)01335-4</pub-id><pub-id pub-id-type="pmid">12890485</pub-id>
</element-citation></ref><ref id="B110-vaccines-13-00191"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Concha</surname><given-names>C.</given-names></name>
<name><surname>Ca&#x000f1;as</surname><given-names>R.</given-names></name>
<name><surname>Macuer</surname><given-names>J.</given-names></name>
<name><surname>Torres</surname><given-names>M.J.</given-names></name>
<name><surname>Herrada</surname><given-names>A.A.</given-names></name>
<name><surname>Jamett</surname><given-names>F.</given-names></name>
<name><surname>Ib&#x000e1;&#x000f1;ez</surname><given-names>C.</given-names></name>
</person-group><article-title>Disease Prevention: An Opportunity to Expand Edible Plant-Based Vaccines?</article-title><source>Vaccines</source><year>2017</year><volume>5</volume><elocation-id>14</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines5020014</pub-id><pub-id pub-id-type="pmid">28556800</pub-id>
</element-citation></ref><ref id="B111-vaccines-13-00191"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>H.-T.</given-names></name>
<name><surname>Daniell</surname><given-names>H.</given-names></name>
</person-group><article-title>Plant-made oral vaccines against human infectious diseases&#x02014;Are we there yet?</article-title><source>Plant Biotechnol. J.</source><year>2015</year><volume>13</volume><fpage>1056</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1111/pbi.12471</pub-id><pub-id pub-id-type="pmid">26387509</pub-id>
</element-citation></ref><ref id="B112-vaccines-13-00191"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Eerde</surname><given-names>A.</given-names></name>
<name><surname>Gottschamel</surname><given-names>J.</given-names></name>
<name><surname>Bock</surname><given-names>R.</given-names></name>
<name><surname>Hansen</surname><given-names>K.E.A.</given-names></name>
<name><surname>Munang&#x02019;andu</surname><given-names>H.M.</given-names></name>
<name><surname>Daniell</surname><given-names>H.</given-names></name>
<name><surname>Liu Clarke</surname><given-names>J.</given-names></name>
</person-group><article-title>Production of tetravalent dengue virus envelope protein domain III based antigens in lettuce chloroplasts and immunologic analysis for future oral vaccine development</article-title><source>Plant Biotechnol. J.</source><year>2019</year><volume>17</volume><fpage>1408</fpage><lpage>1417</lpage><pub-id pub-id-type="doi">10.1111/pbi.13065</pub-id><pub-id pub-id-type="pmid">30578710</pub-id>
</element-citation></ref><ref id="B113-vaccines-13-00191"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clarke</surname><given-names>J.L.</given-names></name>
<name><surname>Paruch</surname><given-names>L.</given-names></name>
<name><surname>Dobrica</surname><given-names>M.-O.</given-names></name>
<name><surname>Caras</surname><given-names>I.</given-names></name>
<name><surname>Tucureanu</surname><given-names>C.</given-names></name>
<name><surname>Onu</surname><given-names>A.</given-names></name>
<name><surname>Ciulean</surname><given-names>S.</given-names></name>
<name><surname>Stavaru</surname><given-names>C.</given-names></name>
<name><surname>Eerde</surname><given-names>A.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Lettuce-produced hepatitis C virus E1E2 heterodimer triggers immune responses in mice and antibody production after oral vaccination</article-title><source>Plant Biotechnol. J.</source><year>2017</year><volume>15</volume><fpage>1611</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.1111/pbi.12743</pub-id><pub-id pub-id-type="pmid">28419665</pub-id>
</element-citation></ref><ref id="B114-vaccines-13-00191"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davod</surname><given-names>J.</given-names></name>
<name><surname>Fatemeh</surname><given-names>D.N.</given-names></name>
<name><surname>Honari</surname><given-names>H.</given-names></name>
<name><surname>Hosseini</surname><given-names>R.</given-names></name>
</person-group><article-title>Constructing and transient expression of a gene cassette containing edible vaccine elements and shigellosis, anthrax and cholera recombinant antigens in tomato</article-title><source>Mol. Biol. Rep.</source><year>2018</year><volume>45</volume><fpage>2237</fpage><lpage>2246</lpage><pub-id pub-id-type="doi">10.1007/s11033-018-4385-3</pub-id><pub-id pub-id-type="pmid">30244396</pub-id>
</element-citation></ref><ref id="B115-vaccines-13-00191"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schillberg</surname><given-names>S.</given-names></name>
<name><surname>Twyman</surname><given-names>R.M.</given-names></name>
<name><surname>Fischer</surname><given-names>R.</given-names></name>
</person-group><article-title>Opportunities for recombinant antigen and antibody expression in transgenic plants&#x02014;Technology assessment</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>1764</fpage><lpage>1769</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.11.002</pub-id><pub-id pub-id-type="pmid">15734038</pub-id>
</element-citation></ref><ref id="B116-vaccines-13-00191"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fischer</surname><given-names>R.</given-names></name>
<name><surname>Stoger</surname><given-names>E.</given-names></name>
<name><surname>Schillberg</surname><given-names>S.</given-names></name>
<name><surname>Christou</surname><given-names>P.</given-names></name>
<name><surname>Twyman</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Plant-based production of biopharmaceuticals</article-title><source>Curr. Opin. Plant Biol.</source><year>2004</year><volume>7</volume><fpage>152</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.pbi.2004.01.007</pub-id><pub-id pub-id-type="pmid">15003215</pub-id>
</element-citation></ref><ref id="B117-vaccines-13-00191"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Timko</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Improving Protein Quantity and Quality&#x02014;The Next Level of Plant Molecular Farming</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>1326</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23031326</pub-id><pub-id pub-id-type="pmid">35163249</pub-id>
</element-citation></ref><ref id="B118-vaccines-13-00191"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruf</surname><given-names>S.</given-names></name>
<name><surname>Hermann</surname><given-names>M.</given-names></name>
<name><surname>Berger</surname><given-names>I.J.</given-names></name>
<name><surname>Carrer</surname><given-names>H.</given-names></name>
<name><surname>Bock</surname><given-names>R.</given-names></name>
</person-group><article-title>Stable genetic transformation of tomato plastids and expression of a foreign protein in fruit</article-title><source>Nat. Biotechnol.</source><year>2001</year><volume>19</volume><fpage>870</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1038/nbt0901-870</pub-id><pub-id pub-id-type="pmid">11533648</pub-id>
</element-citation></ref><ref id="B119-vaccines-13-00191"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramessar</surname><given-names>K.</given-names></name>
<name><surname>Sabalza</surname><given-names>M.</given-names></name>
<name><surname>Capell</surname><given-names>T.</given-names></name>
<name><surname>Christou</surname><given-names>P.</given-names></name>
</person-group><article-title>Maize plants: An ideal production platform for effective and safe molecular pharming</article-title><source>Plant Sci.</source><year>2008</year><volume>174</volume><fpage>409</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1016/j.plantsci.2008.02.002</pub-id></element-citation></ref><ref id="B120-vaccines-13-00191"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwestka</surname><given-names>J.</given-names></name>
<name><surname>Stoger</surname><given-names>E.</given-names></name>
</person-group><article-title>Microparticles and Nanoparticles from Plants&#x02014;The Benefits of Bioencapsulation</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>369</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9040369</pub-id><pub-id pub-id-type="pmid">33920425</pub-id>
</element-citation></ref><ref id="B121-vaccines-13-00191"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clark</surname><given-names>M.</given-names></name>
<name><surname>Maselko</surname><given-names>M.</given-names></name>
</person-group><article-title>Transgene biocontainment strategies for molecular farming</article-title><source>Front. Plant Sci.</source><year>2020</year><volume>11</volume><elocation-id>210</elocation-id><pub-id pub-id-type="doi">10.3389/fpls.2020.00210</pub-id><pub-id pub-id-type="pmid">32194598</pub-id>
</element-citation></ref><ref id="B122-vaccines-13-00191"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Xia</surname><given-names>N.</given-names></name>
<name><surname>Zhao</surname><given-names>Q.</given-names></name>
</person-group><article-title>Escherichia coli-derived virus-like particles in vaccine development</article-title><source>npj Vaccines</source><year>2017</year><volume>2</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1038/s41541-017-0006-8</pub-id><pub-id pub-id-type="pmid">29263864</pub-id>
</element-citation></ref><ref id="B123-vaccines-13-00191"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuruti</surname><given-names>K.</given-names></name>
<name><surname>Vittaladevaram</surname><given-names>V.</given-names></name>
<name><surname>Urity</surname><given-names>S.V.</given-names></name>
<name><surname>Palaniappan</surname><given-names>P.</given-names></name>
<name><surname>Bhaskar</surname><given-names>R.U.</given-names></name>
</person-group><article-title>Evolution of Pichia pastoris as a model organism for vaccines production in healthcare industry</article-title><source>Gene Rep.</source><year>2020</year><volume>21</volume><fpage>100937</fpage><pub-id pub-id-type="doi">10.1016/j.genrep.2020.100937</pub-id></element-citation></ref><ref id="B124-vaccines-13-00191"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Demirden</surname><given-names>S.F.</given-names></name>
<name><surname>Kimiz-Gebologlu</surname><given-names>I.</given-names></name>
<name><surname>Oncel</surname><given-names>S.S.</given-names></name>
</person-group><article-title>Animal Cell Lines as Expression Platforms in Viral Vaccine Production: A Post COVID-19 Perspective</article-title><source>ACS Omega</source><year>2024</year><volume>9</volume><fpage>16904</fpage><lpage>16926</lpage><pub-id pub-id-type="doi">10.1021/acsomega.3c10484</pub-id><pub-id pub-id-type="pmid">38645343</pub-id>
</element-citation></ref><ref id="B125-vaccines-13-00191"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Venkataraman</surname><given-names>S.</given-names></name>
<name><surname>Hefferon</surname><given-names>K.</given-names></name>
<name><surname>Makhzoum</surname><given-names>A.</given-names></name>
<name><surname>Abouhaidar</surname><given-names>M.</given-names></name>
</person-group><article-title>Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer?</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>761</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9070761</pub-id><pub-id pub-id-type="pmid">34358177</pub-id>
</element-citation></ref><ref id="B126-vaccines-13-00191"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cummings</surname><given-names>J.F.</given-names></name>
<name><surname>Guerrero</surname><given-names>M.L.</given-names></name>
<name><surname>Moon</surname><given-names>J.E.</given-names></name>
<name><surname>Waterman</surname><given-names>P.</given-names></name>
<name><surname>Nielsen</surname><given-names>R.K.</given-names></name>
<name><surname>Jefferson</surname><given-names>S.</given-names></name>
<name><surname>Gross</surname><given-names>F.L.</given-names></name>
<name><surname>Hancock</surname><given-names>K.</given-names></name>
<name><surname>Katz</surname><given-names>J.M.</given-names></name>
<name><surname>Yusibov</surname><given-names>V.</given-names></name>
</person-group><article-title>Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: A Phase 1 dose-escalation study in healthy adults</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>2251</fpage><lpage>2259</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.10.017</pub-id><pub-id pub-id-type="pmid">24126211</pub-id>
</element-citation></ref><ref id="B127-vaccines-13-00191"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Makarkov</surname><given-names>A.I.</given-names></name>
<name><surname>Golizeh</surname><given-names>M.</given-names></name>
<name><surname>Ruiz-Lancheros</surname><given-names>E.</given-names></name>
<name><surname>Gopal</surname><given-names>A.A.</given-names></name>
<name><surname>Costas-Cancelas</surname><given-names>I.N.</given-names></name>
<name><surname>Chierzi</surname><given-names>S.</given-names></name>
<name><surname>Pillet</surname><given-names>S.</given-names></name>
<name><surname>Charland</surname><given-names>N.</given-names></name>
<name><surname>Landry</surname><given-names>N.</given-names></name>
<name><surname>Rouiller</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages</article-title><source>npj Vaccines</source><year>2019</year><volume>4</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1038/s41541-019-0111-y</pub-id><pub-id pub-id-type="pmid">31123605</pub-id>
</element-citation></ref><ref id="B128-vaccines-13-00191"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gaobotse</surname><given-names>G.</given-names></name>
<name><surname>Venkataraman</surname><given-names>S.</given-names></name>
<name><surname>Mmereke</surname><given-names>K.M.</given-names></name>
<name><surname>Moustafa</surname><given-names>K.</given-names></name>
<name><surname>Hefferon</surname><given-names>K.</given-names></name>
<name><surname>Makhzoum</surname><given-names>A.</given-names></name>
</person-group><article-title>Recent Progress on Vaccines Produced in Transgenic Plants</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1861</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10111861</pub-id><pub-id pub-id-type="pmid">36366370</pub-id>
</element-citation></ref><ref id="B129-vaccines-13-00191"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mardanova</surname><given-names>E.S.</given-names></name>
<name><surname>Vasyagin</surname><given-names>E.A.</given-names></name>
<name><surname>Ravin</surname><given-names>N.V.</given-names></name>
</person-group><article-title>Virus-like Particles Produced in Plants: A Promising Platform for Recombinant Vaccine Development</article-title><source>Plants</source><year>2024</year><volume>13</volume><elocation-id>3564</elocation-id><pub-id pub-id-type="doi">10.3390/plants13243564</pub-id><pub-id pub-id-type="pmid">39771262</pub-id>
</element-citation></ref><ref id="B130-vaccines-13-00191"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moradi Vahdat</surname><given-names>M.</given-names></name>
<name><surname>Hemmati</surname><given-names>F.</given-names></name>
<name><surname>Ghorbani</surname><given-names>A.</given-names></name>
<name><surname>Rutkowska</surname><given-names>D.</given-names></name>
<name><surname>Afsharifar</surname><given-names>A.</given-names></name>
<name><surname>Eskandari</surname><given-names>M.H.</given-names></name>
<name><surname>Rezaei</surname><given-names>N.</given-names></name>
<name><surname>Niazi</surname><given-names>A.</given-names></name>
</person-group><article-title>Hepatitis B core-based virus-like particles: A platform for vaccine development in plants</article-title><source>Biotechnol. Rep.</source><year>2021</year><volume>29</volume><elocation-id>e00605</elocation-id><pub-id pub-id-type="doi">10.1016/j.btre.2021.e00605</pub-id></element-citation></ref><ref id="B131-vaccines-13-00191"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jones</surname><given-names>R.M.</given-names></name>
<name><surname>Chichester</surname><given-names>J.A.</given-names></name>
<name><surname>Mett</surname><given-names>V.</given-names></name>
<name><surname>Jaje</surname><given-names>J.</given-names></name>
<name><surname>Tottey</surname><given-names>S.</given-names></name>
<name><surname>Manceva</surname><given-names>S.</given-names></name>
<name><surname>Casta</surname><given-names>L.J.</given-names></name>
<name><surname>Gibbs</surname><given-names>S.K.</given-names></name>
<name><surname>Musiychuk</surname><given-names>K.</given-names></name>
<name><surname>Shamloul</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e79538</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0079538</pub-id><pub-id pub-id-type="pmid">24260245</pub-id>
</element-citation></ref><ref id="B132-vaccines-13-00191"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>S.-J.</given-names></name>
<name><surname>Kim</surname><given-names>H.</given-names></name>
<name><surname>Jang</surname><given-names>E.Y.</given-names></name>
<name><surname>Jeon</surname><given-names>H.</given-names></name>
<name><surname>Diao</surname><given-names>H.-P.</given-names></name>
<name><surname>Khan</surname><given-names>M.R.I.</given-names></name>
<name><surname>Lee</surname><given-names>M.-S.</given-names></name>
<name><surname>Lee</surname><given-names>Y.J.</given-names></name>
<name><surname>Nam</surname><given-names>J.-h.</given-names></name>
<name><surname>Kim</surname><given-names>S.-R.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 spike trimer vaccine expressed in <italic toggle="yes">Nicotiana benthamiana</italic> adjuvanted with Alum elicits protective immune responses in mice</article-title><source>Plant Biotechnol. J.</source><year>2022</year><volume>20</volume><fpage>2298</fpage><lpage>2312</lpage><pub-id pub-id-type="doi">10.1111/pbi.13908</pub-id><pub-id pub-id-type="pmid">36062974</pub-id>
</element-citation></ref><ref id="B133-vaccines-13-00191"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lemmer</surname><given-names>Y.</given-names></name>
<name><surname>Chapman</surname><given-names>R.</given-names></name>
<name><surname>Abolnik</surname><given-names>C.</given-names></name>
<name><surname>Smith</surname><given-names>T.</given-names></name>
<name><surname>Sch&#x000e4;fer</surname><given-names>G.</given-names></name>
<name><surname>Hermanus</surname><given-names>T.</given-names></name>
<name><surname>du Preez</surname><given-names>I.</given-names></name>
<name><surname>Goosen</surname><given-names>K.</given-names></name>
<name><surname>Sepotokele</surname><given-names>K.M.</given-names></name>
<name><surname>Gers</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><fpage>738</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.01.036</pub-id><pub-id pub-id-type="pmid">38238112</pub-id>
</element-citation></ref><ref id="B134-vaccines-13-00191"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Landry</surname><given-names>N.</given-names></name>
<name><surname>Pillet</surname><given-names>S.</given-names></name>
<name><surname>Favre</surname><given-names>D.</given-names></name>
<name><surname>Poulin</surname><given-names>J.-F.</given-names></name>
<name><surname>Tr&#x000e9;panier</surname><given-names>S.</given-names></name>
<name><surname>Yassine-Diab</surname><given-names>B.</given-names></name>
<name><surname>Ward</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Influenza virus-like particle vaccines made in <italic toggle="yes">Nicotiana benthamiana</italic> elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens</article-title><source>Clin. Immunol.</source><year>2014</year><volume>154</volume><fpage>164</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2014.08.003</pub-id><pub-id pub-id-type="pmid">25128897</pub-id>
</element-citation></ref><ref id="B135-vaccines-13-00191"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chichester</surname><given-names>J.A.</given-names></name>
<name><surname>Green</surname><given-names>B.J.</given-names></name>
<name><surname>Jones</surname><given-names>R.M.</given-names></name>
<name><surname>Shoji</surname><given-names>Y.</given-names></name>
<name><surname>Miura</surname><given-names>K.</given-names></name>
<name><surname>Long</surname><given-names>C.A.</given-names></name>
<name><surname>Lee</surname><given-names>C.K.</given-names></name>
<name><surname>Ockenhouse</surname><given-names>C.F.</given-names></name>
<name><surname>Morin</surname><given-names>M.J.</given-names></name>
<name><surname>Streatfield</surname><given-names>S.J.</given-names></name>
<etal/>
</person-group><article-title>Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>5865</fpage><lpage>5871</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.08.033</pub-id><pub-id pub-id-type="pmid">30126674</pub-id>
</element-citation></ref><ref id="B136-vaccines-13-00191"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mathew</surname><given-names>L.G.</given-names></name>
<name><surname>Herbst-Kralovetz</surname><given-names>M.M.</given-names></name>
<name><surname>Mason</surname><given-names>H.S.</given-names></name>
</person-group><article-title>Norovirus Narita 104 Virus-Like Particles Expressed in <italic toggle="yes">Nicotiana benthamiana</italic> Induce Serum and Mucosal Immune Responses</article-title><source>BioMed Res. Int.</source><year>2014</year><volume>2014</volume><elocation-id>807539</elocation-id><pub-id pub-id-type="doi">10.1155/2014/807539</pub-id><pub-id pub-id-type="pmid">24949472</pub-id>
</element-citation></ref><ref id="B137-vaccines-13-00191"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>Y.</given-names></name>
<name><surname>Kang</surname><given-names>H.</given-names></name>
<name><surname>Min</surname><given-names>K.</given-names></name>
<name><surname>Kim</surname><given-names>N.H.</given-names></name>
<name><surname>Park</surname><given-names>M.</given-names></name>
<name><surname>Ouh</surname><given-names>I.-O.</given-names></name>
<name><surname>Ha-Hyun</surname><given-names>K.</given-names></name>
<name><surname>Jae-Young</surname><given-names>S.</given-names></name>
<name><surname>Dong-Kun</surname><given-names>Y.</given-names></name>
<name><surname>Sohn</surname><given-names>E.-J.</given-names></name>
</person-group><article-title>Rabies virus glycoprotein produced in <italic toggle="yes">Nicotiana benthamiana</italic> is an immunogenic antigen in mice</article-title><source>Czech J. Genet. Plant Breed.</source><year>2021</year><volume>57</volume><fpage>26</fpage><pub-id pub-id-type="doi">10.17221/25/2020-CJGPB</pub-id></element-citation></ref><ref id="B138-vaccines-13-00191"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamorsky</surname><given-names>K.T.</given-names></name>
<name><surname>Kouokam</surname><given-names>J.C.</given-names></name>
<name><surname>Jurkiewicz</surname><given-names>J.M.</given-names></name>
<name><surname>Nelson</surname><given-names>B.</given-names></name>
<name><surname>Moore</surname><given-names>L.J.</given-names></name>
<name><surname>Husk</surname><given-names>A.S.</given-names></name>
<name><surname>Kajiura</surname><given-names>H.</given-names></name>
<name><surname>Fujiyama</surname><given-names>K.</given-names></name>
<name><surname>Matoba</surname><given-names>N.</given-names></name>
</person-group><article-title>N-Glycosylation of cholera toxin B subunit in <italic toggle="yes">Nicotiana benthamiana</italic>: Impacts on host stress response, production yield and vaccine potential</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><elocation-id>8003</elocation-id><pub-id pub-id-type="doi">10.1038/srep08003</pub-id><pub-id pub-id-type="pmid">25614217</pub-id>
</element-citation></ref><ref id="B139-vaccines-13-00191"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Warzecha</surname><given-names>H.</given-names></name>
<name><surname>Mason Hugh</surname><given-names>S.</given-names></name>
<name><surname>Lane</surname><given-names>C.</given-names></name>
<name><surname>Tryggvesson</surname><given-names>A.</given-names></name>
<name><surname>Rybicki</surname><given-names>E.</given-names></name>
<name><surname>Williamson</surname><given-names>A.-L.</given-names></name>
<name><surname>Clements John</surname><given-names>D.</given-names></name>
<name><surname>Rose Robert</surname><given-names>C.</given-names></name>
</person-group><article-title>Oral Immunogenicity of Human Papillomavirus-Like Particles Expressed in Potato</article-title><source>J. Virol.</source><year>2003</year><volume>77</volume><fpage>8702</fpage><lpage>8711</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.16.8702-8711.2003</pub-id><pub-id pub-id-type="pmid">12885889</pub-id>
</element-citation></ref><ref id="B140-vaccines-13-00191"><label>140.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Bhatia</surname><given-names>S.</given-names></name>
<name><surname>Dahiya</surname><given-names>R.</given-names></name>
</person-group><article-title>Chapter 9&#x02014;Edible Vaccines</article-title><source>Modern Applications of Plant Biotechnology in Pharmaceutical Sciences</source><person-group person-group-type="editor">
<name><surname>Bhatia</surname><given-names>S.</given-names></name>
<name><surname>Sharma</surname><given-names>K.</given-names></name>
<name><surname>Dahiya</surname><given-names>R.</given-names></name>
<name><surname>Bera</surname><given-names>T.</given-names></name>
</person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Boston, MA, USA</publisher-loc><year>2015</year><fpage>333</fpage><lpage>343</lpage></element-citation></ref><ref id="B141-vaccines-13-00191"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jain</surname><given-names>A.</given-names></name>
<name><surname>Saini</surname><given-names>V.</given-names></name>
<name><surname>Veer Kohli</surname><given-names>D.</given-names></name>
</person-group><article-title>Edible transgenic plant vaccines for different diseases</article-title><source>Curr. Pharm. Biotechnol.</source><year>2013</year><volume>14</volume><fpage>594</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.2174/138920101131400225</pub-id><pub-id pub-id-type="pmid">24016268</pub-id>
</element-citation></ref><ref id="B142-vaccines-13-00191"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miquel-Clop&#x000e9;s</surname><given-names>A.</given-names></name>
<name><surname>Bentley</surname><given-names>E.G.</given-names></name>
<name><surname>Stewart</surname><given-names>J.P.</given-names></name>
<name><surname>Carding</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Mucosal vaccines and technology</article-title><source>Clin. Exp. Immunol.</source><year>2019</year><volume>196</volume><fpage>205</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1111/cei.13285</pub-id><pub-id pub-id-type="pmid">30963541</pub-id>
</element-citation></ref><ref id="B143-vaccines-13-00191"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klojdov&#x000e1;</surname><given-names>I.</given-names></name>
<name><surname>Milota</surname><given-names>T.</given-names></name>
<name><surname>Smetanov&#x000e1;</surname><given-names>J.</given-names></name>
<name><surname>Stathopoulos</surname><given-names>C.</given-names></name>
</person-group><article-title>Encapsulation: A Strategy to Deliver Therapeutics and Bioactive Compounds?</article-title><source>Pharmaceuticals</source><year>2023</year><volume>16</volume><elocation-id>362</elocation-id><pub-id pub-id-type="doi">10.3390/ph16030362</pub-id><pub-id pub-id-type="pmid">36986462</pub-id>
</element-citation></ref><ref id="B144-vaccines-13-00191"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weerarathna</surname><given-names>I.N.</given-names></name>
<name><surname>Doelakeh</surname><given-names>E.S.</given-names></name>
<name><surname>Kiwanuka</surname><given-names>L.</given-names></name>
<name><surname>Kumar</surname><given-names>P.</given-names></name>
<name><surname>Arora</surname><given-names>S.</given-names></name>
</person-group><article-title>Prophylactic and therapeutic vaccine development: Advancements and challenges</article-title><source>Mol. Biomed.</source><year>2024</year><volume>5</volume><elocation-id>57</elocation-id><pub-id pub-id-type="doi">10.1186/s43556-024-00222-x</pub-id><pub-id pub-id-type="pmid">39527305</pub-id>
</element-citation></ref><ref id="B145-vaccines-13-00191"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wong-Arce</surname><given-names>A.</given-names></name>
<name><surname>Gonz&#x000e1;lez-Ortega</surname><given-names>O.</given-names></name>
<name><surname>Rosales-Mendoza</surname><given-names>S.</given-names></name>
</person-group><article-title>Plant-Made Vaccines in the Fight Against Cancer</article-title><source>Trends Biotechnol.</source><year>2017</year><volume>35</volume><fpage>241</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2016.12.002</pub-id><pub-id pub-id-type="pmid">28153391</pub-id>
</element-citation></ref><ref id="B146-vaccines-13-00191"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dent</surname><given-names>M.</given-names></name>
<name><surname>Matoba</surname><given-names>N.</given-names></name>
</person-group><article-title>Cancer biologics made in plants</article-title><source>Curr. Opin. Biotechnol.</source><year>2020</year><volume>61</volume><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2019.11.004</pub-id><pub-id pub-id-type="pmid">31785553</pub-id>
</element-citation></ref><ref id="B147-vaccines-13-00191"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>B.</given-names></name>
<name><surname>Sadaria</surname><given-names>D.</given-names></name>
<name><surname>Warrier</surname><given-names>V.U.</given-names></name>
<name><surname>Kirtonia</surname><given-names>A.</given-names></name>
<name><surname>Kant</surname><given-names>R.</given-names></name>
<name><surname>Awasthi</surname><given-names>A.</given-names></name>
<name><surname>Baligar</surname><given-names>P.</given-names></name>
<name><surname>Pal</surname><given-names>J.K.</given-names></name>
<name><surname>Yuba</surname><given-names>E.</given-names></name>
<name><surname>Sethi</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy</article-title><source>Semin. Cancer Biol.</source><year>2022</year><volume>80</volume><fpage>87</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2020.02.005</pub-id><pub-id pub-id-type="pmid">32068087</pub-id>
</element-citation></ref><ref id="B148-vaccines-13-00191"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamley</surname><given-names>I.W.</given-names></name>
</person-group><article-title>Peptides for Vaccine Development</article-title><source>ACS Appl. Bio Mater.</source><year>2022</year><volume>5</volume><fpage>905</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1021/acsabm.1c01238</pub-id><pub-id pub-id-type="pmid">35195008</pub-id>
</element-citation></ref><ref id="B149-vaccines-13-00191"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCormick</surname><given-names>A.A.</given-names></name>
<name><surname>Reddy</surname><given-names>S.</given-names></name>
<name><surname>Reinl</surname><given-names>S.J.</given-names></name>
<name><surname>Cameron</surname><given-names>T.I.</given-names></name>
<name><surname>Czerwinkski</surname><given-names>D.K.</given-names></name>
<name><surname>Vojdani</surname><given-names>F.</given-names></name>
<name><surname>Hanley</surname><given-names>K.M.</given-names></name>
<name><surname>Garger</surname><given-names>S.J.</given-names></name>
<name><surname>White</surname><given-names>E.L.</given-names></name>
<name><surname>Novak</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Plant-produced idiotype vaccines for the treatment of non-Hodgkin&#x02019;s lymphoma: Safety and immunogenicity in a phase I clinical study</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>10131</fpage><lpage>10136</lpage><pub-id pub-id-type="doi">10.1073/pnas.0803636105</pub-id><pub-id pub-id-type="pmid">18645180</pub-id>
</element-citation></ref><ref id="B150-vaccines-13-00191"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zampieri</surname><given-names>R.</given-names></name>
<name><surname>Brozzetti</surname><given-names>A.</given-names></name>
<name><surname>Pericolini</surname><given-names>E.</given-names></name>
<name><surname>Bartoloni</surname><given-names>E.</given-names></name>
<name><surname>Gabrielli</surname><given-names>E.</given-names></name>
<name><surname>Roselletti</surname><given-names>E.</given-names></name>
<name><surname>Lomonosoff</surname><given-names>G.</given-names></name>
<name><surname>Meshcheriakova</surname><given-names>Y.</given-names></name>
<name><surname>Santi</surname><given-names>L.</given-names></name>
<name><surname>Imperatori</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Prevention and treatment of autoimmune diseases with plant virus nanoparticles</article-title><source>Sci. Adv.</source><year>2020</year><volume>6</volume><fpage>eaaz0295</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aaz0295</pub-id><pub-id pub-id-type="pmid">32494704</pub-id>
</element-citation></ref><ref id="B151-vaccines-13-00191"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>A.</given-names></name>
<name><surname>Xie</surname><given-names>F.</given-names></name>
<name><surname>Abed</surname><given-names>O.A.</given-names></name>
<name><surname>Moon</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Vaccines for immune tolerance against autoimmune disease</article-title><source>Adv. Drug Deliv. Rev.</source><year>2023</year><volume>203</volume><fpage>115140</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2023.115140</pub-id><pub-id pub-id-type="pmid">37980949</pub-id>
</element-citation></ref><ref id="B152-vaccines-13-00191"><label>152.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Takaiwa</surname><given-names>F.</given-names></name>
</person-group><article-title>Antigen-Specific Immunotherapy for Allergic and Autoimmune Diseases Using Plant-Made Antigens</article-title><source>Applications of Plant Molecular Farming</source><person-group person-group-type="editor">
<name><surname>Kole</surname><given-names>C.</given-names></name>
<name><surname>Chaurasia</surname><given-names>A.</given-names></name>
<name><surname>Hefferon</surname><given-names>K.L.</given-names></name>
<name><surname>Panigrahi</surname><given-names>J.</given-names></name>
</person-group><publisher-name>Springer Nature</publisher-name><publisher-loc>Singapore</publisher-loc><year>2024</year><fpage>415</fpage><lpage>454</lpage></element-citation></ref><ref id="B153-vaccines-13-00191"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shakya</surname><given-names>A.K.</given-names></name>
<name><surname>Mallick</surname><given-names>B.</given-names></name>
<name><surname>Nandakumar</surname><given-names>K.S.</given-names></name>
</person-group><article-title>A Perspective on Oral Immunotherapeutic Tools and Strategies for Autoimmune Disorders</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1031</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11061031</pub-id><pub-id pub-id-type="pmid">37376420</pub-id>
</element-citation></ref><ref id="B154-vaccines-13-00191"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishiura</surname><given-names>S.</given-names></name>
<name><surname>Yoshida</surname><given-names>T.</given-names></name>
</person-group><article-title>Plant-based vaccines for Alzheimer&#x02019;s disease</article-title><source>Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.</source><year>2019</year><volume>95</volume><fpage>290</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.2183/pjab.95.020</pub-id></element-citation></ref><ref id="B155-vaccines-13-00191"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salazar-Gonzalez</surname><given-names>J.A.</given-names></name>
<name><surname>Rosales-Mendoza</surname><given-names>S.</given-names></name>
<name><surname>Romero-Maldonado</surname><given-names>A.</given-names></name>
<name><surname>Monreal-Escalante</surname><given-names>E.</given-names></name>
<name><surname>Uresti-Rivera</surname><given-names>E.E.</given-names></name>
<name><surname>Ba&#x000f1;uelos-Hern&#x000e1;ndez</surname><given-names>B.</given-names></name>
</person-group><article-title>Production of a Plant-Derived Immunogenic Protein Targeting ApoB100 and CETP: Toward a Plant-Based Atherosclerosis Vaccine</article-title><source>Mol. Biotechnol.</source><year>2014</year><volume>56</volume><fpage>1133</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1007/s12033-014-9793-6</pub-id><pub-id pub-id-type="pmid">25143122</pub-id>
</element-citation></ref><ref id="B156-vaccines-13-00191"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>A.A.</given-names></name>
<name><surname>Pooe</surname><given-names>O.</given-names></name>
<name><surname>Kwezi</surname><given-names>L.</given-names></name>
<name><surname>Lotter-Stark</surname><given-names>T.</given-names></name>
<name><surname>Stoychev</surname><given-names>S.H.</given-names></name>
<name><surname>Alexandra</surname><given-names>K.</given-names></name>
<name><surname>Gerber</surname><given-names>I.</given-names></name>
<name><surname>Bhiman</surname><given-names>J.N.</given-names></name>
<name><surname>Vorster</surname><given-names>J.</given-names></name>
<name><surname>Pauly</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>6201</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-63052-1</pub-id><pub-id pub-id-type="pmid">32277089</pub-id>
</element-citation></ref><ref id="B157-vaccines-13-00191"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karasev</surname><given-names>A.V.</given-names></name>
<name><surname>Foulke</surname><given-names>S.</given-names></name>
<name><surname>Wellens</surname><given-names>C.</given-names></name>
<name><surname>Rich</surname><given-names>A.</given-names></name>
<name><surname>Shon</surname><given-names>K.J.</given-names></name>
<name><surname>Zwierzynski</surname><given-names>I.</given-names></name>
<name><surname>Hone</surname><given-names>D.</given-names></name>
<name><surname>Koprowski</surname><given-names>H.</given-names></name>
<name><surname>Reitz</surname><given-names>M.</given-names></name>
</person-group><article-title>Plant based HIV-1 vaccine candidate: Tat protein produced in spinach</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>1875</fpage><lpage>1880</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.11.021</pub-id><pub-id pub-id-type="pmid">15734059</pub-id>
</element-citation></ref><ref id="B158-vaccines-13-00191"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>H.</given-names></name>
<name><surname>Kwon</surname><given-names>K.W.</given-names></name>
<name><surname>Park</surname><given-names>J.</given-names></name>
<name><surname>Kang</surname><given-names>H.</given-names></name>
<name><surname>Lee</surname><given-names>Y.</given-names></name>
<name><surname>Sohn</surname><given-names>E.-J.</given-names></name>
<name><surname>Hwang</surname><given-names>I.</given-names></name>
<name><surname>Eum</surname><given-names>S.-Y.</given-names></name>
<name><surname>Shin</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Plant-Produced N-glycosylated Ag85A Exhibits Enhanced Vaccine Efficacy Against Mycobacterium tuberculosis HN878 Through Balanced Multifunctional Th1 T Cell Immunity</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>189</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8020189</pub-id><pub-id pub-id-type="pmid">32325740</pub-id>
</element-citation></ref><ref id="B159-vaccines-13-00191"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kolotilin</surname><given-names>I.</given-names></name>
<name><surname>Topp</surname><given-names>E.</given-names></name>
<name><surname>Cox</surname><given-names>E.</given-names></name>
<name><surname>Devriendt</surname><given-names>B.</given-names></name>
<name><surname>Conrad</surname><given-names>U.</given-names></name>
<name><surname>Joensuu</surname><given-names>J.</given-names></name>
<name><surname>St&#x000f6;ger</surname><given-names>E.</given-names></name>
<name><surname>Warzecha</surname><given-names>H.</given-names></name>
<name><surname>McAllister</surname><given-names>T.</given-names></name>
<name><surname>Potter</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Plant-based solutions for veterinary immunotherapeutics and prophylactics</article-title><source>Vet. Res.</source><year>2014</year><volume>45</volume><fpage>117</fpage><pub-id pub-id-type="doi">10.1186/s13567-014-0117-4</pub-id><pub-id pub-id-type="pmid">25559098</pub-id>
</element-citation></ref><ref id="B160-vaccines-13-00191"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zahmanova</surname><given-names>G.</given-names></name>
<name><surname>Takova</surname><given-names>K.</given-names></name>
<name><surname>Valkova</surname><given-names>R.</given-names></name>
<name><surname>Toneva</surname><given-names>V.</given-names></name>
<name><surname>Minkov</surname><given-names>I.</given-names></name>
<name><surname>Andonov</surname><given-names>A.</given-names></name>
<name><surname>Lukov</surname><given-names>G.L.</given-names></name>
</person-group><article-title>Plant-Derived Recombinant Vaccines against Zoonotic Viruses</article-title><source>Life</source><year>2022</year><volume>12</volume><elocation-id>156</elocation-id><pub-id pub-id-type="doi">10.3390/life12020156</pub-id><pub-id pub-id-type="pmid">35207444</pub-id>
</element-citation></ref><ref id="B161-vaccines-13-00191"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rybicki</surname><given-names>E.P.</given-names></name>
</person-group><article-title>Plant-based vaccines against viruses</article-title><source>Virol. J.</source><year>2014</year><volume>11</volume><fpage>205</fpage><pub-id pub-id-type="doi">10.1186/s12985-014-0205-0</pub-id><pub-id pub-id-type="pmid">25465382</pub-id>
</element-citation></ref><ref id="B162-vaccines-13-00191"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ryu</surname><given-names>G.</given-names></name>
<name><surname>Ahn</surname><given-names>G.</given-names></name>
<name><surname>Cha</surname><given-names>J.-Y.</given-names></name>
<name><surname>Silvano</surname><given-names>K.J.</given-names></name>
<name><surname>Lee</surname><given-names>C.</given-names></name>
<name><surname>Lee</surname><given-names>K.-R.</given-names></name>
<name><surname>Hwang</surname><given-names>I.</given-names></name>
<name><surname>Kim</surname><given-names>W.-Y.</given-names></name>
<name><surname>Kim</surname><given-names>M.G.</given-names></name>
</person-group><article-title>Production of Plant-Based Recombinant Vaccine Against Porcine Deltacoronavirus in the Form of Bacteria-Like Particles Using Lactococcus lactis</article-title><source>J. Plant Biol.</source><year>2024</year><volume>67</volume><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1007/s12374-023-09416-2</pub-id></element-citation></ref><ref id="B163-vaccines-13-00191"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramos-Vega</surname><given-names>A.</given-names></name>
<name><surname>Monreal-Escalante</surname><given-names>E.</given-names></name>
<name><surname>Dumonteil</surname><given-names>E.</given-names></name>
<name><surname>Ba&#x000f1;uelos-Hern&#x000e1;ndez</surname><given-names>B.</given-names></name>
<name><surname>Angulo</surname><given-names>C.</given-names></name>
</person-group><article-title>Plant-made vaccines against parasites: Bioinspired perspectives to fight against Chagas disease</article-title><source>Expert Rev. Vaccines</source><year>2021</year><volume>20</volume><fpage>1373</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1080/14760584.2021.1893170</pub-id><pub-id pub-id-type="pmid">33612044</pub-id>
</element-citation></ref><ref id="B164-vaccines-13-00191"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zwanenburg</surname><given-names>L.</given-names></name>
<name><surname>Borloo</surname><given-names>J.</given-names></name>
<name><surname>Decorte</surname><given-names>B.</given-names></name>
<name><surname>Bunte</surname><given-names>M.J.M.</given-names></name>
<name><surname>Mokhtari</surname><given-names>S.</given-names></name>
<name><surname>Serna</surname><given-names>S.</given-names></name>
<name><surname>Reichardt</surname><given-names>N.-C.</given-names></name>
<name><surname>Seys</surname><given-names>L.J.M.</given-names></name>
<name><surname>van Diepen</surname><given-names>A.</given-names></name>
<name><surname>Schots</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Plant-based production of a protective vaccine antigen against the bovine parasitic nematode <italic toggle="yes">Ostertagia ostertagi</italic></article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>20488</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-47480-3</pub-id><pub-id pub-id-type="pmid">37993516</pub-id>
</element-citation></ref><ref id="B165-vaccines-13-00191"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gebreyes</surname><given-names>W.A.</given-names></name>
<name><surname>Dupouy-Camet</surname><given-names>J.</given-names></name>
<name><surname>Newport</surname><given-names>M.J.</given-names></name>
<name><surname>Oliveira</surname><given-names>C.J.B.</given-names></name>
<name><surname>Schlesinger</surname><given-names>L.S.</given-names></name>
<name><surname>Saif</surname><given-names>Y.M.</given-names></name>
<name><surname>Kariuki</surname><given-names>S.</given-names></name>
<name><surname>Saif</surname><given-names>L.J.</given-names></name>
<name><surname>Saville</surname><given-names>W.</given-names></name>
<name><surname>Wittum</surname><given-names>T.</given-names></name>
</person-group><article-title>The global one health paradigm: Challenges and opportunities for tackling infectious diseases at the human, animal, and environment interface in low-resource settings</article-title><source>PLoS Neglected Trop. Dis.</source><year>2014</year><volume>8</volume><elocation-id>e3257</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0003257</pub-id><pub-id pub-id-type="pmid">25393303</pub-id>
</element-citation></ref><ref id="B166-vaccines-13-00191"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hahn</surname><given-names>B.-S.</given-names></name>
<name><surname>Jeon</surname><given-names>I.-S.</given-names></name>
<name><surname>Jung</surname><given-names>Y.-J.</given-names></name>
<name><surname>Kim</surname><given-names>J.-B.</given-names></name>
<name><surname>Park</surname><given-names>J.-S.</given-names></name>
<name><surname>Ha</surname><given-names>S.-H.</given-names></name>
<name><surname>Kim</surname><given-names>K.-H.</given-names></name>
<name><surname>Kim</surname><given-names>H.-M.</given-names></name>
<name><surname>Yang</surname><given-names>J.-S.</given-names></name>
<name><surname>Kim</surname><given-names>Y.-H.</given-names></name>
</person-group><article-title>Expression of hemagglutinin-neuraminidase protein of Newcastle disease virus in transgenic tobacco</article-title><source>Plant Biotechnol. Rep.</source><year>2007</year><volume>1</volume><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/s11816-007-0012-9</pub-id></element-citation></ref><ref id="B167-vaccines-13-00191"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andrianova</surname><given-names>E.P.</given-names></name>
<name><surname>Krementsugskaia</surname><given-names>S.R.</given-names></name>
<name><surname>Lugovskaia</surname><given-names>N.N.</given-names></name>
<name><surname>Mayorova</surname><given-names>T.K.</given-names></name>
<name><surname>Borisov</surname><given-names>V.V.</given-names></name>
<name><surname>Eldarov</surname><given-names>M.A.</given-names></name>
<name><surname>Ravin</surname><given-names>N.V.</given-names></name>
<name><surname>Folimonov</surname><given-names>A.S.</given-names></name>
<name><surname>Skryabin</surname><given-names>K.G.</given-names></name>
</person-group><article-title>Foot and mouth disease virus polyepitope protein produced in bacteria and plants induces protective immunity in guinea pigs</article-title><source>Biochemistry</source><year>2011</year><volume>76</volume><fpage>339</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1134/S0006297911030072</pub-id><pub-id pub-id-type="pmid">21568869</pub-id>
</element-citation></ref><ref id="B168-vaccines-13-00191"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Modelska</surname><given-names>A.</given-names></name>
<name><surname>Dietzschold</surname><given-names>B.</given-names></name>
<name><surname>Sleysh</surname><given-names>N.</given-names></name>
<name><surname>Fu</surname><given-names>Z.F.</given-names></name>
<name><surname>Steplewski</surname><given-names>K.</given-names></name>
<name><surname>Hooper</surname><given-names>D.C.</given-names></name>
<name><surname>Koprowski</surname><given-names>H.</given-names></name>
<name><surname>Yusibov</surname><given-names>V.</given-names></name>
</person-group><article-title>Immunization against rabies with plant-derived antigen</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1998</year><volume>95</volume><fpage>2481</fpage><lpage>2485</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.5.2481</pub-id><pub-id pub-id-type="pmid">9482911</pub-id>
</element-citation></ref><ref id="B169-vaccines-13-00191"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nurzijah</surname><given-names>I.</given-names></name>
<name><surname>Elbohy</surname><given-names>O.A.</given-names></name>
<name><surname>Kanyuka</surname><given-names>K.</given-names></name>
<name><surname>Daly</surname><given-names>J.M.</given-names></name>
<name><surname>Dunham</surname><given-names>S.</given-names></name>
</person-group><article-title>Development of Plant-Based Vaccines for Prevention of Avian Influenza and Newcastle Disease in Poultry</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>478</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10030478</pub-id><pub-id pub-id-type="pmid">35335110</pub-id>
</element-citation></ref><ref id="B170-vaccines-13-00191"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>R.K.</given-names></name>
<name><surname>Sharma</surname><given-names>G.K.</given-names></name>
<name><surname>Mahajan</surname><given-names>S.</given-names></name>
<name><surname>Dhama</surname><given-names>K.</given-names></name>
<name><surname>Basagoudanavar</surname><given-names>S.H.</given-names></name>
<name><surname>Hosamani</surname><given-names>M.</given-names></name>
<name><surname>Sreenivasa</surname><given-names>B.P.</given-names></name>
<name><surname>Chaicumpa</surname><given-names>W.</given-names></name>
<name><surname>Gupta</surname><given-names>V.K.</given-names></name>
<name><surname>Sanyal</surname><given-names>A.</given-names></name>
</person-group><article-title>Foot-and-Mouth Disease Virus: Immunobiology, Advances in Vaccines and Vaccination Strategies Addressing Vaccine Failures&#x02014;An Indian Perspective</article-title><source>Vaccines</source><year>2019</year><volume>7</volume><elocation-id>90</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines7030090</pub-id><pub-id pub-id-type="pmid">31426368</pub-id>
</element-citation></ref><ref id="B171-vaccines-13-00191"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saeed</surname><given-names>A.</given-names></name>
<name><surname>Kanwal</surname><given-names>S.</given-names></name>
<name><surname>Arshad</surname><given-names>M.</given-names></name>
<name><surname>Ali</surname><given-names>M.</given-names></name>
<name><surname>Shaikh</surname><given-names>R.S.</given-names></name>
<name><surname>Abubakar</surname><given-names>M.</given-names></name>
</person-group><article-title>Foot-and-mouth disease: Overview of motives of disease spread and efficacy of available vaccines</article-title><source>J. Anim. Sci. Technol.</source><year>2015</year><volume>57</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/s40781-015-0042-8</pub-id><pub-id pub-id-type="pmid">26290730</pub-id>
</element-citation></ref><ref id="B172-vaccines-13-00191"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Merlin</surname><given-names>M.</given-names></name>
<name><surname>Pezzotti</surname><given-names>M.</given-names></name>
<name><surname>Avesani</surname><given-names>L.</given-names></name>
</person-group><article-title>Edible plants for oral delivery of biopharmaceuticals</article-title><source>Br. J. Clin. Pharmacol.</source><year>2017</year><volume>83</volume><fpage>71</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1111/bcp.12949</pub-id><pub-id pub-id-type="pmid">27037892</pub-id>
</element-citation></ref><ref id="B173-vaccines-13-00191"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yusibov</surname><given-names>V.</given-names></name>
<name><surname>Rabindran</surname><given-names>S.</given-names></name>
</person-group><article-title>Recent progress in the development of plant derived vaccines</article-title><source>Expert Rev. Vaccines</source><year>2008</year><volume>7</volume><fpage>1173</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1586/14760584.7.8.1173</pub-id><pub-id pub-id-type="pmid">18844592</pub-id>
</element-citation></ref><ref id="B174-vaccines-13-00191"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yin</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>G.</given-names></name>
<name><surname>Ren</surname><given-names>X.</given-names></name>
<name><surname>Herrler</surname><given-names>G.</given-names></name>
</person-group><article-title>Select what you need: A comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes</article-title><source>J. Biotechnol.</source><year>2007</year><volume>127</volume><fpage>335</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2006.07.012</pub-id><pub-id pub-id-type="pmid">16959350</pub-id>
</element-citation></ref><ref id="B175-vaccines-13-00191"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huebbers</surname><given-names>J.W.</given-names></name>
<name><surname>Buyel</surname><given-names>J.F.</given-names></name>
</person-group><article-title>On the verge of the market&#x02014;Plant factories for the automated and standardized production of biopharmaceuticals</article-title><source>Biotechnol. Adv.</source><year>2021</year><volume>46</volume><elocation-id>107681</elocation-id><pub-id pub-id-type="doi">10.1016/j.biotechadv.2020.107681</pub-id><pub-id pub-id-type="pmid">33326816</pub-id>
</element-citation></ref><ref id="B176-vaccines-13-00191"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Lai</surname><given-names>H.</given-names></name>
</person-group><article-title>Plant-derived virus-like particles as vaccines</article-title><source>Hum. Vaccines Immunother.</source><year>2013</year><volume>9</volume><fpage>26</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.4161/hv.22218</pub-id><pub-id pub-id-type="pmid">22995837</pub-id>
</element-citation></ref><ref id="B177-vaccines-13-00191"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hosseini Bamakan</surname><given-names>S.M.</given-names></name>
<name><surname>Ghasemzadeh Moghaddam</surname><given-names>S.</given-names></name>
<name><surname>Dehghan Manshadi</surname><given-names>S.</given-names></name>
</person-group><article-title>Blockchain-enabled pharmaceutical cold chain: Applications, key challenges, and future trends</article-title><source>J. Clean. Prod.</source><year>2021</year><volume>302</volume><fpage>127021</fpage><pub-id pub-id-type="doi">10.1016/j.jclepro.2021.127021</pub-id></element-citation></ref><ref id="B178-vaccines-13-00191"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cid</surname><given-names>R.</given-names></name>
<name><surname>Bol&#x000ed;var</surname><given-names>J.</given-names></name>
</person-group><article-title>Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><elocation-id>1072</elocation-id><pub-id pub-id-type="doi">10.3390/biom11081072</pub-id><pub-id pub-id-type="pmid">34439738</pub-id>
</element-citation></ref><ref id="B179-vaccines-13-00191"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spoel</surname><given-names>S.H.</given-names></name>
<name><surname>Dong</surname><given-names>X.</given-names></name>
</person-group><article-title>How do plants achieve immunity? Defence without specialized immune cells</article-title><source>Nat. Rev. Immunol.</source><year>2012</year><volume>12</volume><fpage>89</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1038/nri3141</pub-id><pub-id pub-id-type="pmid">22273771</pub-id>
</element-citation></ref><ref id="B180-vaccines-13-00191"><label>180.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Govea-Alonso</surname><given-names>D.O.</given-names></name>
<name><surname>Rybicki</surname><given-names>E.</given-names></name>
<name><surname>Rosales-Mendoza</surname><given-names>S.</given-names></name>
</person-group><article-title>Plant-Based Vaccines as a Global Vaccination Approach: Current Perspectives</article-title><source>Genetically Engineered Plants as a Source of Vaccines Against Wide Spread Diseases: An Integrated View</source><person-group person-group-type="editor">
<name><surname>Rosales-Mendoza</surname><given-names>S.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2014</year><fpage>265</fpage><lpage>280</lpage></element-citation></ref><ref id="B181-vaccines-13-00191"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rigano</surname><given-names>M.M.</given-names></name>
<name><surname>Walmsley</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Expression systems and developments in plant-made vaccines</article-title><source>Immunol. Cell Biol.</source><year>2005</year><volume>83</volume><fpage>271</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1711.2005.01336.x</pub-id><pub-id pub-id-type="pmid">15877605</pub-id>
</element-citation></ref><ref id="B182-vaccines-13-00191"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Streatfield</surname><given-names>S.J.</given-names></name>
<name><surname>Jilka</surname><given-names>J.M.</given-names></name>
<name><surname>Hood</surname><given-names>E.E.</given-names></name>
<name><surname>Turner</surname><given-names>D.D.</given-names></name>
<name><surname>Bailey</surname><given-names>M.R.</given-names></name>
<name><surname>Mayor</surname><given-names>J.M.</given-names></name>
<name><surname>Woodard</surname><given-names>S.L.</given-names></name>
<name><surname>Beifuss</surname><given-names>K.K.</given-names></name>
<name><surname>Horn</surname><given-names>M.E.</given-names></name>
<name><surname>Delaney</surname><given-names>D.E.</given-names></name>
<etal/>
</person-group><article-title>Plant-based vaccines: Unique advantages</article-title><source>Vaccine</source><year>2001</year><volume>19</volume><fpage>2742</fpage><lpage>2748</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00512-0</pub-id><pub-id pub-id-type="pmid">11257418</pub-id>
</element-citation></ref><ref id="B183-vaccines-13-00191"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moon</surname><given-names>K.-B.</given-names></name>
<name><surname>Park</surname><given-names>J.-S.</given-names></name>
<name><surname>Park</surname><given-names>Y.-I.</given-names></name>
<name><surname>Song</surname><given-names>I.-J.</given-names></name>
<name><surname>Lee</surname><given-names>H.-J.</given-names></name>
<name><surname>Cho</surname><given-names>H.S.</given-names></name>
<name><surname>Jeon</surname><given-names>J.-H.</given-names></name>
<name><surname>Kim</surname><given-names>H.-S.</given-names></name>
</person-group><article-title>Development of Systems for the Production of Plant-Derived Biopharmaceuticals</article-title><source>Plants</source><year>2020</year><volume>9</volume><elocation-id>30</elocation-id><pub-id pub-id-type="doi">10.3390/plants9010030</pub-id><pub-id pub-id-type="pmid">31878277</pub-id>
</element-citation></ref><ref id="B184-vaccines-13-00191"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Su</surname><given-names>H.</given-names></name>
<name><surname>Yakovlev</surname><given-names>I.A.</given-names></name>
<name><surname>Van Eerde</surname><given-names>A.</given-names></name>
<name><surname>Su</surname><given-names>J.</given-names></name>
<name><surname>Clarke</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Plant-produced vaccines: Future applications in aquaculture</article-title><source>Front. Plant Sci.</source><year>2021</year><volume>12</volume><elocation-id>718775</elocation-id><pub-id pub-id-type="doi">10.3389/fpls.2021.718775</pub-id><pub-id pub-id-type="pmid">34456958</pub-id>
</element-citation></ref><ref id="B185-vaccines-13-00191"><label>185.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Chanda</surname><given-names>A.</given-names></name>
</person-group><article-title>Environment-Friendly Plant-Based Edible Vaccines&#x02013;A Novel Technique to Fight SARS-CoV-2 and Other PandemicsA Review</article-title><source>Multidimensional Approaches to Impacts of Changing Environment on Human Health</source><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2021</year><fpage>307</fpage><lpage>316</lpage></element-citation></ref><ref id="B186-vaccines-13-00191"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaushik</surname><given-names>N.</given-names></name>
<name><surname>Patel</surname><given-names>P.</given-names></name>
<name><surname>Gupta</surname><given-names>R.</given-names></name>
<name><surname>Jaiswal</surname><given-names>A.</given-names></name>
<name><surname>Negi</surname><given-names>M.</given-names></name>
<name><surname>Borkar</surname><given-names>S.B.</given-names></name>
<name><surname>Mishra</surname><given-names>Y.K.</given-names></name>
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Choi</surname><given-names>E.H.</given-names></name>
<name><surname>Kaushik</surname><given-names>N.K.</given-names></name>
</person-group><article-title>Eco-friendly materials for next-generation vaccination: From concept to clinical reality</article-title><source>SmartMat</source><year>2024</year><volume>5</volume><fpage>e1274</fpage><pub-id pub-id-type="doi">10.1002/smm2.1274</pub-id></element-citation></ref><ref id="B187-vaccines-13-00191"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yusibov</surname><given-names>V.</given-names></name>
<name><surname>Kushnir</surname><given-names>N.</given-names></name>
<name><surname>Streatfield</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Advances and challenges in the development and production of effective plant-based influenza vaccines</article-title><source>Expert Rev. Vaccines</source><year>2015</year><volume>14</volume><fpage>519</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1586/14760584.2015.989988</pub-id><pub-id pub-id-type="pmid">25487788</pub-id>
</element-citation></ref><ref id="B188-vaccines-13-00191"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laere</surname><given-names>E.</given-names></name>
<name><surname>Ling</surname><given-names>A.P.K.</given-names></name>
<name><surname>Wong</surname><given-names>Y.P.</given-names></name>
<name><surname>Koh</surname><given-names>R.Y.</given-names></name>
<name><surname>Mohd Lila</surname><given-names>M.A.</given-names></name>
<name><surname>Hussein</surname><given-names>S.</given-names></name>
</person-group><article-title>Plant-Based Vaccines: Production and Challenges</article-title><source>J. Bot.</source><year>2016</year><volume>2016</volume><fpage>4928637</fpage><pub-id pub-id-type="doi">10.1155/2016/4928637</pub-id></element-citation></ref><ref id="B189-vaccines-13-00191"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uthaya Kumar</surname><given-names>A.</given-names></name>
<name><surname>Kadiresen</surname><given-names>K.</given-names></name>
<name><surname>Gan</surname><given-names>W.C.</given-names></name>
<name><surname>Ling</surname><given-names>A.P.K.</given-names></name>
</person-group><article-title>Current updates and research on plant-based vaccines for coronavirus disease 2019</article-title><source>Clin. Exp. Vaccine Res.</source><year>2021</year><volume>10</volume><fpage>13</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.7774/cevr.2021.10.1.13</pub-id><pub-id pub-id-type="pmid">33628750</pub-id>
</element-citation></ref><ref id="B190-vaccines-13-00191"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>T.-K.</given-names></name>
<name><surname>McDonald</surname><given-names>K.A.</given-names></name>
</person-group><article-title>Bioreactor engineering for recombinant protein production in plant cell suspension cultures</article-title><source>Biochem. Eng. J.</source><year>2009</year><volume>45</volume><fpage>168</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/j.bej.2009.02.008</pub-id></element-citation></ref><ref id="B191-vaccines-13-00191"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Ge</surname><given-names>X.</given-names></name>
<name><surname>Dolan</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Towards high-yield production of pharmaceutical proteins with plant cell suspension cultures</article-title><source>Biotechnol. Adv.</source><year>2011</year><volume>29</volume><fpage>278</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2011.01.002</pub-id><pub-id pub-id-type="pmid">21236330</pub-id>
</element-citation></ref><ref id="B192-vaccines-13-00191"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Desai</surname><given-names>P.N.</given-names></name>
<name><surname>Shrivastava</surname><given-names>N.</given-names></name>
<name><surname>Padh</surname><given-names>H.</given-names></name>
</person-group><article-title>Production of heterologous proteins in plants: Strategies for optimal expression</article-title><source>Biotechnol. Adv.</source><year>2010</year><volume>28</volume><fpage>427</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2010.01.005</pub-id><pub-id pub-id-type="pmid">20152894</pub-id>
</element-citation></ref><ref id="B193-vaccines-13-00191"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x00141;ojewska</surname><given-names>E.</given-names></name>
<name><surname>Kowalczyk</surname><given-names>T.</given-names></name>
<name><surname>Olejniczak</surname><given-names>S.</given-names></name>
<name><surname>Sakowicz</surname><given-names>T.</given-names></name>
</person-group><article-title>Extraction and purification methods in downstream processing of plant-based recombinant proteins</article-title><source>Protein Expr. Purif.</source><year>2016</year><volume>120</volume><fpage>110</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2015.12.018</pub-id><pub-id pub-id-type="pmid">26742898</pub-id>
</element-citation></ref><ref id="B194-vaccines-13-00191"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buyel</surname><given-names>J.F.</given-names></name>
<name><surname>Twyman</surname><given-names>R.M.</given-names></name>
<name><surname>Fischer</surname><given-names>R.</given-names></name>
</person-group><article-title>Extraction and downstream processing of plant-derived recombinant proteins</article-title><source>Biotechnol. Adv.</source><year>2015</year><volume>33</volume><fpage>902</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2015.04.010</pub-id><pub-id pub-id-type="pmid">25922318</pub-id>
</element-citation></ref><ref id="B195-vaccines-13-00191"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Venkataraman</surname><given-names>S.</given-names></name>
<name><surname>Khan</surname><given-names>I.</given-names></name>
<name><surname>Habibi</surname><given-names>P.</given-names></name>
<name><surname>Le</surname><given-names>M.</given-names></name>
<name><surname>Lippert</surname><given-names>R.</given-names></name>
<name><surname>Hefferon</surname><given-names>K.</given-names></name>
</person-group><article-title>Recent advances in expression and purification strategies for plant made vaccines</article-title><source>Front. Plant Sci.</source><year>2023</year><volume>14</volume><elocation-id>1273958</elocation-id><pub-id pub-id-type="doi">10.3389/fpls.2023.1273958</pub-id><pub-id pub-id-type="pmid">38078091</pub-id>
</element-citation></ref><ref id="B196-vaccines-13-00191"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>J.K.C.</given-names></name>
<name><surname>Drake</surname><given-names>P.M.W.</given-names></name>
<name><surname>Chargelegue</surname><given-names>D.</given-names></name>
<name><surname>Obregon</surname><given-names>P.</given-names></name>
<name><surname>Prada</surname><given-names>A.</given-names></name>
</person-group><article-title>Antibody processing and engineering in plants, and new strategies for vaccine production</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>1814</fpage><lpage>1818</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.11.011</pub-id><pub-id pub-id-type="pmid">15734047</pub-id>
</element-citation></ref><ref id="B197-vaccines-13-00191"><label>197.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Rupprecht</surname><given-names>C.E.</given-names></name>
<name><surname>Chikwamba</surname><given-names>R.</given-names></name>
</person-group><article-title>Rabies and Related Lyssaviruses</article-title><source>Prospects of Plant-Based Vaccines in Veterinary Medicine</source><person-group person-group-type="editor">
<name><surname>MacDonald</surname><given-names>J.</given-names></name>
</person-group><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2018</year><fpage>45</fpage><lpage>87</lpage></element-citation></ref><ref id="B198-vaccines-13-00191"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gutierrez-Valdes</surname><given-names>N.</given-names></name>
<name><surname>Cunyat</surname><given-names>F.</given-names></name>
<name><surname>Balieu</surname><given-names>J.</given-names></name>
<name><surname>Walet-Balieu</surname><given-names>M.-L.</given-names></name>
<name><surname>Paul</surname><given-names>M.J.</given-names></name>
<name><surname>de Groot</surname><given-names>J.</given-names></name>
<name><surname>Blanco-Perera</surname><given-names>A.</given-names></name>
<name><surname>Carrillo</surname><given-names>J.</given-names></name>
<name><surname>Lerouge</surname><given-names>P.</given-names></name>
<name><surname>Seters</surname><given-names>M.J.-v.</given-names></name>
<etal/>
</person-group><article-title>Production and characterization of novel Anti-HIV Fc-fusion proteins in plant-based systems: <italic toggle="yes">Nicotiana benthamiana</italic> &#x00026; tobacco BY-2 cell suspension</article-title><source>New Biotechnol.</source><year>2024</year><volume>83</volume><fpage>142</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.nbt.2024.08.499</pub-id></element-citation></ref><ref id="B199-vaccines-13-00191"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fischer</surname><given-names>R.</given-names></name>
<name><surname>Schillberg</surname><given-names>S.</given-names></name>
<name><surname>Hellwig</surname><given-names>S.</given-names></name>
<name><surname>Twyman</surname><given-names>R.M.</given-names></name>
<name><surname>Drossard</surname><given-names>J.</given-names></name>
</person-group><article-title>GMP issues for recombinant plant-derived pharmaceutical proteins</article-title><source>Biotechnol. Adv.</source><year>2012</year><volume>30</volume><fpage>434</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2011.08.007</pub-id><pub-id pub-id-type="pmid">21856403</pub-id>
</element-citation></ref><ref id="B200-vaccines-13-00191"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tus&#x000e9;</surname><given-names>D.</given-names></name>
</person-group><article-title>Safety of plant-made pharmaceuticals: Product development and regulatory considerations based on case studies of two autologous human cancer vaccines</article-title><source>Hum. Vaccines</source><year>2011</year><volume>7</volume><fpage>322</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.4161/hv.7.3.14213</pub-id></element-citation></ref><ref id="B201-vaccines-13-00191"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Streatfield</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Regulatory issues for plant-made pharmaceuticals and vaccines</article-title><source>Expert Rev. Vaccines</source><year>2005</year><volume>4</volume><fpage>591</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1586/14760584.4.4.591</pub-id><pub-id pub-id-type="pmid">16117714</pub-id>
</element-citation></ref><ref id="B202-vaccines-13-00191"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>MacDonald</surname><given-names>J.</given-names></name>
<name><surname>Doshi</surname><given-names>K.</given-names></name>
<name><surname>Dussault</surname><given-names>M.</given-names></name>
<name><surname>Hall</surname><given-names>J.C.</given-names></name>
<name><surname>Holbrook</surname><given-names>L.</given-names></name>
<name><surname>Jones</surname><given-names>G.</given-names></name>
<name><surname>Kaldis</surname><given-names>A.</given-names></name>
<name><surname>Klima</surname><given-names>C.L.</given-names></name>
<name><surname>Macdonald</surname><given-names>P.</given-names></name>
<name><surname>McAllister</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Bringing plant-based veterinary vaccines to market: Managing regulatory and commercial hurdles</article-title><source>Biotechnol. Adv.</source><year>2015</year><volume>33</volume><fpage>1572</fpage><lpage>1581</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2015.07.007</pub-id><pub-id pub-id-type="pmid">26232717</pub-id>
</element-citation></ref><ref id="B203-vaccines-13-00191"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sp&#x000f6;k</surname><given-names>A.</given-names></name>
<name><surname>Twyman</surname><given-names>R.M.</given-names></name>
<name><surname>Fischer</surname><given-names>R.</given-names></name>
<name><surname>Ma</surname><given-names>J.K.C.</given-names></name>
<name><surname>Sparrow</surname><given-names>P.A.C.</given-names></name>
</person-group><article-title>Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants</article-title><source>Trends Biotechnol.</source><year>2008</year><volume>26</volume><fpage>506</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2008.05.007</pub-id><pub-id pub-id-type="pmid">18676047</pub-id>
</element-citation></ref><ref id="B204-vaccines-13-00191"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kirk</surname><given-names>D.D.</given-names></name>
<name><surname>McIntosh</surname><given-names>K.</given-names></name>
<name><surname>Walmsley</surname><given-names>A.M.</given-names></name>
<name><surname>Peterson</surname><given-names>R.K.D.</given-names></name>
</person-group><article-title>Risk analysis for plant-made vaccines</article-title><source>Transgenic Res.</source><year>2005</year><volume>14</volume><fpage>449</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1007/s11248-005-5697-3</pub-id><pub-id pub-id-type="pmid">16201411</pub-id>
</element-citation></ref><ref id="B205-vaccines-13-00191"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghimire</surname><given-names>B.K.</given-names></name>
<name><surname>Yu</surname><given-names>C.Y.</given-names></name>
<name><surname>Kim</surname><given-names>W.-R.</given-names></name>
<name><surname>Moon</surname><given-names>H.-S.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>S.H.</given-names></name>
<name><surname>Chung</surname><given-names>I.M.</given-names></name>
</person-group><article-title>Assessment of Benefits and Risk of Genetically Modified Plants and Products: Current Controversies and Perspective</article-title><source>Sustainability</source><year>2023</year><volume>15</volume><elocation-id>1722</elocation-id><pub-id pub-id-type="doi">10.3390/su15021722</pub-id></element-citation></ref><ref id="B206-vaccines-13-00191"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nap</surname><given-names>J.-P.</given-names></name>
<name><surname>Metz</surname><given-names>P.L.J.</given-names></name>
<name><surname>Escaler</surname><given-names>M.</given-names></name>
<name><surname>Conner</surname><given-names>A.J.</given-names></name>
</person-group><article-title>The release of genetically modified crops into the environment</article-title><source>Plant J.</source><year>2003</year><volume>33</volume><fpage>19</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1046/j.0960-7412.2003.01602.x</pub-id><pub-id pub-id-type="pmid">12943539</pub-id>
</element-citation></ref><ref id="B207-vaccines-13-00191"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sp&#x000f6;k</surname><given-names>A.</given-names></name>
<name><surname>Sprink</surname><given-names>T.</given-names></name>
<name><surname>Allan</surname><given-names>A.C.</given-names></name>
<name><surname>Yamaguchi</surname><given-names>T.</given-names></name>
<name><surname>Day&#x000e9;</surname><given-names>C.</given-names></name>
</person-group><article-title>Towards social acceptability of genome-edited plants in industrialised countries? Emerging evidence from Europe, United States, Canada, Australia, New Zealand, and Japan</article-title><source>Front. Genome Ed.</source><year>2022</year><volume>4</volume><elocation-id>899331</elocation-id><pub-id pub-id-type="doi">10.3389/fgeed.2022.899331</pub-id><pub-id pub-id-type="pmid">36120531</pub-id>
</element-citation></ref><ref id="B208-vaccines-13-00191"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bird</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Anti-GMO and vaccine-Autism public policy campaigns in the court of public opinion</article-title><source>Hastings LJ</source><year>2020</year><volume>72</volume><fpage>719</fpage><pub-id pub-id-type="doi">10.2139/ssrn.3541806</pub-id></element-citation></ref><ref id="B209-vaccines-13-00191"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>J.K.C.</given-names></name>
<name><surname>Barros</surname><given-names>E.</given-names></name>
<name><surname>Bock</surname><given-names>R.</given-names></name>
<name><surname>Christou</surname><given-names>P.</given-names></name>
<name><surname>Dale</surname><given-names>P.J.</given-names></name>
<name><surname>Dix</surname><given-names>P.J.</given-names></name>
<name><surname>Fischer</surname><given-names>R.</given-names></name>
<name><surname>Irwin</surname><given-names>J.</given-names></name>
<name><surname>Mahoney</surname><given-names>R.</given-names></name>
<name><surname>Pezzotti</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Molecular farming for new drugs and vaccines</article-title><source>EMBO Rep.</source><year>2005</year><volume>6</volume><fpage>593</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1038/sj.embor.7400470</pub-id><pub-id pub-id-type="pmid">15995674</pub-id>
</element-citation></ref><ref id="B210-vaccines-13-00191"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fischer</surname><given-names>R.</given-names></name>
<name><surname>Buyel</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Molecular farming&#x02014;The slope of enlightenment</article-title><source>Biotechnol. Adv.</source><year>2020</year><volume>40</volume><elocation-id>107519</elocation-id><pub-id pub-id-type="doi">10.1016/j.biotechadv.2020.107519</pub-id><pub-id pub-id-type="pmid">31954848</pub-id>
</element-citation></ref><ref id="B211-vaccines-13-00191"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bortesi</surname><given-names>L.</given-names></name>
<name><surname>Fischer</surname><given-names>R.</given-names></name>
</person-group><article-title>The CRISPR/Cas9 system for plant genome editing and beyond</article-title><source>Biotechnol. Adv.</source><year>2015</year><volume>33</volume><fpage>41</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2014.12.006</pub-id><pub-id pub-id-type="pmid">25536441</pub-id>
</element-citation></ref><ref id="B212-vaccines-13-00191"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Osakabe</surname><given-names>K.</given-names></name>
<name><surname>Wada</surname><given-names>N.</given-names></name>
<name><surname>Miyaji</surname><given-names>T.</given-names></name>
<name><surname>Murakami</surname><given-names>E.</given-names></name>
<name><surname>Marui</surname><given-names>K.</given-names></name>
<name><surname>Ueta</surname><given-names>R.</given-names></name>
<name><surname>Hashimoto</surname><given-names>R.</given-names></name>
<name><surname>Abe-Hara</surname><given-names>C.</given-names></name>
<name><surname>Kong</surname><given-names>B.</given-names></name>
<name><surname>Yano</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Genome editing in plants using CRISPR type I-D nuclease</article-title><source>Commun. Biol.</source><year>2020</year><volume>3</volume><elocation-id>648</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-020-01366-6</pub-id><pub-id pub-id-type="pmid">33159140</pub-id>
</element-citation></ref><ref id="B213-vaccines-13-00191"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
</person-group><article-title>Highly efficient DNA-free plant genome editing using virally delivered CRISPR&#x02013;Cas9</article-title><source>Nat. Plants</source><year>2020</year><volume>6</volume><fpage>773</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1038/s41477-020-0704-5</pub-id><pub-id pub-id-type="pmid">32601419</pub-id>
</element-citation></ref><ref id="B214-vaccines-13-00191"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Gao</surname><given-names>C.</given-names></name>
</person-group><article-title>Applications of CRISPR&#x02013;Cas in agriculture and plant biotechnology</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2020</year><volume>21</volume><fpage>661</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1038/s41580-020-00288-9</pub-id><pub-id pub-id-type="pmid">32973356</pub-id>
</element-citation></ref><ref id="B215-vaccines-13-00191"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>H.-J.</given-names></name>
<name><surname>Jian</surname><given-names>L.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Jin</surname><given-names>M.</given-names></name>
<name><surname>Peng</surname><given-names>Y.</given-names></name>
<name><surname>Yan</surname><given-names>J.</given-names></name>
<name><surname>Han</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>High-Throughput CRISPR/Cas9 Mutagenesis Streamlines Trait Gene Identification in Maize[OPEN]</article-title><source>Plant Cell</source><year>2020</year><volume>32</volume><fpage>1397</fpage><lpage>1413</lpage><pub-id pub-id-type="doi">10.1105/tpc.19.00934</pub-id><pub-id pub-id-type="pmid">32102844</pub-id>
</element-citation></ref><ref id="B216-vaccines-13-00191"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Charland</surname><given-names>N.</given-names></name>
<name><surname>Gobeil</surname><given-names>P.</given-names></name>
<name><surname>Pillet</surname><given-names>S.</given-names></name>
<name><surname>Boulay</surname><given-names>I.</given-names></name>
<name><surname>S&#x000e9;guin</surname><given-names>A.</given-names></name>
<name><surname>Makarkov</surname><given-names>A.</given-names></name>
<name><surname>Heizer</surname><given-names>G.</given-names></name>
<name><surname>Bhutada</surname><given-names>K.</given-names></name>
<name><surname>Mahmood</surname><given-names>A.</given-names></name>
<name><surname>Tr&#x000e9;panier</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities</article-title><source>npj Vaccines</source><year>2022</year><volume>7</volume><fpage>142</fpage><pub-id pub-id-type="doi">10.1038/s41541-022-00561-2</pub-id><pub-id pub-id-type="pmid">36351931</pub-id>
</element-citation></ref><ref id="B217-vaccines-13-00191"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andrasevic</surname><given-names>I.</given-names></name>
<name><surname>Su</surname><given-names>H.</given-names></name>
<name><surname>Rimstad</surname><given-names>E.</given-names></name>
<name><surname>Clarke</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Production and characterization of nervous necrosis virus vaccine antigens in wild type and CRISPR/Cas9 genome edited <italic toggle="yes">Nicotiana benthamiana</italic> and edible crop lettuce Lactuca sativa</article-title><source>Aquac. Rep.</source><year>2025</year><volume>40</volume><fpage>102546</fpage><pub-id pub-id-type="doi">10.1016/j.aqrep.2024.102546</pub-id></element-citation></ref><ref id="B218-vaccines-13-00191"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bezbaruah</surname><given-names>R.</given-names></name>
<name><surname>Chavda</surname><given-names>V.P.</given-names></name>
<name><surname>Nongrang</surname><given-names>L.</given-names></name>
<name><surname>Alom</surname><given-names>S.</given-names></name>
<name><surname>Deka</surname><given-names>K.</given-names></name>
<name><surname>Kalita</surname><given-names>T.</given-names></name>
<name><surname>Ali</surname><given-names>F.</given-names></name>
<name><surname>Bhattacharjee</surname><given-names>B.</given-names></name>
<name><surname>Vora</surname><given-names>L.</given-names></name>
</person-group><article-title>Nanoparticle-Based Delivery Systems for Vaccines</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1946</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10111946</pub-id><pub-id pub-id-type="pmid">36423041</pub-id>
</element-citation></ref><ref id="B219-vaccines-13-00191"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>D&#x02019;Aoust</surname><given-names>M.-A.</given-names></name>
<name><surname>Couture</surname><given-names>M.M.J.</given-names></name>
<name><surname>Charland</surname><given-names>N.</given-names></name>
<name><surname>Tr&#x000e9;panier</surname><given-names>S.</given-names></name>
<name><surname>Landry</surname><given-names>N.</given-names></name>
<name><surname>Ors</surname><given-names>F.</given-names></name>
<name><surname>V&#x000e9;zina</surname><given-names>L.-P.</given-names></name>
</person-group><article-title>The production of hemagglutinin-based virus-like particles in plants: A rapid, efficient and safe response to pandemic influenza</article-title><source>Plant Biotechnol. J.</source><year>2010</year><volume>8</volume><fpage>607</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1111/j.1467-7652.2009.00496.x</pub-id><pub-id pub-id-type="pmid">20199612</pub-id>
</element-citation></ref><ref id="B220-vaccines-13-00191"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ortega-Rivera</surname><given-names>O.A.</given-names></name>
<name><surname>Shukla</surname><given-names>S.</given-names></name>
<name><surname>Shin</surname><given-names>M.D.</given-names></name>
<name><surname>Chen</surname><given-names>A.</given-names></name>
<name><surname>Beiss</surname><given-names>V.</given-names></name>
<name><surname>Moreno-Gonzalez</surname><given-names>M.A.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Clark</surname><given-names>A.E.</given-names></name>
<name><surname>Carlin</surname><given-names>A.F.</given-names></name>
<name><surname>Pokorski</surname><given-names>J.K.</given-names></name>
<etal/>
</person-group><article-title>Cowpea Mosaic Virus Nanoparticle Vaccine Candidates Displaying Peptide Epitopes Can Neutralize the Severe Acute Respiratory Syndrome Coronavirus</article-title><source>ACS Infect. Dis.</source><year>2021</year><volume>7</volume><fpage>3096</fpage><lpage>3110</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.1c00410</pub-id><pub-id pub-id-type="pmid">34672530</pub-id>
</element-citation></ref><ref id="B221-vaccines-13-00191"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sneh-Edri</surname><given-names>H.</given-names></name>
<name><surname>Likhtenshtein</surname><given-names>D.</given-names></name>
<name><surname>Stepensky</surname><given-names>D.</given-names></name>
</person-group><article-title>Intracellular Targeting of PLGA Nanoparticles Encapsulating Antigenic Peptide to the Endoplasmic Reticulum of Dendritic Cells and Its Effect on Antigen Cross-Presentation In Vitro</article-title><source>Mol. Pharm.</source><year>2011</year><volume>8</volume><fpage>1266</fpage><lpage>1275</lpage><pub-id pub-id-type="doi">10.1021/mp200198c</pub-id><pub-id pub-id-type="pmid">21661745</pub-id>
</element-citation></ref><ref id="B222-vaccines-13-00191"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suffian</surname><given-names>I.F.B.M.</given-names></name>
<name><surname>Al-Jamal</surname><given-names>K.T.</given-names></name>
</person-group><article-title>Bioengineering of virus-like particles as dynamic nanocarriers for in vivo delivery and targeting to solid tumours</article-title><source>Adv. Drug Deliv. Rev.</source><year>2022</year><volume>180</volume><fpage>114030</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.114030</pub-id><pub-id pub-id-type="pmid">34736988</pub-id>
</element-citation></ref><ref id="B223-vaccines-13-00191"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohsen</surname><given-names>M.O.</given-names></name>
<name><surname>Gomes</surname><given-names>A.C.</given-names></name>
<name><surname>Vogel</surname><given-names>M.</given-names></name>
<name><surname>Bachmann</surname><given-names>M.F.</given-names></name>
</person-group><article-title>Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System</article-title><source>Vaccines</source><year>2018</year><volume>6</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines6030037</pub-id><pub-id pub-id-type="pmid">30004398</pub-id>
</element-citation></ref><ref id="B224-vaccines-13-00191"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marsian</surname><given-names>J.</given-names></name>
<name><surname>Fox</surname><given-names>H.</given-names></name>
<name><surname>Bahar</surname><given-names>M.W.</given-names></name>
<name><surname>Kotecha</surname><given-names>A.</given-names></name>
<name><surname>Fry</surname><given-names>E.E.</given-names></name>
<name><surname>Stuart</surname><given-names>D.I.</given-names></name>
<name><surname>Macadam</surname><given-names>A.J.</given-names></name>
<name><surname>Rowlands</surname><given-names>D.J.</given-names></name>
<name><surname>Lomonossoff</surname><given-names>G.P.</given-names></name>
</person-group><article-title>Plant-made polio type 3 stabilized VLPs&#x02014;A candidate synthetic polio vaccine</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>245</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-00090-w</pub-id><pub-id pub-id-type="pmid">28811473</pub-id>
</element-citation></ref><ref id="B225-vaccines-13-00191"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohammadinejad</surname><given-names>R.</given-names></name>
<name><surname>Shavandi</surname><given-names>A.</given-names></name>
<name><surname>Raie</surname><given-names>D.S.</given-names></name>
<name><surname>Sangeetha</surname><given-names>J.</given-names></name>
<name><surname>Soleimani</surname><given-names>M.</given-names></name>
<name><surname>Hajibehzad</surname><given-names>S.S.</given-names></name>
<name><surname>Thangadurai</surname><given-names>D.</given-names></name>
<name><surname>Hospet</surname><given-names>R.</given-names></name>
<name><surname>Popoola</surname><given-names>J.O.</given-names></name>
<name><surname>Arzani</surname><given-names>A.</given-names></name>
</person-group><article-title>Plant molecular farming: Production of metallic nanoparticles and therapeutic proteins using green factories</article-title><source>Green Chem.</source><year>2019</year><volume>21</volume><fpage>1845</fpage><lpage>1865</lpage><pub-id pub-id-type="doi">10.1039/C9GC00335E</pub-id></element-citation></ref><ref id="B226-vaccines-13-00191"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lebel</surname><given-names>M.-&#x000c8;.</given-names></name>
<name><surname>Chartrand</surname><given-names>K.</given-names></name>
<name><surname>Leclerc</surname><given-names>D.</given-names></name>
<name><surname>Lamarre</surname><given-names>A.</given-names></name>
</person-group><article-title>Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants</article-title><source>Vaccines</source><year>2015</year><volume>3</volume><fpage>620</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.3390/vaccines3030620</pub-id><pub-id pub-id-type="pmid">26350598</pub-id>
</element-citation></ref><ref id="B227-vaccines-13-00191"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jain</surname><given-names>N.</given-names></name>
<name><surname>Jain</surname><given-names>P.</given-names></name>
<name><surname>Rajput</surname><given-names>D.</given-names></name>
<name><surname>Patil</surname><given-names>U.K.</given-names></name>
</person-group><article-title>Green synthesized plant-based silver nanoparticles: Therapeutic prospective for anticancer and antiviral activity</article-title><source>Micro Nano Syst. Lett.</source><year>2021</year><volume>9</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.1186/s40486-021-00131-6</pub-id></element-citation></ref><ref id="B228-vaccines-13-00191"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kwon</surname><given-names>K.-C.</given-names></name>
<name><surname>Verma</surname><given-names>D.</given-names></name>
<name><surname>Singh</surname><given-names>N.D.</given-names></name>
<name><surname>Herzog</surname><given-names>R.</given-names></name>
<name><surname>Daniell</surname><given-names>H.</given-names></name>
</person-group><article-title>Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells</article-title><source>Adv. Drug Deliv. Rev.</source><year>2013</year><volume>65</volume><fpage>782</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2012.10.005</pub-id><pub-id pub-id-type="pmid">23099275</pub-id>
</element-citation></ref><ref id="B229-vaccines-13-00191"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>N.T.T.</given-names></name>
<name><surname>Nguyen</surname><given-names>L.M.</given-names></name>
<name><surname>Nguyen</surname><given-names>T.T.T.</given-names></name>
<name><surname>Nguyen</surname><given-names>T.T.</given-names></name>
<name><surname>Nguyen</surname><given-names>D.T.C.</given-names></name>
<name><surname>Tran</surname><given-names>T.V.</given-names></name>
</person-group><article-title>Formation, antimicrobial activity, and biomedical performance of plant-based nanoparticles: A review</article-title><source>Environ. Chem. Lett.</source><year>2022</year><volume>20</volume><fpage>2531</fpage><lpage>2571</lpage><pub-id pub-id-type="doi">10.1007/s10311-022-01425-w</pub-id><pub-id pub-id-type="pmid">35369682</pub-id>
</element-citation></ref><ref id="B230-vaccines-13-00191"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lung</surname><given-names>P.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
</person-group><article-title>Nanoparticle formulated vaccines: Opportunities and challenges</article-title><source>Nanoscale</source><year>2020</year><volume>12</volume><fpage>5746</fpage><lpage>5763</lpage><pub-id pub-id-type="doi">10.1039/C9NR08958F</pub-id><pub-id pub-id-type="pmid">32124894</pub-id>
</element-citation></ref><ref id="B231-vaccines-13-00191"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laxmi</surname><given-names>B.</given-names></name>
<name><surname>Devi</surname><given-names>P.U.M.</given-names></name>
<name><surname>Thanjavur</surname><given-names>N.</given-names></name>
<name><surname>Buddolla</surname><given-names>V.</given-names></name>
</person-group><article-title>The Applications of Artificial Intelligence (AI)-Driven Tools in Virus-Like Particles (VLPs) Research</article-title><source>Curr. Microbiol.</source><year>2024</year><volume>81</volume><elocation-id>234</elocation-id><pub-id pub-id-type="doi">10.1007/s00284-024-03750-5</pub-id><pub-id pub-id-type="pmid">38904765</pub-id>
</element-citation></ref><ref id="B232-vaccines-13-00191"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parthiban</surname><given-names>S.</given-names></name>
<name><surname>Vijeesh</surname><given-names>T.</given-names></name>
<name><surname>Gayathri</surname><given-names>T.</given-names></name>
<name><surname>Shanmugaraj</surname><given-names>B.</given-names></name>
<name><surname>Sharma</surname><given-names>A.</given-names></name>
<name><surname>Sathishkumar</surname><given-names>R.</given-names></name>
</person-group><article-title>Artificial intelligence-driven systems engineering for next-generation plant-derived biopharmaceuticals</article-title><source>Front. Plant Sci.</source><year>2023</year><volume>14</volume><elocation-id>1252166</elocation-id><pub-id pub-id-type="doi">10.3389/fpls.2023.1252166</pub-id><pub-id pub-id-type="pmid">38034587</pub-id>
</element-citation></ref><ref id="B233-vaccines-13-00191"><label>233.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Bharadwaj</surname><given-names>K.K.</given-names></name>
<name><surname>Srivastava</surname><given-names>A.</given-names></name>
<name><surname>Panda</surname><given-names>M.K.</given-names></name>
<name><surname>Singh</surname><given-names>Y.D.</given-names></name>
<name><surname>Maharana</surname><given-names>R.</given-names></name>
<name><surname>Mandal</surname><given-names>K.</given-names></name>
<name><surname>Manisha Singh</surname><given-names>B.S.</given-names></name>
<name><surname>Singh</surname><given-names>D.</given-names></name>
<name><surname>Das</surname><given-names>M.</given-names></name>
<name><surname>Murmu</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Computational Intelligence in Vaccine Design Against COVID-19</article-title><source>Computational Intelligence Methods in COVID-19: Surveillance, Prevention, Prediction and Diagnosis</source><person-group person-group-type="editor">
<name><surname>Raza</surname><given-names>K.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Singapore</publisher-loc><year>2021</year><fpage>311</fpage><lpage>329</lpage></element-citation></ref><ref id="B234-vaccines-13-00191"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malone</surname><given-names>B.</given-names></name>
<name><surname>Simovski</surname><given-names>B.</given-names></name>
<name><surname>Molin&#x000e9;</surname><given-names>C.</given-names></name>
<name><surname>Cheng</surname><given-names>J.</given-names></name>
<name><surname>Gheorghe</surname><given-names>M.</given-names></name>
<name><surname>Fontenelle</surname><given-names>H.</given-names></name>
<name><surname>Vardaxis</surname><given-names>I.</given-names></name>
<name><surname>Tenn&#x000f8;e</surname><given-names>S.</given-names></name>
<name><surname>Malmberg</surname><given-names>J.-A.</given-names></name>
<name><surname>Stratford</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>22375</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-78758-5</pub-id><pub-id pub-id-type="pmid">33361777</pub-id>
</element-citation></ref><ref id="B235-vaccines-13-00191"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keshavarzi Arshadi</surname><given-names>A.</given-names></name>
<name><surname>Webb</surname><given-names>J.</given-names></name>
<name><surname>Salem</surname><given-names>M.</given-names></name>
<name><surname>Cruz</surname><given-names>E.</given-names></name>
<name><surname>Calad-Thomson</surname><given-names>S.</given-names></name>
<name><surname>Ghadirian</surname><given-names>N.</given-names></name>
<name><surname>Collins</surname><given-names>J.</given-names></name>
<name><surname>Diez-Cecilia</surname><given-names>E.</given-names></name>
<name><surname>Kelly</surname><given-names>B.</given-names></name>
<name><surname>Goodarzi</surname><given-names>H.</given-names></name>
</person-group><article-title>Artificial intelligence for COVID-19 drug discovery and vaccine development</article-title><source>Front. Artif. Intell.</source><year>2020</year><volume>3</volume><elocation-id>65</elocation-id><pub-id pub-id-type="doi">10.3389/frai.2020.00065</pub-id><pub-id pub-id-type="pmid">33733182</pub-id>
</element-citation></ref><ref id="B236-vaccines-13-00191"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farooq</surname><given-names>M.A.</given-names></name>
<name><surname>Gao</surname><given-names>S.</given-names></name>
<name><surname>Hassan</surname><given-names>M.A.</given-names></name>
<name><surname>Huang</surname><given-names>Z.</given-names></name>
<name><surname>Rasheed</surname><given-names>A.</given-names></name>
<name><surname>Hearne</surname><given-names>S.</given-names></name>
<name><surname>Prasanna</surname><given-names>B.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
</person-group><article-title>Artificial intelligence in plant breeding</article-title><source>Trends Genet.</source><year>2024</year><volume>40</volume><fpage>891</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2024.07.001</pub-id><pub-id pub-id-type="pmid">39117482</pub-id>
</element-citation></ref><ref id="B237-vaccines-13-00191"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khuat</surname><given-names>T.T.</given-names></name>
<name><surname>Bassett</surname><given-names>R.</given-names></name>
<name><surname>Otte</surname><given-names>E.</given-names></name>
<name><surname>Grevis-James</surname><given-names>A.</given-names></name>
<name><surname>Gabrys</surname><given-names>B.</given-names></name>
</person-group><article-title>Applications of machine learning in antibody discovery, process development, manufacturing and formulation: Current trends, challenges, and opportunities</article-title><source>Comput. Chem. Eng.</source><year>2024</year><volume>182</volume><fpage>108585</fpage><pub-id pub-id-type="doi">10.1016/j.compchemeng.2024.108585</pub-id></element-citation></ref><ref id="B238-vaccines-13-00191"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prajapati</surname><given-names>M.</given-names></name>
<name><surname>Malik</surname><given-names>P.</given-names></name>
<name><surname>Sinha</surname><given-names>A.</given-names></name>
<name><surname>Yadav</surname><given-names>H.</given-names></name>
<name><surname>Jaiwal</surname><given-names>Y.K.</given-names></name>
<name><surname>Ahlawat</surname><given-names>Y.K.</given-names></name>
<name><surname>Chaudhary</surname><given-names>D.</given-names></name>
<name><surname>Jaiwal</surname><given-names>R.</given-names></name>
<name><surname>Sharma</surname><given-names>N.</given-names></name>
<name><surname>Jaiwal</surname><given-names>P.K.</given-names></name>
<etal/>
</person-group><article-title>Biotechnological Interventions for the Production of Subunit Vaccines Against Group A Rotavirus</article-title><source>Cell Biochem. Funct.</source><year>2024</year><volume>42</volume><elocation-id>e70031</elocation-id><pub-id pub-id-type="doi">10.1002/cbf.70031</pub-id><pub-id pub-id-type="pmid">39707603</pub-id>
</element-citation></ref><ref id="B239-vaccines-13-00191"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mujtaba</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Carvalho</surname><given-names>L.B.</given-names></name>
<name><surname>Oliveira</surname><given-names>J.L.</given-names></name>
<name><surname>Espirito Santo Pereira</surname><given-names>A.d.</given-names></name>
<name><surname>Sharif</surname><given-names>R.</given-names></name>
<name><surname>Jogaiah</surname><given-names>S.</given-names></name>
<name><surname>Paidi</surname><given-names>M.K.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Ali</surname><given-names>Q.</given-names></name>
<etal/>
</person-group><article-title>Nanocarrier-Mediated Delivery of miRNA, RNAi, and CRISPR-Cas for Plant Protection: Current Trends and Future Directions</article-title><source>ACS Agric. Sci. Technol.</source><year>2021</year><volume>1</volume><fpage>417</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1021/acsagscitech.1c00146</pub-id></element-citation></ref><ref id="B240-vaccines-13-00191"><label>240.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Vasudevan</surname><given-names>S.S.</given-names></name>
<name><surname>Kandrikar</surname><given-names>T.Y.</given-names></name>
<name><surname>Sayyed</surname><given-names>A.A.</given-names></name>
<name><surname>Sridhar</surname><given-names>S.</given-names></name>
<name><surname>Prasad</surname><given-names>A.</given-names></name>
<name><surname>Khandelwal</surname><given-names>S.</given-names></name>
<name><surname>Baniya</surname><given-names>S.</given-names></name>
<name><surname>Miguela</surname><given-names>C.A.C.</given-names></name>
<name><surname>Gondaliya</surname><given-names>P.</given-names></name>
</person-group><article-title>Chapter 13&#x02014;Personalized vaccines, novel vaccination technologies, and future prospects</article-title><source>Advanced Vaccination Technologies for Infectious and Chronic Diseases</source><person-group person-group-type="editor">
<name><surname>Chavda</surname><given-names>V.P.</given-names></name>
<name><surname>Vora</surname><given-names>L.K.</given-names></name>
<name><surname>Apostolopoulos</surname><given-names>V.</given-names></name>
</person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2024</year><fpage>225</fpage><lpage>242</lpage></element-citation></ref><ref id="B241-vaccines-13-00191"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>Z.</given-names></name>
<name><surname>Ott</surname><given-names>P.A.</given-names></name>
<name><surname>Wu</surname><given-names>C.J.</given-names></name>
</person-group><article-title>Towards personalized, tumour-specific, therapeutic vaccines for cancer</article-title><source>Nat. Rev. Immunol.</source><year>2018</year><volume>18</volume><fpage>168</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.131</pub-id><pub-id pub-id-type="pmid">29226910</pub-id>
</element-citation></ref><ref id="B242-vaccines-13-00191"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lizotte</surname><given-names>P.H.</given-names></name>
<name><surname>Wen</surname><given-names>A.M.</given-names></name>
<name><surname>Sheen</surname><given-names>M.R.</given-names></name>
<name><surname>Fields</surname><given-names>J.</given-names></name>
<name><surname>Rojanasopondist</surname><given-names>P.</given-names></name>
<name><surname>Steinmetz</surname><given-names>N.F.</given-names></name>
<name><surname>Fiering</surname><given-names>S.</given-names></name>
</person-group><article-title>In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer</article-title><source>Nat. Nanotechnol.</source><year>2016</year><volume>11</volume><fpage>295</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1038/nnano.2015.292</pub-id><pub-id pub-id-type="pmid">26689376</pub-id>
</element-citation></ref><ref id="B243-vaccines-13-00191"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Posgai</surname><given-names>A.L.</given-names></name>
<name><surname>Wasserfall</surname><given-names>C.H.</given-names></name>
<name><surname>Kwon</surname><given-names>K.-C.</given-names></name>
<name><surname>Daniell</surname><given-names>H.</given-names></name>
<name><surname>Schatz</surname><given-names>D.A.</given-names></name>
<name><surname>Atkinson</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Plant-based vaccines for oral delivery of type 1 diabetes-related autoantigens: Evaluating oral tolerance mechanisms and disease prevention in NOD mice</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>42372</elocation-id><pub-id pub-id-type="doi">10.1038/srep42372</pub-id><pub-id pub-id-type="pmid">28205558</pub-id>
</element-citation></ref><ref id="B244-vaccines-13-00191"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thuenemann</surname><given-names>E.C.</given-names></name>
<name><surname>Meyers</surname><given-names>A.E.</given-names></name>
<name><surname>Verwey</surname><given-names>J.</given-names></name>
<name><surname>Rybicki</surname><given-names>E.P.</given-names></name>
<name><surname>Lomonossoff</surname><given-names>G.P.</given-names></name>
</person-group><article-title>A method for rapid production of heteromultimeric protein complexes in plants: Assembly of protective bluetongue virus-like particles</article-title><source>Plant Biotechnol. J.</source><year>2013</year><volume>11</volume><fpage>839</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.1111/pbi.12076</pub-id><pub-id pub-id-type="pmid">23647743</pub-id>
</element-citation></ref><ref id="B245-vaccines-13-00191"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ponndorf</surname><given-names>D.</given-names></name>
<name><surname>Meshcheriakova</surname><given-names>Y.</given-names></name>
<name><surname>Thuenemann</surname><given-names>E.C.</given-names></name>
<name><surname>Dobon Alonso</surname><given-names>A.</given-names></name>
<name><surname>Overman</surname><given-names>R.</given-names></name>
<name><surname>Holton</surname><given-names>N.</given-names></name>
<name><surname>Dowall</surname><given-names>S.</given-names></name>
<name><surname>Kennedy</surname><given-names>E.</given-names></name>
<name><surname>Stocks</surname><given-names>M.</given-names></name>
<name><surname>Lomonossoff</surname><given-names>G.P.</given-names></name>
<etal/>
</person-group><article-title>Plant-made dengue virus-like particles produced by co-expression of structural and non-structural proteins induce a humoral immune response in mice</article-title><source>Plant Biotechnol. J.</source><year>2021</year><volume>19</volume><fpage>745</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1111/pbi.13501</pub-id><pub-id pub-id-type="pmid">33099859</pub-id>
</element-citation></ref><ref id="B246-vaccines-13-00191"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pomatto</surname><given-names>M.A.C.</given-names></name>
<name><surname>Gai</surname><given-names>C.</given-names></name>
<name><surname>Negro</surname><given-names>F.</given-names></name>
<name><surname>Massari</surname><given-names>L.</given-names></name>
<name><surname>Deregibus</surname><given-names>M.C.</given-names></name>
<name><surname>De Rosa</surname><given-names>F.G.</given-names></name>
<name><surname>Camussi</surname><given-names>G.</given-names></name>
</person-group><article-title>Oral Delivery of mRNA Vaccine by Plant-Derived Extracellular Vesicle Carriers</article-title><source>Cells</source><year>2023</year><volume>12</volume><elocation-id>1826</elocation-id><pub-id pub-id-type="doi">10.3390/cells12141826</pub-id><pub-id pub-id-type="pmid">37508491</pub-id>
</element-citation></ref><ref id="B247-vaccines-13-00191"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tremouillaux-Guiller</surname><given-names>J.</given-names></name>
<name><surname>Moustafa</surname><given-names>K.</given-names></name>
<name><surname>Hefferon</surname><given-names>K.</given-names></name>
<name><surname>Gaobotse</surname><given-names>G.</given-names></name>
<name><surname>Makhzoum</surname><given-names>A.</given-names></name>
</person-group><article-title>Plant-made HIV vaccines and potential candidates</article-title><source>Curr. Opin. Biotechnol.</source><year>2020</year><volume>61</volume><fpage>209</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2020.01.004</pub-id><pub-id pub-id-type="pmid">32058899</pub-id>
</element-citation></ref><ref id="B248-vaccines-13-00191"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Guo</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Feng</surname><given-names>L.</given-names></name>
<name><surname>Xie</surname><given-names>N.</given-names></name>
<name><surname>Shen</surname><given-names>G.</given-names></name>
</person-group><article-title>Nanotechnology&#x02019;s frontier in combatting infectious and inflammatory diseases: Prevention and treatment</article-title><source>Signal Transduct. Target. Ther.</source><year>2024</year><volume>9</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1038/s41392-024-01745-z</pub-id><pub-id pub-id-type="pmid">38378653</pub-id>
</element-citation></ref><ref id="B249-vaccines-13-00191"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tariq</surname><given-names>H.</given-names></name>
<name><surname>Batool</surname><given-names>S.</given-names></name>
<name><surname>Asif</surname><given-names>S.</given-names></name>
<name><surname>Ali</surname><given-names>M.</given-names></name>
<name><surname>Abbasi</surname><given-names>B.H.</given-names></name>
</person-group><article-title>Virus-like particles: Revolutionary platforms for developing vaccines against emerging infectious diseases</article-title><source>Front. Microbiol.</source><year>2022</year><volume>12</volume><elocation-id>790121</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2021.790121</pub-id><pub-id pub-id-type="pmid">35046918</pub-id>
</element-citation></ref><ref id="B250-vaccines-13-00191"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosales-Mendoza</surname><given-names>S.</given-names></name>
<name><surname>M&#x000e1;rquez-Escobar</surname><given-names>V.A.</given-names></name>
<name><surname>Gonz&#x000e1;lez-Ortega</surname><given-names>O.</given-names></name>
<name><surname>Nieto-G&#x000f3;mez</surname><given-names>R.</given-names></name>
<name><surname>Ar&#x000e9;valo-Villalobos</surname><given-names>J.I.</given-names></name>
</person-group><article-title>What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>183</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8020183</pub-id><pub-id pub-id-type="pmid">32295153</pub-id>
</element-citation></ref><ref id="B251-vaccines-13-00191"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chattopadhyay</surname><given-names>A.</given-names></name>
<name><surname>Jailani</surname><given-names>A.A.</given-names></name>
<name><surname>Mandal</surname><given-names>B.</given-names></name>
</person-group><article-title>Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1347</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11081347</pub-id><pub-id pub-id-type="pmid">37631915</pub-id>
</element-citation></ref><ref id="B252-vaccines-13-00191"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumraj</surname><given-names>G.</given-names></name>
<name><surname>Pathak</surname><given-names>S.</given-names></name>
<name><surname>Shah</surname><given-names>S.</given-names></name>
<name><surname>Majumder</surname><given-names>P.</given-names></name>
<name><surname>Jain</surname><given-names>J.</given-names></name>
<name><surname>Bhati</surname><given-names>D.</given-names></name>
<name><surname>Hanif</surname><given-names>S.</given-names></name>
<name><surname>Mukherjee</surname><given-names>S.</given-names></name>
<name><surname>Ahmed</surname><given-names>S.</given-names></name>
</person-group><article-title>Capacity Building for Vaccine Manufacturing Across Developing Countries: The Way Forward</article-title><source>Hum. Vaccines Immunother.</source><year>2022</year><volume>18</volume><fpage>2020529</fpage><pub-id pub-id-type="doi">10.1080/21645515.2021.2020529</pub-id><pub-id pub-id-type="pmid">35086416</pub-id>
</element-citation></ref><ref id="B253-vaccines-13-00191"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Royal</surname><given-names>J.M.</given-names></name>
<name><surname>Simpson</surname><given-names>C.A.</given-names></name>
<name><surname>McCormick</surname><given-names>A.A.</given-names></name>
<name><surname>Phillips</surname><given-names>A.</given-names></name>
<name><surname>Hume</surname><given-names>S.</given-names></name>
<name><surname>Morton</surname><given-names>J.</given-names></name>
<name><surname>Shepherd</surname><given-names>J.</given-names></name>
<name><surname>Oh</surname><given-names>Y.</given-names></name>
<name><surname>Swope</surname><given-names>K.</given-names></name>
<name><surname>DeBeauchamp</surname><given-names>J.L.</given-names></name>
<etal/>
</person-group><article-title>Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1347</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9111347</pub-id><pub-id pub-id-type="pmid">34835278</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00191-f001"><label>Figure 1</label><caption><p>Schematic diagram of the &#x02018;launch&#x02019; vector. Following agroinfiltration of plants, the sequence between the left border (LB) and the right border (RB) of the plasmid vector is transferred from Agrobacteria into plant cells where expression of the engineered TMV genome is driven by the Cauliflower mosaic virus (CaMV) 35S promoter. TMV replicase then drives the amplification of the primary transcript, and Pfs25-CP accumulation is then driven by the TMV CP subgenomic promoter (light blue box). The movement protein (MP) facilitates cell-to-cell transfer of viral sequences and is driven by the MP subgenomic promoter (dark blue box). &#x0201c;CP&#x0201d; refers to &#x0201c;coat protein&#x0201d;. Copyright Public Library of Science (2013) [<xref rid="B28-vaccines-13-00191" ref-type="bibr">28</xref>].</p></caption><graphic xlink:href="vaccines-13-00191-g001" position="float"/></fig><fig position="float" id="vaccines-13-00191-f002"><label>Figure 2</label><caption><p>The procedure involved in the development of the edible vaccine. Copyright Elsevier (2020) [<xref rid="B35-vaccines-13-00191" ref-type="bibr">35</xref>].</p></caption><graphic xlink:href="vaccines-13-00191-g002" position="float"/></fig><fig position="float" id="vaccines-13-00191-f003"><label>Figure 3</label><caption><p>The general principles of plant-produced vaccine therapeutic applications.</p></caption><graphic xlink:href="vaccines-13-00191-g003" position="float"/></fig><fig position="float" id="vaccines-13-00191-f004"><label>Figure 4</label><caption><p>Schematic representation of the transmission of zoonotic diseases and the plant-based production technologies (stable, transient, and suspension cultures) for recombinant vaccine production. The figure contains the reprinted disposable bioreactor image from PROTALIX Biotherapeutics under the Copyright MDPI (2022) [<xref rid="B160-vaccines-13-00191" ref-type="bibr">160</xref>].</p></caption><graphic xlink:href="vaccines-13-00191-g004" position="float"/></fig><fig position="float" id="vaccines-13-00191-f005"><label>Figure 5</label><caption><p>Schematic representation of different nanoparticle-based delivery systems: (<bold>A</bold>) VLP, (<bold>B</bold>) liposome, (<bold>C</bold>) Immune stimulating complexes (ISCOM), (<bold>D</bold>) polymeric nanoparticle, (<bold>E</bold>) inorganic nanoparticle, (<bold>F</bold>) emulsion, and (<bold>G</bold>) exosome. Copyright MDPI (2022) [<xref rid="B218-vaccines-13-00191" ref-type="bibr">218</xref>].</p></caption><graphic xlink:href="vaccines-13-00191-g005" position="float"/></fig><table-wrap position="float" id="vaccines-13-00191-t001"><object-id pub-id-type="pii">vaccines-13-00191-t001_Table 1</object-id><label>Table 1</label><caption><p>Plant-Based Vaccines for Infectious Diseases.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Plant Host</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Animal Species for Study </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2 Spike Protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">N. benthamiana</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B132-vaccines-13-00191" ref-type="bibr">132</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2 Spike Protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">N. benthamiana</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Golden Syrian hamsters</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B133-vaccines-13-00191" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemagglutinin (HA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">N. benthamiana</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Healthy Subjects</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B134-vaccines-13-00191" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Malaria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pfs25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">N. benthamiana</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B131-vaccines-13-00191" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Malaria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pfs25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">N. benthamiana</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Healthy Subjects</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B135-vaccines-13-00191" ref-type="bibr">135</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Norovirus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Narita 104 virus capsid protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">N. benthamiana</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B136-vaccines-13-00191" ref-type="bibr">136</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBsAg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Lactuca sativa</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice and Healthy Subjects </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B58-vaccines-13-00191" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rabies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rabies virus glycoprotein (G protein)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">N. benthamiana</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B137-vaccines-13-00191" ref-type="bibr">137</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cholera</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cholera Toxin B (CTB)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">N. benthamiana</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B138-vaccines-13-00191" ref-type="bibr">138</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-13-00191-t002"><object-id pub-id-type="pii">vaccines-13-00191-t002_Table 2</object-id><label>Table 2</label><caption><p>Examples of Plant-Based Vaccines in Veterinary Medicine.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Animal Species</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Plant Host</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Notes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Newcastle Disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poultry</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tobacco</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemagglutinin-Neuraminidase (HN) protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Provides immune protection in chickens</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B166-vaccines-13-00191" ref-type="bibr">166</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Foot-and-Mouth Disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Livestock</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alfalfa</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VP1 capsid protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Effective immunogenicity in cattle and pigs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B167-vaccines-13-00191" ref-type="bibr">167</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rabies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dogs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tomato, tobacco</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rabies glycoprotein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Offers a cost-effective alternative for rabies prevention</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B168-vaccines-13-00191" ref-type="bibr">168</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avian Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poultry</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duckweed, tobacco</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemagglutinin (HA) protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prevents viral outbreaks in poultry populations</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B169-vaccines-13-00191" ref-type="bibr">169</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>